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A análise genética molecular dos genes COL4A5, COL4A4 e COL4A3
genes é a melhor abordagem não invasiva disponível para
estabelecer o diagnóstico, tratamento, prognóstico e aconselhamento
genético de nefropatias associadas ao colagéneo tipo IV – síndrome 
de Alport e hematúria familiar benigna / nefropatia de membrana basal 
fina. Neste estudo multicêntrico nacional, foram estudadas 65 famílias 
não relacionadas com o diagnóstico clínico de síndrome de Alport ou 
de nefropatia de membrana basal fina. Foram identificadas mutações 
patogénicas no gene COL4A5 em 22 famílias (22/60; 37%), que 
confirmaram o diagnóstico de síndrome de Alport ligada ao 
cromossoma X. Foi identificada uma nova correlação genótipo-
fenótipo, dado ter sido detectada uma deleção que envolve o gene 
COL4A5, mas não o gene COL4A6, numa família com leiomiomatose 
difusa associada a síndrome de Alport ligada ao cromossoma X. Este 
resultado sugere que a deleção dos exões 5’ do gene COL4A6 e da 
região promotora comum aos genes COL4A5_COL4A6 não é 
essencial para o desenvolvimento de leiomiomatose difusa nestes
doentes. Foi efetuada sequenciação directa dos genes COL4A3 e 
COL4A4 em cinco famílias com padrão de hereditariedade 
autossómico, como abordagem de primeira linha, e em 35 famílias 
com padrão de hereditariedade incerto e nas quais não foram 
detectadas mutações patogénicas no gene COL4A5. Foram 
detectadas mutações patogénicas nos genes COL4A3 ou COL4A4
em 25 famílias (25/40; 63%), confirmando o diagnóstico de síndrome 
de Alport autossómica ou de nefropatia de membrana basal fina.
Observou-se uma  proporção semelhante de famílias com síndrome 
de Alport ligado ao cromossoma X e de famílias com síndrome de 
Alport autossómica ou com nefropatia de membrana basal fina, sendo 
as prevalências de 37% (22/62) e de 40% (25/62), respetivamente. No 
seu conjunto estes resultados sugerem que a abordagem laboratorial
por método de sequenciação de ADN de próxima geração será mais 
eficaz e menos dispendiosa para diagnóstico genético molecular da 
síndrome de Alport na população portuguesa. 
Palavras-chave: Síndrome de Alport; COL4A3; COL4A4; COL4A5. 
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Abstract 
 
 
Molecular genetic analysis of the COL4A5, COL4A4 and COL4A3
genes is the best non-invasive available approach for diagnosis, 
treatment, prognosis, and genetic couseling of collagen IV-related 
nephropathies – Alport syndrome and thin basement membrane 
nephropathy. In this national multicenter study, 65 unrelated families 
with a clinical diagnosis of Alport syndrome or thin basement 
membrane nephropathy were studied. Pathogenic COL4A5 mutations
were identified by direct sequencing and multiplex-ligation dependent 
amplification in 22 families (22/65; 34%), confirming a diagnosis of X-
linked AS. A novel genotype-phenotype correlation was disclosed, as 
a deletion involving COL4A5, but not COL4A6, was detected in a 
family with diffuse leiomyomatosis associated with X-linked AS. This 
result suggests that the deletion of the 5’ exons of COL4A6 and of the 
common COL4A5_COL4A6 promoter region is not essential for the 
development of diffuse leiomyomatosis in patients with Alport 
syndrome and diffuse leiomyomatosis. COL4A3 and COL4A4 were 
analyzed by direct sequencing in five families with autosomal 
inheritance pattern, as a first-tier approach, and in 35 families with an 
unclear inheritance pattern and no pathogenic mutations in the 
COL4A5 gene. Pathogenic mutations in COL4A3 or COL4A4 were 
detected in 25 unrelated families (25/40; 63%), confirming the 
diagnosis of autosomal Alport syndrome or thin basement membrane 
nephropathy. A similar proportion of families with X-linked Alport 
syndrome and of families with autosomal Alport syndrome or with thin 
basement membrane nephropathy was observed, with prevalences of 
37% (22/62) and 40% (25/62), respectively. Altogether, these results 
suggest that Next-Generation Sequencing would be a more effective 
and less expensive approach to the genetic molecular study of Alport 
syndrome in the Portuguese population. 
Keywords: Alport syndrome; COL4A3; COL4A4; COL4A5. 
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Chapter 1 Introduction 
 
1. Alport syndrome 
 
1.1. Diagnosis: Historical perspective 
In 1927, Arthur Cecil Alport recognized that the association of hematuria 
and sensorineural deafness, reported in a previously studied family, belong to a 
unique clinical entity (Alport 1927), which in time became known as Alport 
syndrome (AS) (Williamson 1961). This family had been the subject of several 
successive observations (Guthrie 1902; Kendall 1912; Hurst 1923; Alport 1927). 
Guthrie described the familial occurrence of hematuria of unknown cause, which 
he called hereditary hematuria, since it was observed in two consecutive 
generations of the family and it was congenital or presented during childhood 
(Guthrie 1902). Hematuria occurred in both genders, was microscopic and/or 
macroscopic, was persistent or recurrent and was prone to paroxysmal 
exacerbations concomitantly with flue-like symptoms. Phenotypic heterogeneity 
was emphasized by reporting that affected males manifested uremia and died at a 
younger age, while females were usually mildly affected (Hurst 1923; Eason J 
1924; Alport 1927). Eason mentioned that, in this family, a non-affected female did 
not transmit the disorder, while affected females and another non-affected female 
did; and that infections by non-haemolytic streptococcus predisposed to the 
exacerbation of the kidney disease (Eason J 1924). Hurst had noted the 
occurrence of deafness in three patients of the family, but he did not make a 
comment on this (Hurst 1923). However, Authur C. Alport who, observing “nerve” 
deafness in both affected males and females, recognized auditory loss as an 
integral sign of this hereditary disease (Alport 1927). Perkoff and colleagues 
published a detailed study of a much larger Mormon family from Utah with similar 
clinical features and hypothesized for the first time a mechanism of inheritance for 
the disease – a partially sex-linked dominant inheritance with crossing-over 
between X and Y chromosomes, which was subsequently contested (Perkoff, 
Stephens et al. 1951; Stephens, Perkoff et al. 1951; Perkoff, Nugent et al. 1958). 
Ocular manifestations were first reported as part of the syndrome in 1954 
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(Reyersbach and Butler 1954; Sohar 1954; Sohar 1956). As there were no specific 
diagnostic criteria for the diagnosis of AS until 1988, a variety of clinically 
heterogeneous inherited nephritis were included in the AS phenotype for many 
years and a multiplicity of hypotheses were posed regarding the inheritance of AS 
(Crawfurd 1988).  
The pathophysiology of AS was clarified by the observation of characteristic 
ultrastructural changes in the glomerular basement membrane (GBM) of the 
kidney (Kinoshita, Osawa et al. 1969; Hinglais, Grunfeld et al. 1972; Spear and 
Slusser 1972; Churg and Sherman 1973). In the late 60s, Kefalides had identified 
a unique collagen in the GBM (Kefalides 1966; Kefalides 1968). Three identical α-
chains were suggested to form the scaffold of the GBM (Kefalides 1971). With 
advances in electron microscopy in the early 1970s, several laboratories reported 
typical ultrastructural changes in the GBM of AS patients, namely focal or diffuse 
thinning, thickening and splitting of the GBM containing granular material 
(Kinoshita, Osawa et al. 1969; Hinglais, Grunfeld et al. 1972; Spear and Slusser 
1972; Churg and Sherman 1973). These findings lead Spear to hypothesize that 
mutations in the gene for this unique structural GBM component could cause AS 
(Spear 1973). Two additional observations were fundamental to the recognition of 
a possible type IV collagen defect as the cause of AS: (i) the Goodpasture (human 
anti-GBM) antigen, which was later known to be directed against the globular 
domain of collagen type IV (Wieslander, Barr et al. 1984), did not bind GBM of 
patients with AS (Olson, Anand et al. 1980; McCoy, Johnson et al. 1982); and (ii) 
the development of post-transplant glomerulonephritis in AS patients was due to 
the synthesis of antibodies directed against collagen type IV chain epitopes 
(Milliner, Pierides et al. 1982; Kashtan, Fish et al. 1986), more specifically 
antibodies directed against α3 and α5 collagen type IV chains (Fleming, Savage et 
al. 1988; Kleppel, Kashtan et al. 1989; Kleppel, Santi et al. 1989; Savage, Noel et 
al. 1989; vd Heuvel, Schroder et al. 1989; Kashtan, Butkowski et al. 1990).  
Framing the reported findings, Flinter and colleagues (1988) proposed four 
criteria for the clinical diagnosis of classic AS, also known as X-linked Alport 
syndrome (XLAS). An individual with unexplained hematuria would probably have 
XLAS if, at least, three of the following four criteria were present: (i) Positive family 
history of hematuria with or without chronic renal failure (CRF); (ii) Typical 
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ultrastructural GBM changes in a renal biopsy specimen; (iii) High-tone 
sensorineural deafness; (iv) Characteristic ophthalmological signs (lenticonus 
and/or macular flecks) (Flinter, Cameron et al. 1988).  
It was not until 1990 that molecular genetic techniques enabled the 
elucidation of the genetic basis of XLAS. By immunohistochemical analysis, α5(IV) 
chains were shown to localize to the GBM of the kidney and the COL4A5 gene, 
coding for α5(IV) chain of collagen type IV, was found to be located to Xq22 
(Hostikka, Eddy et al. 1990; Myers, Jones et al. 1990; Pihlajaniemi, Pohjolainen et 
al. 1990). The same locus had previously been identified by linkage analysis 
(Atkin, Hasstedt et al. 1988; Brunner, Schroder et al. 1988; Szpiro-Tapia, Bobrie et 
al. 1988). In addition, changes in the COL4A5 sequence were identified in patients 
with AS, giving support to its X-linked inheritance pattern (Barker, Hostikka et al. 
1990). In 1994, some families with AS were found to carry mutations in the 
COL4A3 or COL4A4 genes, located to the autosomal chromosome 2 (2q36-q37), 
molecularly demonstrating an autosomal recessive pattern of inheritance 
(Mochizuki, Lemmink et al. 1994) and proving the locus heterogeneity of AS. 
Diagnostic criteria were further extended by Gregory and colleagues (1996), who 
suggested two additional clinical criteria, namely the association of diffuse 
leiomyomatosis with AS (Cochat, Guibaud et al. 1988) and immunohistochemical 
absence of α3-5(IV) chains in the GBM or in the epidermal basement membrane 
(EBM) (Gregory, Terreros et al. 1996) (Table I). Finally, molecular genetic testing 
was also included as a major diagnostic criterion. Indeed, since the clinical 
diagnosis of AS is challenging due to the great spectrum of symptoms, the 
identification of pathogenic COL4A5, COL4A4 or COL4A3 mutation(s) became the 
most informative diagnostic criterion, also providing support for the prognosis, 
treatment and prevention of AS. 
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Table I. Diagnostic criteria of Alport syndrome. 
 
 Flinter et al. (1988) * Gregory et al. (1996) ** 
Hematuria Unexplained hematuria 
(obligatory criterion) 
Persistent hematuria, 
without evidence of another possibly 
inherited nephropathy such as thin GBM 
disease, polycystic kidney disease, or IgA 
nephropathy 
Family history Hematuria and /or CRF Family history of nephritis or 
unexplained hematuria, 
in a first-degree relative of the index case or 
in a male relative linked through any number 
of females 
ESRD - Gradual progression to ESRD, 
in the index case or at least two family 
members 
Ultrastructural 
GBM 
abnormalities 
Thinning of the GBM; 
Thickening of the GBM; 
Splitting of lamina densa; 
Electron-dense bodies in 
lacunae of lamina densa 
Widespread GBM ultrastructural 
abnormalities, 
in particular thickening, thinning, and splitting 
Immuno-
histochemical 
GBM 
abnormalities 
- Immunohistochemical evidence of 
complete or partial lack of the α3(IV), 
α4(IV), and α5(IV)-chain, 
in the GBM, EBM or both 
Hearing loss Bilateral high-tone SNHL Bilateral SNHL in the 2,000-8,000 Hz 
range: the hearing loss develops gradually, 
is not present in early infancy, and commonly 
presents before the age of 30 years 
Ophthalmological 
abnormalities 
Anterior lenticonus; 
Macular flecks 
Ocular lesions, 
including anterior lenticonus, posterior 
subcapsular cataract, posterior 
polymorphous dystrophy, and retinal flecks 
Leiomyomatosis - Diffuse leiomyomatosis 
of oesophagus, female genitalia, or both 
[Absence of] 
Hematologic 
abnormalities † 
- Macrothrombocytopenia or 
granulocytic inclusions 
Genetic molecular 
analysis 
- A COL4A3, COL4A4, or COL4A5 
mutation 
 
* Combination of unexplained hematuria and at least three of the four criteria must be observed for 
clinical diagnosis of AS to be made. ** Combination of at least four of the ten criteria must be 
observed for diagnosis of AS to be made in an individual without family history; probable diagnosis 
of AS is made if family history is positive and one additional criterion is observed; definitive 
diagnosis of AS is made if family history is positive and two additional criteria are observed. CRF: 
Chornic renal failure. ESRD: End-stage renal disease. GBM: Glomerular basement membrane. 
EBM: epidermal basement membrane. SNHL: sensorineural hearing loss. † This criterion is now 
known to be diagnostic of Epstein and Fechtner syndromes, caused by a pathogenic MYH9 
mutation; thus excluding the diagnosis of Alport syndrome. 
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1.2. Prevalence 
AS is one of the most frequent hereditary causes of end-stage renal 
disease (ESRD). The most widely used estimate of the prevalence of AS is 
1:5,000 live births, based on the finding of about 300 cases in Utah and southern 
Idaho in a population of 1,500,000 people (Hasstedt and Atkin 1983). According to 
the United States Renal Data System (USRDS), approximately 0.2% of adults and 
3% of children in the United States with ESRD carry a diagnosis of AS (United 
States Renal Data System. Annual Data Report 2008. USRDS - ADR. Available at 
http://www.usrds.org/adr.htm. Accessed June 19, 2013). In Europe, AS accounts 
for 0.56% of patients starting renal replacement therapy (RRT) (Rigden, Mehls et 
al. 1996; Levy and Feingold 2000; System, Health et al. 2010). The incidence of 
AS was found to be 1:53,000 in Finland (Pajari, Kaariainen et al. 1996), and 
1:17,000 in southern Sweden (Persson, Hertz et al. 2005). 
 
1.3. Clinicopathologic features 
 
“For decades, the syndrome was diagnosed solely based on  
its clinical manifestations.” 
(Khoshnoodi, Pedchenko et al. 2008) 
 
Collagen type IV-related nephropathies – a group of kidney diseases 
encompassing AS and Benign Familial Hematuria / Thin Basement Membrane 
Nephropathy (BFH/TBMN; MIM#141200) –, are hereditary glomerulopathies with 
three different inheritance patterns: X-linked, autosomal recessive and autosomal 
dominant. X-linked AS (XLAS; MIM#301050) explain approximately 80-85% of 
families with AS (Flinter, Cameron et al. 1988), while autosomal recessive AS 
(ARAS; MIM#203780) occurs in about 10-15% of families. An autosomal dominant 
inheritance pattern has been observed in around 5% of families with AS (ADAS; 
MIM#104200).  
Since intrafamilial variability occurs, following examination of the proband 
and relatives, at least three out of four clinical criteria, as defined by Flinter and 
colleagues (1988) should be present (Flinter, Cameron et al. 1988) (Table I). 
Methodic investigation searching for a positive family history is important, as 
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patients are often not aware of the presence or severity of the disease in relatives. 
Urinalysis, audiological and ophthalmological examinations of parents and other 
first-degree relatives of a patient with unexplained hematuria will often be 
informative (Savige, Gregory et al. 2013). When diagnostic criteria are satisfied 
within a family, the pedigree should be studied to define the mode of inheritance of 
AS. When facing a patient with clinical diagnosis of AS and without evidence of 
family history of hematuria or CRF, both the occurrence of a de novo pathogenic 
COL4A5 mutation, which is observed in 10-15% of males with XLAS, and ARAS 
should be considered (Kruegel, Rubel et al. 2013). 
 
1.3.1. Impaired renal function 
 
X-linked Alport syndrome in males 
In XLAS, males often present with urinary abnormalities during childhood, 
the renal function gradually declines and ESRD is reached in late adolescence or 
young adulthood. In one third of males affected with XLAS, macrohematuria is 
observed during the course of an infectious event or a physical effort, at an 
average age of 3 years old (Flinter 1997) and all affected males have persistent 
microhematuria. These observations make hematuria the most prominent familial 
trait of the syndrome (Flinter, Cameron et al. 1988; Jais, Knebelmann et al. 2000). 
As a consequence, a 5 years old boy with consistent absence of hematuria in 
repeated urinalysis is very unlikely to develop AS (Flinter, Maher et al. 2003). 
Nearly all affected males develop proteinuria and become nephrotic, developing 
hypertension during adolescence (Grunfeld 1985; Kashtan and Michael 1996). 
Proteinuria does not precede hematuria (Firth and Hurst 2007). However, it may 
be the first sign to be noticed, as well as hearing loss, hypertension, end-stage 
renal disease (ESRD) or leiomyomatosis (Jais, Knebelmann et al. 2000). In the 
end, virtually all males with XLAS will develop ESRD. Two phenotypic types of AS 
were initially defined, according to the age of onset of ESRD: a “juvenile” type, in 
which male patients reach ESRD at an average age of 31 years or lower, and an 
“adult” type, in which ESRD develops only after 31 years (Schneider 1963). Extra-
renal involvement was reported to be more frequently observed in “juvenile” type. 
However, with increasing knowledge in genotype-phenotype correlations, this 
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classification was rendered to more reliable diagnostic methods for genetic 
counselling, management and prognosis. Although inter- and intra-familial 
variability exists regarding the age at ESRD, 51%, 76.5% and 94% of males 
patients carrying a pathogenic COL4A5 mutation reach ESRD before 20, 31 and 
41 years old, respectively (Jais, Knebelmann et al. 2000).  
 
X-linked Alport syndrome in females 
Among females with XLAS, the clinical course is extraordinarily variable, 
presumably due to the X-chromosome inactivation (Rheault 2012). Somatic 
mosaicism in XLAS may also account for some cases of apparent non-penetrance 
in female carriers (Bruttini, Vitelli et al. 2000; Plant, Boye et al. 2000). More than 
90% of females with molecularly confirmed XLAS manifested microscopic 
hematuria (Jais, Knebelmann et al. 2003). However, since it may be intermittent in 
the great majority of females, several urinalyses should be performed before 
excluding its occurrence. Macroscopic hematuria presents in around 35% of 
females with XLAS at an average age of 9 years and one-third develop 
hypertension (usually in middle-age) (Flinter 1997). Approximately 12% of females 
with XLAS develop ESRD before age 40 years, increasing to 30% by age 60 years 
and 40% by age 80 years (Jais, Knebelmann et al. 2003). Accordingly, whenever 
XLAS is molecularly confirmed in a female relative and she is being considered for 
living related kidney donation for transplant, the risk of the donor developing 
impaired renal function needs to be discussed (Kashtan 1990; Sessa, Pietrucci et 
al. 1995; Kashtan 2009; Rheault 2012). Proteinuria should be an exclusion 
criterion and even female donors with isolated microhematuria should be aware of 
an increased risk of CRF (Gross, Weber et al. 2009; Savige, Gregory et al. 2013). 
 
Autosomal recessive Alport syndrome: patients and carriers 
In ARAS, the course of the disease is similar to the affected males with 
XLAS, in both males and females. In particular, most patients who are affected 
with ARAS develop significant proteinuria in late childhood or early adolescence 
and ESRD before age 30 years (Kashtan and Michael 1996). An autosomal 
recessive inheritance pattern is suggested by parental consanguinity, by evidence 
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of equally severely affected male and female siblings at a young age and by 
occurrence of severe manifestations of the disorder in only one generation. 
The parents of affected individuals with ARAS may develop isolated 
microscopic hematuria, although not manifesting hearing loss or ocular signs of 
the disease (Dagher, Buzza et al. 2001). Still, ARAS carriers show normal 
urinalysis in approximately half of the cases. A diagnosis of TBMN is established, 
in an ARAS carrier, when besides presenting with microscopic hematuria, 
associated or not with mild proteinuria, a thin GBM is visualized by electron 
microscopy on renal biopsy, an ultrastructural finding also observed as a normal 
variant in 5-10% of the population (Firth and Hurst 2007). TBMN is genetically 
heterogeneous, being caused by heterozygous pathogenic mutations in the 
COL4A3 and COL4A4 in 40-50% of the affected families and being transmitted in 
an autosomal dominant pattern, where male-to-male transmission may occur 
(Temme, Peters et al. 2012). Although TBMN was initially thought to be benign 
with excellent prognosis, the reason why it was previously called BFH, the work of 
two independent groups revealed that it was not indeed a benign disorder and that 
it should be the subject of annual long term follow-up (Voskarides, Damianou et al. 
2007; Marcocci, Uliana et al. 2009). In some families with TBMN, it may be 
observed progression to CRF. In autosomal dominant AS (ADAS), age of onset of 
ESRD is later and progression may be more insidious than in ARAS (Kashtan and 
Michael 1996; Flinter, Maher et al. 2003). In summary, the spectrum of renal 
manifestations in ARAS carriers is wider and less benign than previously thought, 
as these individuals may express a gradient in severity of urinary abnormalities 
(hematuria with or without proteinuria) and renal function deterioration that may 
progress with age to ESRD. So, similarly to what is observed in XLAS females, 
due to the risk of progressive chronic kidney disease (CKD) with increasing age, 
long-term yearly follow-up of patients with BFH/TBMN by a nephrologist is advised 
(Temme, Peters et al. 2012).  
 
Treatment of renal manifestations 
Several therapeutic approaches proved effective in the treatment and 
prevention of renal manifestations. Pharmacologic inhibition of the renin-
angiotensin-aldosterone system by using angiotensin-converting enzyme (ACE) 
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inhibition and angiotensin receptor blockade (ARB), tested in AS animal models 
and in clinical trials, has been shown to delay renal function impairment (Grodecki, 
Gains et al. 1997; Gross, Beirowski et al. 2003; Gross, Schulze-Lohoff et al. 2004). 
ACE inhibitors and/or ARBs should be administered to patients with AS who have 
proteinuria with or without hypertension. Both classes of drugs apparently help to 
reduce proteinuria by decreasing intraglomerular pressure. In children with AS and 
CKD, the decline in renal function is lower in those receiving ACEI and intensified 
blood-pressure control (Wuhl, Mehls et al. 2004; Wuhl, Trivelli et al. 2009). 
Moreover, the inhibition of angiotensin II, a growth factor that is implicated in 
glomerular sclerosis, can slow sclerotic progression. Furthermore, molecular 
genetic diagnosis before the onset of proteinuria would theoretically allow early 
effective medical intervention (Gross and Kashtan 2009). Also in females with 
XLAS who consider kidney donation, the risk of developing CRF might be 
minimized by post-transplant nephroprotective strategies (Gross, Weber et al. 
2009). Cyclosporine treatment is not recommended due to its nephrotoxicity and 
the transient effect on proteinuria reduction (Charbit, Gubler et al. 2007; Massella, 
Muda et al. 2010).  
Dialytic therapy and, ultimately, kidney transplantation, are usually offered to 
patients developing ESRD secondary to AS (Kashtan, McEnery et al. 1995; 
Haberal, Emiroglu et al. 2001; Byrne, Budisavljevic et al. 2002). This is due to 
several reasons: (i) renal transplantation significantly increases AS patients 
survival (Gobel, Olbricht et al. 1992; Karakayali, Pehlivan et al. 2008); (ii) recurrent 
disease does not occur in the transplanted kidney; (iii) the allograft survival rate in 
these patients is similar to that in patients with other renal diseases. However, 
post-transplant anti-glomerular basement membrane (anti-GBM) antibody 
nephritis, although rare, occurs in 1-5% of transplanted AS patients (Milliner, 
Pierides et al. 1982; Brainwood, Kashtan et al. 1998), increasing the risk of 
recurrence of this complication in this group of patients. 
Biological treatment is under investigation and includes mainly two types: 
gene and cell based therapies. GBM reparation is the principal aim of biological 
treatment, since renal disease may be the only life-threatening complication of AS. 
Absence of life-threatening extra-renal manifestations turns the GBM of AS 
patients into the key target for gene therapy for several reasons: (i) the therapy 
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can be targeted solely at the kidney, with a specific circulatory system, decreasing 
systemic side effects; (ii) the turnover of type IV collagen is fairly slow, with a more 
than one year half-life. A lesson that was learnt from carriers is that concomitant 
expression of abnormal gene product is not an obstacle for gene therapy. Despite 
encouraging results in animal model studies, several issues need to be overtaken 
before translation of gene therapy into clinical practice (Heikkila, Tryggvason et al. 
2000), including: (i) availability of an appropriate gene delivery system into cells of 
renal glomeruli; (ii) expression of the delivered type IV collagen gene in those 
cells; (iii) proper post-translational modifications and folding of the respective α(IV) 
chains which facilitate intracellular association into an α3α4α5(IV) triple helical 
molecule; (iv) incorporation of those heterotrimers, extracellulary, into the GBM, 
which could restore the deteriorated GBM structure (Heikkila, Tibell et al. 2001); 
(v) greater knowledge of the regulation of the genes requiring treatment 
(Tryggvason, Heikkila et al. 1997). Regarding cell based therapy, bone marrow-
derived stem cells were shown to improve renal histology and function in COL4A3 
knockout mice (Prodromidi, Poulsom et al. 2006; Sugimoto, Mundel et al. 2006; 
LeBleu, Sugimoto et al. 2009). Mesenchymal stem cell therapy however was not 
proved to delay onset of end-stage renal disease (Ninichuk, Gross et al. 2006). 
The available experimental data on biological treatment antecipate a further 
therapeutic approach to AS patients, as soon as risks are addressed and prove to 
be minimal (Gross and Kashtan 2009). Furthermore, success of clinical trials will 
benefit from further efforts in gathering detailed information about the natural 
history of the disease, in order to show treatment efficacy by identifying a change 
in the disease natural course. The “European Alport Registry” and the “Alport 
Syndrome Treatments and Outcomes Registry (ASTOR)” aim to be large 
databases of AS patients followed in multiple centers, in Europe and North 
America, respectively. The active maintenance of both databases will be decisive 
for the development of future clinical trials (www.clinicaltrials.gov). 
 
1.3.2. Impaired renal and skin structure 
Renal biopsy from AS patients reveals characteristic, although not specific 
immunohistochemical and ultrastructural changes (Mazzucco, Barsotti et al. 1998; 
Mazzucco, De Marchi et al. 2002). Indications for renal biopsy are controversial; 
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however, when there is a clear familial segregation of microscopic hematuria, 
intermittent or persistent (>6 months), obtaining a kidney biopsy from an affected 
individual may be extremely informative, preventing the need of additional kidney 
biopsies in other affected family members.  
Focal thinning of the lamina densa of the GBM in childhood is the first 
ultrastructural change, however it may be mistaken with TBMN, which may have a 
benign course (Grunfeld 1985). A renal biopsy of a patient with AS, performed at 
an older age, usually shows progressive widespread of characteristic 
ultrastructural findings of AS (Cangiotti, Sessa et al. 1996). Often indicated as 
pathognomonic, AS specific GBM changes include areas of GBM thinning and 
thickening, splitting and splintering of its lamina densa and entrapment of electron-
dense granules within electron lucent areas of the GBM (Hinglais, Grunfeld et al. 
1972; Spear and Slusser 1972) (Figure 1). The severity of GBM splitting correlates 
with degree of proteinuria and is indicative of progressive disease course (Rumpelt 
1980; Basta-Jovanovic, Venkataseshan et al. 1990). Due to the diagnostic and 
prognostic information given by electron microscopy examination of a renal biopsy 
from a patient suspected of having AS, it is crucial that pathologists search for 
ultrastructural changes, specifically those typical of AS. Light microscopy is helpful 
solely in excluding diferential diagnosis (Pirson 1999).  
Immunohistochemical analyses of collagen type IV expression in renal or 
skin biopsies are helpful diagnostic criteria. In the majority of males with XLAS, 
α5(IV) chains are lacking in the GBM. It is often found that α3(IV) and α4(IV) chain 
are simultaneously absent, since inability to synthesize α5 (IV) chains interferes 
with the assembling of α3α4α5 heterotrimers. In XLAS females, due to random 
inactivation of one X chromosome during the embryonic period, some cells will 
express α5(IV) chains necessary for the assembly of α3α4α5 triple helix of type IV 
collagen (Pirson 1999). As a result of the mosaic expression of α5(IV) chains, 
females (heterozygotes) show a patchy distribution of the collagen triple helix, in 
contrast with males (hemizygotes) who present a homogeneous co-absence of α-
chains. Immunohistochemical analysis distinguishes XLAS from ARAS, because, 
in the latter, although there is absence of α3(IV) and α4(IV) chains, α5 (IV) chains 
are produced (Pirson 1999). Although not detectable in the GBM, they are 
visualized in Bowman’s capsule and tubuli basement membranes. The failure of 
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anti-GBM antibodies to bind to the GBM in patients with AS can be diagnostically 
useful, but has limited sensitivity and specificity (Mazzucco, Barsotti et al. 1997).  
 
 
Figure 1. Photograph of the GBM ultrastructure of a patient with ARAS (25 
years), showing alternating thinning (Tn), thickening (Tc) and lamellation (L) of the 
GBM with electrondense bodies (EB) surrounded by a halo [courtesy of Dr. 
Susana Sampaio, Unit of Renal Morphology, Department of Nephrology, São João 
Hospital Centre, Porto, Portugal]. 
 
In skin biopsies of individuals affected with XLAS, expression of α5(IV) 
chains in the EBM is similar to the observed in GBM. Absence of α5(IV) 
expression in the EBM of a male patient, or clearly mosaic α5(IV) expression in a 
female, suggests the diagnosis of XLAS. However, a discordant pattern with 
α5(IV) present in the EBM and absence in the GBM has been reported (Naito, 
Nomura et al. 1997). Importantly, normal expression of collagen type IV chains in 
the EBM does not exclude AS. Normal skin reactivity to α5(IV) chains antigens 
occurs in: (i) EBM of patients with ARAS, since only α3(IV) or α4(IV) chains are 
lacking (Gubler, Knebelmann et al. 1995); (ii) patients carrying a pathogenic 
COL4A5 mutation which allows skin expression of α5(IV) chains. So, although 
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defective, all α3, α4 and α5(IV) chains may be present in X-linked and autosomal 
AS. Therefore, when α5(IV) chains are detected in the EBM, it is advisable to 
perform a renal biopsy to confirm whether the typical ultrastructural features of AS 
are observed (Kashtan 1999). On the other hand, immunohistochemical studies 
may be particularly helpful when standard electron microscopy examination of the 
GBM has given equivocal results (Flinter, Maher et al. 2003). The combination of 
electron microscopy and immunohistochemical studies enabled a diagnosis of AS 
in 92% of a cohort of 108 Italian patients (Mazzucco, Barsotti et al. 1998). 
 
1.3.3. Sensorineural hearing loss 
In the majority of XLAS and ARAS families, hematuria and CRF are 
accompanied by sensorineural hearing loss (SNHL) in the range of 2,000-8,000 
Hz. According to Jais and colleagues, the proportion of XLAS males with SNHL is 
approximately 79% (Jais, Knebelmann et al. 2000). In XLAS females, SNHL is 
less frequent (Jais, Knebelmann et al. 2003). High-frequency SNHL may be 
asymmetrical, but is often bilateral. It is not present at birth and becomes apparent 
in late childhood or early adolescence, at an average age of 11 years old, in male 
patients with XLAS and patients with ARAS, and only exceptionally before 20 
years old in females with XLAS (Flinter 1997; Jais, Knebelmann et al. 2003). 
SNHL may begin in adulthood in some families with autosomal dominant and X-
linked inheritance patterns of AS (Barker, Pruchno et al. 1996).  
SNHL is associated with the deterioration of renal function (Alves and 
Ribeiro Fde 2008). Consequently, its progression may be slowly and not easily 
perceptible during childhood, rapid in teens (especially in XLAS males and ARAS) 
and often reaches a plateau (Grunfeld 1985). SNHL may extend to lower 
frequencies and interfere with frequencies of conversational speech (Myers and 
Tyler 1972). However, patients do not usually become completely deaf. Hearing 
aids often show limited effectiveness (Flinter, Maher et al. 2003). Occasionally, 
there is some improvement in hearing post-transplant (Mitschke, Schmidt et al. 
1975; McDonald, Zincke et al. 1978), but this may be secondary to the treatment 
of uremia (Mitschke, Schmidt et al. 1977). Since tonal audiometry detects SNHL 
before it is self-noticed, it should be performed in the evaluation of the affected 
patient and first degree relatives with suspected AS. Likewise, formal assessment 
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of hearing is indicated in any patient with unexplained hematuria. Conversely, a 
patient with SNHL with childhood or later onset should be investigated for urinary 
hematuria and CRF, as occasionally awareness of hearing problems may precede 
recognition of hematuria or other evidence of renal disease, and hearing 
impairment in members of families with AS is always accompanied by evidence of 
renal involvement (Flinter, Maher et al. 2003; Alves and de 2005; Alves and 
Ribeiro Fde 2008).  
 
1.3.4. Ocular abnormalities 
Ocular signs were observed in up to 72% of males and 38% of females with 
XLAS (Jais, Knebelmann et al. 2000; Dagher, Buzza et al. 2001; Jais, 
Knebelmann et al. 2003). Autosomal dominant inherited forms of AS are usually 
not associated with the characteristic ophthalmological signs, although ARAS may 
be (Colville, Savige et al. 1997; Colville and Savige 1997). The most frequent 
ocular findings associated with AS are central or peripheral dot-and-fleck 
retinopathy and anterior lenticonus (Sabates, Krachmer et al. 1983; Hentati, 
Sellami et al. 2008), which were observed in 30% and 15-20% of patients, 
respectively (Pirson 1999). They are not congenital, usually presenting in 
adolescents or young adults, in parallel with the decline in renal function (Jais, 
Knebelmann et al. 2000; Flinter, Maher et al. 2003). Lenticonus and retinopathy 
were first noted in 14 and 11 year olds, respectively (Zhang, Colville et al. 2008). 
Lesions of the cornea, as corneal endothelial vesicles (similar to posterior 
polymorphous dystrophy) and recurrent corneal erosion (RCE), occur more rarely 
(Snyers, Rhys et al. 1996; Bower, Edwards et al. 2009; Seymenoglu and Baser 
2009). Patients with posterior polymorphous dystrophy should be examined for 
renal abnormalities and hearing loss (Teekhasaenee, Nimmanit et al. 1991). RCE 
has to be considered as an additional ocular manifestation of AS, with a 
prevalence of 15 to 21%. Ophthalmologists should also be aware of this 
association, when confronted with a patient suffering from non-traumatic RCE. 
(Snyers, Rhys et al. 1996; Rhys, Snyers et al. 1997). The demonstration of a dot-
and-fleck retinopathy in any individual with a family history of AS or with end-stage 
renal disease is diagnostic of AS. The presence of anterior lenticonus or posterior 
polymorphous corneal dystrophy in any individual is highly suggestive of the 
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diagnosis of AS (Colville and Savige 1997). Additional ocular features described in 
XLAS include other corneal dystrophies, microcornea, arcus, iris atrophy, 
cataracts, spontaneous lens rupture, spherophakia, posterior lenticonus, poor 
macular reflex, fluorescein angiogram hyperfluorescence, electrooculogram and 
electroretinogram abnormalities, and retinal pigmentation (Colville and Savige 
1997). These findings underline the great variation of ocular disorders related to 
AS (Herwig, Eter et al. 2011). Consequently, the assistance of an interested 
ophthalmologist is invaluable in the diagnosis of AS (Savige and Colville 2009). 
The main lens abnormalities reported in patients with AS are anterior 
lenticonus, cataracts and spontaneous anterior capsular rupture. Anterior 
lenticonus was considered by some authors a pathognomonic sign of AS (Cheong, 
Kashtan et al. 1994), as more than 90% of cases of anterior lenticonus are 
associated with AS (Junk, Stefani et al. 2000). Consequently, any patient 
presenting with anterior lenticonus should be methodically investigated for 
microhematuria, CRF, SNHL and family history of any of these manifestations 
(Hild, Walter et al. 2009). Often bilateral and manifesting in early adulthood around 
the time the kidneys fail, anterior lenticonus is a conical or spherical protrusion of 
the anterior surface into the anterior chamber (Jacobs and Meire 2000; Junk, 
Stefani et al. 2000). Conversely, posterior lenticonus, often occurring in young 
children, unilaterally, sporadically and without association with systemic features, 
is not considered a specific sign of AS. Only rarely it is found bilaterally in patients 
with AS (Bhatnagar, Kumar et al. 1990; Sukhija, Saini et al. 2003; Vedantham, 
Rajagopal et al. 2005; Al-Mahmood, Al-Swailem et al. 2010). An “oil droplet” reflex 
is a typical sign of anterior lenticonus observed by direct ophthalmoscopy; slit lamp 
and biomicroscopy examination detect both anterior and posterior lenticonus 
(Jacobs and Meire 2000; Junk, Stefani et al. 2000). Anterior lenticonus may lead 
to visual impairment due to progressive myopia, anterior capsular cataract, or 
spontaneous rupture of the anterior lens (Olitsky, Waz et al. 1999; Flinter, Maher 
et al. 2003; Hild, Walter et al. 2009).  
Retinal changes have been recognized for more than 60 years in patients 
with AS and may occur alone or in combination with anterior lenticonus or lens 
opacities (Fehmers and Croughs 1964; Reynolds 1964; Unger and Rother 1964). 
Retinal abnormalities include a perimacular dot-and-fleck retinopathy and a 
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peripheral fleck retinopathy, which might occur independently of each other; a 'dull 
macular reflex' or 'lozenge', when the perimacular flecks are confluent; and, rarely, 
a macular hole caused by retinal thinning (Savige and Colville 2009). The macular 
lesions observed in patients with AS are typically characterized by yellowish or 
whitish areas, which may vary from mainly pigmentary (“dots”) to mainly adjoining 
depigmented areas (“flecks”) within the macular and midperipheral regions of the 
retina (McCarthy and Maino 2000). In XLAS and ARAS the peripheral retinopathy 
occurs even when the central retinopathy is absent (Shaw, Colville et al. 2007). 
Clinicians must be aware that the "lozenge" or "dull macular reflex" described in 
AS is not a normal variant but reflects a severe, almost confluent perimacular dot 
and fleck retinopathy. This sign is useful diagnostically and also prognostically, 
since it is associated with early-onset renal failure (Colville, Wang et al. 2009). In 
contrary to the anterior lenticonus, retinal changes are rarely associated with 
visual impairment (Spraul and Lang 2000). Macular flecks in AS are not 
associated with demonstrable retinal dysfunction (Gehrs, Pollock et al. 1995). 
Retinal abnormalities will be more evidently seen using a hand-held 
ophthalmoscope (fundoscopy), which may be complemented or replaced by 
bilateral ocular fundus photography (retinography), with the advantage of being 
analysed by several professionals at another location and/or time (for example, 
when monitoring the progression of the retinopathy). Careful retinal examination 
and photography that includes the periphery is a safe and inexpensive method that 
may help in the diagnosis of AS especially in carriers of X-linked disease (Shaw, 
Colville et al. 2007). Optical coherence tomography (OCT) has the powerful 
advantage that measurements can be performed over a period of time to 
longitudinally study disease progression (staging of ocular disease). Temporal 
macular thinning is a prominent sign associated with XLAS, suggesting that OCT 
measurements are essential in the diagnosis and prognosis of the disease. The 
pathological basis for the retinal abnormalities of XLAS remains to be established 
(Ahmed, Kamae et al. 2013). Hence, retinal OCT is a powerful technique to track 
the early stages of this disease in order to contribute to a better understanding of 
pathogenesis. 
Although the identification of ocular signs of AS is not mandatory for the 
clinical diagnosis of the disease, eye examination (particularly of adult individuals) 
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may recognize abnormalities of the retina, the lens and the cornea which are 
typical of AS, enabling diagnosis and prognosis of the disease (Hentati, Sellami et 
al. 2008; Zhang, Colville et al. 2008; Xu, Zhang et al. 2010). Furthermore, 
diagnosis of ocular manifestations is crucial for an early surveillance and effective 
therapeutic intervention (Blaise, Delanaye et al. 2003). Regarding the treatment of 
the principal causes of visual impairment in patients with AS: (i) 
phacoemulsification and intraocular lens implantation, rather than correction of 
refractive errors, is a safe and efficient therapeutic choice for the management of 
anterior lenticonus secondary to AS, with or without associated cataract (Chung, 
Lin et al. 2007) (Zare, Rajabi et al. 2007) (Aslanzadeh, Gharabaghi et al. 2008) 
(Liu, Tan et al. 2008) (Seymenoglu and Baser 2009); (ii) routine treatment of 
cataracts is adequate (Kashtan 1993); (iii) assure cornea protection from minor 
trauma to avoid recurrent corneal erosions (Kashtan 1993). 
 
1.3.5. Diffuse leiomyomatosis 
Alport syndrome and diffuse leiomyomatosis (ATS-DL; MIM#308940) is a 
rare clinical association of benign nodular smooth muscle tumors of esophagus, 
tracheo-bronchial tree, and genital tract with XLAS manifestations (Miner 1999). 
This clinical entity was first described by Garcia-Torres in 1975 at the Sixth 
International Congress of Nephrology (Firenze, Italy), but only published in 1983 
(Garcia Torres and Guarner 1983). It is likely that, at least, two formerly 
published reports already referred to this association (Johnston, Clagett et al. 
1953; Kenney 1953). Diffuse leiomyomatosis, although rare, is a significant 
extra-renal cause of morbidity occurring in XLAS patients, both in children and in 
adults (Van Loo, Vanholder et al. 1997). ATS-DL has been regarded as a 
contiguous gene deletion syndrome, caused by deletions partially involving the 
COL4A5 and COL4A6 genes. 
Leiomyomatosis is fully penetrant, both in males and females, while XLAS 
is fully penetrant in males, but has a lower penetrance in females (Dahan, Heidet 
et al. 1995). At least one female has already been reported who presented with DL 
but without signs of nephropathy, in whom a typical causative mutation of ATS-DL 
was found (Dahan, Heidet et al. 1995). Therefore, females with apparently isolated 
leiomyomatosis can be heterozygous for ATS-DL, their sons having a 50% risk of 
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developing ATS-DL, their daughters having a 50% risk of developing 
leiomyomatosis in association with variable degrees of severity of renal and extra-
renal AS manifestations (Dahan, Heidet et al. 1995). 
The clinical expression of ATS-DL is variable, even within the same family 
(Van Loo, Vanholder et al. 1997). The prognosis of ATS-DL depends as much on 
the location of the leiomyomas as on the nephropathy (Cochat, Guibaud et al. 
1988). Typically, leiomyomatosis affects gastrointestinal, respiratory and female 
reproductive systems. The esophageal component is usually the first manifestation 
(Le Bras, David et al. 1998), being reported as earlier as 30 months of age 
(Cochat, Guibaud et al. 1988). Gastrointestinal symptoms can include dysphagia, 
odynophagia and retrosternal pain, regurgitation, and bleeding. (Lerone, Dodero et 
al. 1991). The diagnosis of esophageal leiomyomatosis may be delayed or may be 
mistaken as achalasia, based on the clinical presentation and the results of 
radiographic studies, endoscopy, and manometry (Leborgne, Le Neel et al. 1989; 
Legius, Proesmans et al. 1990; Rabushka, Fishman et al. 1991; Garcia-Torres and 
Orozco 1993). Leiomyoma of the esophagus must be included in the differential 
diagnosis of the mediastinal masses or when achalasia is considered as a 
diagnostic possibility in children (Bourque, Spigland et al. 1989).  
Leiomyoma is the most common benign tumor of the esophagus (Bourque, 
Spigland et al. 1989). Leiomyomatosis associated with XLAS may be differentiated 
from sporadic esophageal leyomiomas, regarding the following clinical 
characteristics: (1) Age of onset: leiomyomas associated with AS are usually 
diagnosed in the pediatric population (mean age 14 years, range 4 to 20 
years)(Bourque, Spigland et al. 1989), as opposed to isolated leiomyomas, usually 
diagnosed in the adult population (mean age 44 years; no patient was <12 years 
of age)(Seremetis, Lyons et al. 1976); (2) Sex ratio: in ATS-DL, leiomyomatosis 
appears 1.71 times more often in females than in males (Bourque, Spigland et al. 
1989), while in the general population the female:male ratio is 1:1.9 (Seremetis, 
Lyons et al. 1976); (3) Extent of lesions: in ATS-DL, localized lesions are found in 
only 9%, whereas the diffuse form predominates in 91% (Bourque, Spigland et al. 
1989), as opposed to the occurrence of only one tumor of variable size in the 
absence of ATS-DL (Seremetis, Lyons et al. 1976); (4) Location of lesions: in ATS-
DL, the entire esophagus may be involved 35% of the time, and encroachment on 
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the cardia or upper stomach occurs in 70% (Bourque, Spigland et al. 1989), 
whereas, in a localized form of leiomyomatosis, the preferential location was the 
lower third of the esophagus, situated intramurally. Of note, the early age of onset 
of leiomyomatosis and its diffuse distribution are in keeping with its genetic 
etiology. 
The genital manifestations are usually confined to women, typically 
involving the perineum. Because unusual, a combination of leiomyoma of vulva 
and esophagus (MIM#150700) should prompt search for other features of AS in 
the female patient herself or in male relatives (Cochat, Guibaud et al. 1988). 
Lesions can extend posteriorly to involve the rectum (Lerone, Dodero et al. 1991) 
and anteriorly to the vesical collar. Urethral leiomyomas have also been reported. 
In addition, uterine leiomyomas may occur in these patients (Cooper, Patterson et 
al. 1999).  
Tracheobronchial leiomyomatosis is barely symptomatic. Histologic 
examination of relevant autopsy samples of three ATS-DL patients, disclosed 
extensive leiomyomas engulfing the trachea and stem bronchi (Cochat, Guibaud 
et al. 1988). Nonetheless, when symptomatic, it usually presents as paroxysmal 
dyspnea, mimicking asthma, and it may be lethal due to bronchospasm (Le 
Bras, David et al. 1998). When there is tracheobronchial involvement, careful 
endoscopic examination probably should be carried out because of the risk of 
sudden death (Cochat, Guibaud et al. 1988). Potentially fatal pulmonary 
complications have been observed in several patients and were attributed to 
tracheobronchial localization of leiomyomas (Garcia Torres and Guarner 1983; 
Van Loo, Vanholder et al. 1997). This diagnosis should be considered not only 
in the presence of esophageal leiomyomas in the child but also when hereditary 
nephritis is associated with digestive or respiratory signs (Cochat, Guibaud et al. 
1988). 
In summary, a timely diagnosis is important, in view of the morbidity and 
the inheritance pattern of the disease (Van Loo, Vanholder et al. 1997). Patients 
with AS should be examined for signs of leiomyomatosis and vice versa (Van 
Loo, Vanholder et al. 1997). Visceral leiomyomatosis is exceptional in children 
outside of the context of ATS-DL. In view of the important clinical and genetic 
implications, renal function and urinary status should be controlled in any patient 
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with esophageal leiomyomatosis. Conversely, the possibility of ATS-DL should 
be considered in AS patients with dysphagia (Van Loo, Vanholder et al. 1997).  
 
1.3.6. Differential Diagnosis 
The most common hereditary cause of hematuria progressing to ESRD is 
AS. However, clinical diagnosis of AS remain challenging due to age-dependent 
and gender-related expression of manifestations. In children, differentiation 
between TBMN and AS can be difficult, because both disorders manifest by 
persistent hematuria and thin GBM at that age (Lemmink, Schroder et al. 1997). 
Additional etiologies of glomerular hematuria include a number of chronic 
glomerulopathies (Table II). In the child with no known family history of hematuria, 
the most likely diagnoses are IgA nephropathy, TBMN, AS, and 
membranoproliferative glomerulonephritis (Kashtan 1993). In addition, glomerular 
disorders including IgA nephropathy and focal segmental glomerulosclerosis may 
occur in individuals with TBMN (Norby and Cosio 2005). In a child with family 
history of hematuria and/or CKD, the causes of familial hematuria are TBMN and 
AS, MYH9-related disorders – previously known as Epstein syndrome, Fechtner 
syndrome, May-Hegglin anomaly, Sebastian syndrome (Arrondel, Vodovar et al. 
2002) –, CFHR5-Related Dense Deposit Disease (DDD), glomerulopathy with 
fibronectin deposits and occasional familial cases of IgA nephropathy. Molecular 
genetics is crucial in discriminating the precise etiologic diagnosis when a patient 
presents with familial hematuria progressing to ESRD (Deltas, Pierides et al. 
2013). 
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Table II. Differential diagnosis of hereditary nephritis syndromes of glomerular origin. 
 
 Collagen IV-related nephropathies MYH9-Related Disorders CFHR5 Nephropathy  Glomerulopathy with 
fibronectin deposits 
Alport 
syndrome 
TBMN ATS-DL ATS-MR  
/ AMME 
Epstein 
syndrome 
Fechtner 
syndrome 
C3 
Glomerulonephritis 
 
Gene(s) COL4A3 
COL4A4 
COL4A5 
COL4A3 
COL4A4 
Contiguous 
deletion of 
COL4A5 and 
COL4A6 
Contiguous 
deletion 
including 
COL4A5 
MYH9 MYH9 CFHR5 FN1 
Genetic loci 2q36.3 
Xq22.3 
2q36.3 Xq22.3 Xq22.3 22q12.3 22q12.3 1q31.3 2q35 
Inheritance 
pattern 
AR, AD, XL AD XL XL AD AD AD AD 
Hematuria 
progressing 
to ESRD 
 
Frequent 
 
 
Rare 
 
Frequent 
 
Frequent 
+ + + + 
Hearing loss + - + + + + - - 
Ocular signs + - + + + + + - 
Ultrastructur
al findings in 
the GBM 
Alternate 
thinning and 
thickening, 
lamellation, 
electron-
dense bodies 
Thinning  Alternate 
thinning and 
thickening, 
lamellation, 
electron-dense 
bodies 
Alternate 
thinning and 
thickening, 
lamellation, 
electron-dense 
bodies 
Irregular 
thickness of 
the GBM 
Irregular 
thickness of 
the GBM 
Segmental, 
discontinuous, or 
diffuse pattern of 
dense deposits in the 
lamina densa 
Mesangial and 
subendothelial 
deposits of fibrils or 
microtubules 
Other 
features 
- - Diffuse 
leiomyomatosis  
 
Mental 
retardation 
Midface 
hypoplasia 
Elliptocytosis 
Congenital 
macrothrombo
cytopenia 
Congenital 
macrothrombo
cytopenia 
Leukocyte 
Inclusions 
Immunohistochemical 
studies (kidney 
biopsy): C3-positive, 
usually in the absence 
of immunoglobulin 
deposition in the GBM 
Immunohistochemical 
studies (kidney 
biopsy): fibronectin 
staining in the 
mesangium and GBM 
TBMN: thin basement membrane nephropathy; ATS-DL: Alport syndrome and diffuse leiomyomatosis; ATS-MR / AMME: Alport syndrome with mental retardation, 
midface hypoplasia and elliptocytosis; XL: X-linked; AR: autosomal recessive; AD: autosomal dominat; + : Clinical sign present; - : Clinical sign absent; GBM: 
glomerular basementmembrane; ESRD: end-stage renal disease.  
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1.4. Molecular genetics and pathogenesis 
 
“In 1990, the role of basement membranes in human disease was established by 
the identification of COL4A5 mutations in Alport's syndrome.”  
(Van Agtmael and Bruckner-Tuderman 2010) 
 
1.4.1. Type IV collagen coding genes  
Genetic defects in genes that code for three of six collagen type IV α-chains – 
COL4A3, COL4A4 and COL4A5 – are the common genetic basis for a 
heterogeneous group of disorders, ranging from AS to TBMN (Table III). Pathogenic 
mutations in COL4A5 result in X-linked inheritance of XLAS, ATS-DL and AMME 
complex. Pathogenic mutations in COL4A3 and/or COL4A4 are the cause of the 
autosomal recessive and the autosomal dominant forms of collagen IV-related 
nephropathies, while pathogenic mutations in COL4A1 (MIM*120130) and COL4A2 
(MIM*120090) are not associated with any of those disorders. 
 
Table III. Location of the human genes coding for α3, α4, α5 and α6 chains of type IV 
collagen. 
Gene MIM number Genetic  
locus 
Genomic coordinates (GRCh37) Protein  
COL4A3 MIM*120070 2q36.3  2: 228,029,280 - 228,179,507 α3(IV) chain 
COL4A4 MIM*120131 2q36.3 2: 227,867,426 - 228,029,274 α4(IV) chain 
COL4A5 MIM*303630 Xq22.3 X: 107,683,073 - 107,940,774 α5(IV) chain 
COL4A6 MIM*303631 Xq22.3 X: 107,398,836 - 107,682,703 α6(IV) chain 
 
These six evolutionarily related mammalian genes code for a family of six long, 
highly homologous polypeptides, designated α1(IV) to α6(IV), with three structurally 
different domains: (i) an amino-terminal 7S domain – thus named for being the 
sedimentation coefficient of the isolated crosslinked tetramer following bacterial 
collagenase treatment of a basement membrane (BM) (Timpl, Risteli et al. 1979; 
Risteli, Bachinger et al. 1980) –, containing a peptide signal and being essential for 
interchain crosslinking of four triple-helical molecules through dissulfide bonds and 
lysine-hydroxylysine crosslinks; (ii) a central collagenous domain, containing glycine-
X-Y repetitions (where X and Y are proline or lysine residues, extensively hydroxy- 
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and glycosylated) separated by a variable number of interruptions, which are 
characteristic of each α-chain and which are responsible for their flexibility within the 
network and for serving as cell-binding sites and interchain crosslinking; and (iii) C-
terminal noncollagenous (NC1) domain, where assembly of heterotrimers starts and 
dimerization of collagen type IV heterotrimers occurs (Table IV) (Hudson, Tryggvason 
et al. 2003; Khoshnoodi, Pedchenko et al. 2008). The crosslinked tetramer is heavily 
glycosylated making it resistant to collagenase activity (Risteli, Bachinger et al. 
1980). 
 
Table IV. Structure of the human α3, α4, α5 and α6 chains of type IV collagen. 
Alpha 
(IV) 
chain 
Chain size 
after 
translation* 
Collagenou
s domain 
size* 
NC1  
domain 
size* 
Number of 
interruptions in 
the collagenous 
domain 
Cysteine 
residues  
(NC1 domain; 
7S+collagenous 
domains) 
α3(IV) 1670 1410 232 23 12; 12 
α4(IV) 1690 1421 231 26 12; 20 
α5(IV) 1685 1430 229 22 12; 8 
α6(IV) 1691 1417 228 25 12; 9 
* Number of amino acids. Adapted from (Khoshnoodi, Pedchenko et al. 2008) 
 
The genes encoding the α1(IV) to α6(IV) chains are organized pairwise with 
head-to-head orientation, the COL4A1 – COL4A2 located at chromosome position 
13q34, the COL4A3 – COL4A4 located at chromosome position 2q36.3, and the 
COL4A5 – COL4A6 located at chromosome position Xq22.3. Due to the genes and 
respective α(IV)-chains similarity, COL4A1, COL4A3 and COL4A5 were grouped into 
α1-like group, while COL4A2, COL4A4 and COL4A6 belong to α2-like group. Based 
on sequence analysis from several mammalian species, Zhou et al. (1994) 
suggested that these gene pairs evolved from a unique gene through three 
consecutive gene duplications (Zhou, Ding et al. 1994). Another characteristic that 
makes type IV collagen unique in the large collagen superfamily is the fact that each 
gene pair shares a bidirectional promoter (Sugimoto, Oohashi et al. 1994; Heikkila 
and Soininen 1996). The bifunctional promoter of COL4A5 and COL4A6 regulates 
the expression of α5(IV) and α6(IV) chains in a distinct cell-specific fashion (Sund, 
Maeshima et al. 2005). Despite extensive studies and identification of the regulatory 
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elements in the promoter regions, the regulation of the differential expression 
collagen IV genes is not well understood (Khoshnoodi, Pedchenko et al. 2008). 
1.4.2. Type IV collagen α-chains and protomers 
The α(IV) chains associate in three different types of triple helical molecules – 
α1α1α2(IV), α3α4α5(IV), α5α5α6(IV) – that make up the building blocks of the 
collagen type IV network in BMs (Hudson, Kalluri et al. 1994; Boutaud, Borza et al. 
2000; Borza, Bondar et al. 2001; Hudson 2004). The α(IV) heterotrimers (which are 
called protomers) assemble in the endoplasmic reticulum, a process starting as result 
of the specific interaction between three NC1 domains that form robust disulfide 
bridges and progressing toward the N terminus (Boutaud, Borza et al. 2000; 
Khoshnoodi, Cartailler et al. 2006). Finally, heterotrimers are secreted to the 
extracellular space, where they interact to form a basket weave collagen type IV 
network. Dimerization of protomers occurs by the interaction of C-terminal domains of 
two heterotrimers, while the N-terminal domain participates in tetramerization of the 
collagen type IV heterotrimers. Other interactions occur between protomer-protomer 
and protomer-extracellular matrix molecules (Vandenberg, Kern et al. 1991; 
Khoshnoodi, Pedchenko et al. 2008). 
 
1.4.3. Type IV collagen networks 
Collagen type IV is a major structural component of human BMs (Khoshnoodi, 
Pedchenko et al. 2008). The BM is a thin layer of specialized extracellular matrix 
found basolaterally to all epithelial and endothelial cell monolayers in the body, which 
compartmentalize tissues and provide important signals for the differentiation of the 
cells they support. BMs are important for the regulation of cell adhesion, migration 
and development and for tissue regeneration and wound healing; are a reservoir of 
growth factors and enzymes; and constitute a molecular sieve, which is a particularly 
important function in the GBM (Khoshnoodi, Pedchenko et al. 2008). In BMs, α(IV)-
chains form a covalently-stabilized supramolecular network polymer, self-assembled 
through complex interactions between the triple helical α(IV)-chain monomers. 
Detailed analyses of high-resolution electron micrographs revealed that collagen 
molecules assemble to form irregular polygonal networks held together 
predominantly by overlapping lateral interactions along the triple-helical domain as 
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well as the N-terminal and C-terminal end-domains (Vandenberg, Kern et al. 1991). 
Supercoil formation by supramolecular twisting is a characteristic feature of lateral 
associations which provides further stability to the BM collagenous network 
(Vandenberg, Kern et al. 1991), important for its function in a complex molecular 
network. Through interactions with specific cellular receptors such as integrins, the 
BM collagen IV networks not only provide structural support to the cells and tissues, 
but they also affect their biological fate during and after development (Khoshnoodi, 
Pedchenko et al. 2008). 
The expression of α(IV) chains is tightly regulated, both temporally and spatially 
(Butkowski, Wieslander et al. 1989; Miner and Sanes 1994; Sugimoto, Oohashi et al. 
1994; Yoshioka, Hino et al. 1994; Gubler, Knebelmann et al. 1995; Ninomiya, 
Kagawa et al. 1995; Peissel, Geng et al. 1995). Unlike the 28 other different types of 
the large collagen superfamily, type IV collagen occurs only in the BMs. Networks 
composed of α1α1α2(IV)-α1α1α2(IV) hexamers are ubiquitously distributed in tissues 
and the first to be expressed during fetal life. It was observed that type IV collagen 
composition of the GBM changes during glomerular development and maturation 
(Abrahamson, Hudson et al. 2009). In some BMs, including the GBM and the tubular 
BM in the kidneys, the alveolar BM in the lungs, and ocular and the cochlear BMs, 
these α1α1α2(IV)-α1α1α2(IV) networks are gradually replaced, since early in the fetal 
development and through adult life, by networks composed of α3α4α5(IV)-
α3α4α5(IV) hexamers (Butkowski, Wieslander et al. 1989). In the BMs of the skin, 
tracheobronchial tree, Bowman’s capsule, and of smooth muscle cells in the 
esophagus and other parts of the gastrointestinal tract, bladder and uterus, a network 
of α1α1α2(IV)-α5α5α6(IV) hexamers is expressed after the embryonic period. In 
comparison to the α1α1α2(IV) network, the α3α4α5(IV) network is more highly 
crosslinked by inter- and intrachain disulfide bonds (Hudson, Kalluri et al. 1992) and 
the switch to a predominant expression of α3(IV), α4(IV) and α5(IV) chains confers to 
the GBM a greater resistance to proteolysis and to the age-related increase of the 
capillary glomerular pressure. In summary, while the α1(IV) and α2(IV) chains are 
present in the BM of all tissues, the remainder α(IV) chains are expressed in tissues 
where its greater structural resistance is required. The α3(IV), α4(IV), and α5(IV) 
chains are expressed in the GBM of the kidney, lung, testis, and eye, whereas the 
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α5(IV) and α6(IV) chains are found in the BM of skin, smooth muscle, and the kidney 
(Khoshnoodi, Pedchenko et al. 2008). 
The developmental switch is abnormal in AS (Kalluri, Shield et al. 1997). In 
males with XLAS or ATS-DL, the α1(IV) and α2(IV) are the predominant α(IV)-chains 
identified by immunohistochemistry of the GBM, a pattern resembling the early 
stages of glomerular development. Most of these patients have no GBM expression 
of α3(IV), α4(IV) and α5(IV), but some COL4A5 mutations allow partial formation of 
α3α4α5(IV) networks, resulting in less severe phenotypes. It has been suggested 
that pathogenic mutations of α3(IV), α4(IV) or α5(IV) might impair the folding and 
assembly of the α(IV) heterotrimers, resulting in their rapid degradation inside the cell 
and arrest of the normal developmental switch, leading to the persistence of 
α1α1α2(IV) networks in the mature GBM (Thorner, Zheng et al. 1996; Kalluri, Shield 
et al. 1997; Harvey, Zheng et al. 1998). Absence of α6(IV) has also been noted in 
renal BMs and the EBMs of XLAS patients, suggesting that the α6(IV) chain cannot 
assemble into these BMs without the α5(IV) chain (Hino, Takemura et al. 1996; Miner 
1999). Irrespective of which gene is affected, mutations that alter normal expression, 
posttranslational modifications or assembly of the α3α4α5(IV) protomers will cause 
an arrest in the developmental switch and persistence of the α1α1α2(IV) network in 
the GBM (Gunwar, Ballester et al. 1998). The differences in their intrinsic physical 
and biological properties most likely underlie the inability of the α1α1α2(IV) network 
to compensate for the lack of the α3α4α5(IV) network in patients with AS (Gunwar, 
Ballester et al. 1998). 
 
1.5. Genotype-phenotype correlations 
The collagen IV-related nephropathies are caused by mutations in any of the 
COL4A5, COL4A4 and COL4A3 genes (Barker, Hostikka et al. 1990). The 
association of diffuse leiomyomatosis and Alport syndrome (ATS-DL) results from a 
contiguous gene deletion with partial loss of the 5’ end of COL4A5 and the first two 
exons of the COL4A6 gene (Cochat, Guibaud et al. 1988; Zhou, Mochizuki et al. 
1993). The association of Alport syndrome with mental retardation, midface 
hypoplasia and elliptocytosis (ATS-MR or AMME; MIM#300194) is another 
contiguous gene deletion syndrome on the same chromosomal locus but, in contrast 
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to ATS-DL, extends in telomeric direction rather than centromerically (Jonsson, 
Renieri et al. 1998; Meloni, Vitelli et al. 2002; Rodriguez, Bhat et al. 2010). 
More than 700, 60 and 90 pathogenic mutations have already been reported 
respectively in COL4A5, COL4A4 and COL4A3 [The Human Gene Mutation 
Database at the Institute of Medical Genetics in Cardiff, 2008. (Available at: 
http://www.hgmd.cf.ac.uk/ac/gene.php?geneCOL4A5. Accessed March 9, 2014)]. 
Other locus-specific databases are: (i) The Alport syndrome COL4A5 variant 
database (http://arup.utah.edu/database/ALPORT/ALPORT_display.php) (Crockett, 
Pont-Kingdon et al. 2010); (ii) COL4A5 homepage - Collagen, type IV, alpha 
(https://grenada.lumc.nl/LOVD2/COL4A/home.php?select_db=COL4A5) (Savige, Ars 
et al. 2013). Pathogenic COL4A5 mutations are found in approximately 80-85% of 
families with clinical diagnosis of AS, while a minority carries pathogenic mutations in 
COL4A3 or COL4A4. Pathogenic COL4A5, COL4A4 and COL4A3 mutations are 
often unique to each family. The nonprivate mutations are probably explained by 
common ancestors (Barker, Pruchno et al. 1996). Pathogenic mutations are 
distributed throughout these genes and include mostly small mutations, as missense, 
nonsense, frameshift and splice site mutations, but also large deletions in 10-15% of 
families. Pathogenic COL4A5 mutations occurred de novo in 10-18% of families 
(Knebelmann, Breillat et al. 1996; Lemmink, Schroder et al. 1997; Inoue, Nishio et al. 
1999; Plant, Green et al. 1999; Jais, Knebelmann et al. 2000). COL4A5 molecular 
testing should be performed in any patient meeting at least two clinical diagnostic 
criteria of AS; COL4A3 and COL4A4 analysis should be considered primarily if 
autosomal inheritance is suspected and if a COL4A5 mutation is not detected 
(Hanson, Storey et al. 2010). Initially, genealogical, clinical, histopathological data, 
and the relative frequencies of collagen IV-related nephropathies should guide 
molecular genetic analysis, which can be quite expensive and time consuming 
(Artuso, Fallerini et al. 2012). More recently, the possibility to simultaneously study 
COL4A5, COL4A4 and COL4A3 by Next Generation Sequencing (NGS) prior to a 
renal or skin biopsy, not only confirms information on the family history and clinical 
features, but it even adds reliable information on the natural history of the disease 
(Artuso, Fallerini et al. 2012). 
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Large genotype-phenotype correlations studies in European and North 
American populations showed that age of onset of ESRD, hearing loss detected by 
audiometry and typical ocular signs in males with XLAS is associated with the type of 
mutation in COL4A5 gene. Although pathogenic COL4A5 mutation types were 
grouped differently in different studies, genotype-phenotype correlations were similar. 
Age of onset of ESRD was earlier and hearing loss and ocular changes were more 
frequent in patients with mutations which lead to premature end of translation (large 
rearrangements, frameshift and premature stop mutations) than in patients with in-
frame deletions/insertions or nucleotide substitutions (missense mutations) (Jais, 
Knebelmann et al. 2000; Gross, Netzer et al. 2002; Bekheirnia, Reed et al. 2010). 
Furthermore, independently of type of mutation, mutations occurring closer to the 5’ 
end of COL4A5 gene were suggested to be significantly correlated with younger age 
at onset of ESRD, presence of hearing loss and occurrence of ocular changes 
(Bekheirnia, Reed et al. 2010). A possible explanation may be the production of 
smaller proteins, in case of emergent truncated collagen IV α-chains, since 
translation begins in direction 5’ → 3’ of the gene. However, glycine substitutions in 
exons 1-20 were associated with a less severe phenotype (Gross, Netzer et al. 
2002). In females heterozygous for COL4A5 mutations no significant genotype-
phenotype correlations were identified, but a high risk of progression to ESRD (50% 
at the age of 40) was emphasized, with hearing loss and proteinuria being adverse 
prognostic factors (Jais, Knebelmann et al. 2003). 
Type of mutations in the COL4A5 gene was shown to have great impact in 
management and genetic counseling of males with XLAS, since it influences 
development of ESRD, hearing loss and ocular abnormalities (Gross, Netzer et al. 
2002). Gross and colleagues (2002) analyzed the genotype of XLAS patients by 
dividing mutations in seven types: 5’ glycine substitutions (class 1), 3’ glycine 
substitutions (class 2), in-frame mutations (class 3), splice donor mutations (class 4), 
splice acceptor mutations (class 5), frameshift and premature stop mutations (class 
6), and large rearrangements (class 7) (Gross, Netzer et al. 2002). Genotype-
phenotype analysis clustered patients with class 4, 6 and 7 mutations in a group with 
mean age of onset of ESRD of 19.8 ± 5.7 years (also referred as “truncated protein 
group”, since these mutations are predicted to prevent the synthesis or lead to the 
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synthesis of a truncated protein); class 2, 3 and 5 mutations formed a group with 
mean age of onset of ESRD 25.7 ± 7.2 years (also called “altered protein structure 
group”); patients with class 1 mutations developed ESRD at an older age (30.1 ± 7.2 
years) (Gross, Netzer et al. 2002). Percentages of patients with hearing loss and 
typical ocular signs were also higher in “truncated protein group” than in “altered 
protein structure group” (80% versus 65-70% and 40% versus 30%, respectively).  
Furthermore, in this meta-analysis, Gross and colleagues (2002) suggested a 
classification of the phenotype based on the genotype: (i) severe phenotype (type S: 
ESRD at ~20 years of age, 80% hearing loss, 40% ocular lesions), which included 
patients with class 4, 6 and 7 mutations; (ii) moderate-severe phenotype (type MS: 
ESRD at ~26 years of age, 65% hearing loss, 30% ocular lesions), which included 
patients with class 2, 3 and 5 mutations; (iii) moderate phenotype (type M: ESRF at 
~30 years of age, 70% hearing loss, 30% ocular lesions), which included patients 
with class 1 mutations (Gross, Netzer et al. 2002). 
If a mutation known to be the cause of AS was previously identified in the 
proband, a family member presenting with hematuria should be tested, independently 
of the need of further clinical tests (Flinter, Maher et al. 2003). Women carrying a 
pathogenic COL4A5 gene mutation have 50% (1/2) probability of transmitting the 
same mutation either to female or male offspring. Affected males do not transmit a 
COL4A5 mutation to their sons, but all his daughters will inherit the pathogenic 
mutation. Germline mosaicism of pathogenic COL4A5 mutations was previously 
reported, and, apart from de novo mutations, it may explain the non-penetrance in 
female carriers without affected ancestors. Germline mosaicism increases the 
recurrence risk of XLAS in the offspring of the molecular mosaic male or female 
(Bruttini, Vitelli et al. 2000). When both parents are carriers of either COL4A3 or 
COL4A4 mutations, the couple has a 25% (1/4) probability of having an affected 
descendent. On the other hand, 50% of the progeny of such couples will be 
heterozygous for one the mutations carried by the parents and should receive 
appropriate long term clinical follow up (Frasca, Onetti-Muda et al. 2005; Marcocci, 
Uliana et al. 2009; Temme, Peters et al. 2012). Carrier status detection and specific 
reproductive options, as prenatal diagnosis (PND) and preimplantation genetic 
diagnosis (PGD), are available after gene mutation identification. 
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Almost one century has passed since the publication of the seminal Arthur C. 
Alport’s clinical report and much has been learned from subsequent research, largely 
through molecular biology approaches in the last three decades. AS should be 
suspected when facing a young patient with hematuria or CRF, especially in the 
presence of family history of glomerulonephritis. Audiologic and ophthalmologic 
evaluations are not only diagnostic tools, but also predictive factors of general 
prognosis of kidney function (Bekheirnia, Reed et al. 2010). Since its availability, the 
molecular diagnosis of collagen IV-related nephropathies became a preferential 
method to confirm the etiologic diagnosis and the mode of transmission of these 
disorders in each family, offering a non-invasive diagnostic approach and making 
pre-symptomatic diagnosis available. Moreover, an earlier genetic diagnosis of a 
patient or a carrier has significant implications in the treatment, family genetic 
counselling, and reproductive options. The genetic diagnosis enables the treatment 
decision-making to be timely and standardized, allowing for earlier therapeutic 
interventions that may favorably impact on the clinical prognosis (Temme, Peters et 
al. 2012). Since intra- and inter-familial phenotypic variability is observed, the 
identification of pathogenic COL4A5, COL4A4 or COL4A3 mutations differentiates 
between X-linked and autosomal inheritance, enabling the recurrence risk to be 
accurately estimated and avoiding kidney donation by potential kidney donors who 
are at-risk of CRF (Gross, Weber et al. 2009). Finally, once the disease-causing 
mutation is identified, reproductive options became broader for the patients and their 
relatives. 
 
2. Significance, Hypothesis and Objectives of the Study 
 
The increasing number of publications describing effective therapeutic options 
for AS and the requirement of the underlying molecular defect characterization for 
precise diagnosis, genetic counseling and appropriate therapy (Savige, Gregory et al. 
2013) determined the need for identifying pathogenic mutations in the genes known 
to cause collagen IV-related nephropathies in the Portuguese population of patients 
with AS. Although not being considered an innovative methodology, the molecular 
genetic analysis of those genes in a never previously genotyped population was 
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expected to reveal novel data on the molecular pathology of this spectrum of 
disorders, due to their locus and allelic heterogeneity. Concomitant clinical 
characterization of index cases and family members would be needed to confirm the 
pathogenicity of the novel DNA variants. Moreover, detailed knowledge on the 
molecular pathology of collagen IV-related nephropathy in the Portuguese population 
would guide the implementation of a molecular genetics study strategy adjusted to 
Portuguese patients with clinical diagnosis of AS, for use in clinical practice. 
The detection of previously unreported as well as reported pathogenic variants 
in the COL4A5, COL4A4 and COL4A3 genes in a cohort of well clinically 
characterized patients with AS would enable the extension of genotype-phenotype 
correlations, clarifying the pathogenic mechanisms involved in collagen type IV 
related disorders, while having a direct utility in the clinical practice by (i) confirming 
the clinical diagnosis, (ii) reducing the time and invasiveness of the diagnostic 
process, (iii) assisting in choosing an adequate treatment and surveillance of 
patients, (iv) supporting the genetic counseling including the identification of at risk 
relatives, (v) preventing kidney donation between affected family members, 
essentially by estimating the risk of living-related female kidney donors developing 
CKD, and (vi) increasing the available reproductive options of couples at-risk of 
having affected offspring. Eventually, the identification of a more restricted group of 
patients with clinical features within the spectrum of collagen IV-related 
nephropathies but no detectable pathogenic variants in the COL4A5, COL4A4 and 
COL4A3 genes would be formed, in whom clinical and molecular genetic analyses 
should be persued with the aim to investigate new genotype-phenotype associations. 
A first challenge of pioneering the study of families with AS in Portugal was the 
lack of knowledge regarding the number and phenotypic variation of Portuguese 
patients affected with collagen type IV glomerulopathy, which lead to the need of 
adopting broad inclusion criteria. The phenotypic variability, as well as the locus and 
allelic genetic heterogeneity underlying AS, would raise further challenges in 
distinguishing pathogenic from benign molecular changes. After identification of 
genetic defects in the COL4A5, COL4A4 or COL4A3 genes, molecular variations 
underlying AS in the population of Portuguese patients were further characterized by 
(i) studying first degree relatives of the proband and other at-risk, affected and 
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unaffected family members, (ii) investigating for the presence of the variation in 
Portuguese healthy controls and in described European-American control 
populations, (iii) predicting in silico the effect of novel genetic variants in the structure 
and function of the corresponding protein using bioinformatic tools. In the end, the 
relevance of the implementation of the clinical and molecular study of Portuguese 
families with AS would be (i) to determine the COL4A5, COL4A4 and COL4A3 
mutation detection rate in Portuguese AS patients and (ii) to broadly describe the 
genetic epidemiology of AS in Portugal. 
Consequently, a largely exploratory research project was undetaken, based on 
the following research questions (Figure 2): 
 
Research question 1: Are the type of pathogenic mutations in the genes 
known to cause collagen IV-related nephropathies – COL4A3, COL4A4, COL4A5 
and COL4A6 – and their frequency among Portuguese families with AS similar to 
other cohorts?  
Hypothesis 1: The type and frequency of pathogenic COL4A3, COL4A4, 
COL4A5 and COL4A6 mutations in Portuguese families are different from mutations 
found in other countries. 
Aim 1: To identify pathogenic mutations in the COL4A3, COL4A4, COL4A5 
and COL4A6 genes in Portuguese families with clinical diagnosis of AS and compare 
them with other previously identified pathogenic mutations. 
 
Research question 2: Are clinical features in Portuguese individuals with 
pathogenic mutations in the genes known to cause collagen IV-related nephropathy 
similar to clinical features seen in other cohorts of patients with collagen IV-related 
nephropathy?  
Hypothesis 2: The phenotype of Portuguese individuals with pathogenic 
mutations identified in the genes known to cause collagen IV-related nephropathy is 
similar to the phenotype observed in other cohorts. 
Aim 2: To perform the clinical characterization of Portuguese individuals with 
pathogenic mutations identified in the genes known to cause collagen IV-related 
nephropathy and compare their phenotype with other cohorts. 
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Research question 3: Is the association between genotype and phenotype in 
Portuguese individuals with pathogenic mutations identified in the genes known to 
cause collagen IV-related nephropathy similar to the genotype-phenotype association 
seen in other cohorts of patients with collagen IV-related nephropathy? 
Hypothesis 3: The association between the genotype and the phenotype in 
Portuguese individuals with mutations identified in the genes known to cause 
collagen IV-related nephropathy is similar to the genotype-phenotype association 
observed in other cohorts. 
Aim 3: To establish genotype-phenotype correlations in a Portuguese cohort of 
individuals with mutations identified in the genes known to cause collagen IV-related 
nephropathy and compare it with other cohorts. 
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Figure 2. Overview of the research project, showing the aims 1, 2 and 3 and the research areas investigated in each manuscript. 
GBM: Glomerular basement membrane. 
59 
 
 
 
Chapter 2 Patients and Methods 
 
1. Study cohort  
The study cohort consisted of patients with a clinical diagnosis of AS, treated or 
followed at clinical nephrology, transplantation or dialysis clinics of public hospitals or 
treated in private hemodialysis clinics in Portugal. Since few mutations in Portuguese 
patients with AS had already been reported (namely patients included in the 
European Community Alport Syndrome Concerted Action – ECASCA) (Jais, 
Knebelmann et al. 2000; Jais, Knebelmann et al. 2003), the cohort assembly was 
also expected to be a largely exploratory process of making an inventory of 
Portuguese families with AS and of recognition of the disease causing mutations in 
each family. The research project was approved by the Health Ethics Committee of 
São João Hospital Centre (CHSJ), Porto, Portugal. 
A closed cohort was gathered between the 1st January 2009 and the 30th June 
2012. Index cases were assembled by simple random sampling, while family 
members were identified by chain-referral sampling (Table V). Probands were 
referred for molecular study of the COL4A5, COL4A4 and COL4A3 genes based on 
the occurrence of at least one of the four clinical criteria proposed by Flinter (Flinter, 
Cameron et al. 1988). This cut-off inclusion criterion would enable the constitution of 
a cohort of patients with hereditary nephropathy, facilitating the enrollment of carriers 
of XLAS or ARAS and patients with early manifestations of XLAS or ARAS, besides 
affected probands with well-founded clinical diagnosis of XLAS or ARAS. Informed 
consent for participation in this research project, and subsequent collection of clinical 
data and biological samples was obtained from 178 individuals who fulfilled the 
eligibility criteria, belonging to 65 unrelated Portuguese families. 
 
Table V. Eligibility criteria for selection of the study sample. 
Subjects eligible for the research study: 
 Index cases with history of hematuria of unknown etiology and one or 
more of the clinical criteria of AS proposed by Flinter et al. (1988) 
 Family members of index cases with clinical signs of AS or ≥ 18 years 
without clinical signs of AS 
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The specific characteristics of the sample that made it reliable as a set of one or 
more examples of the unit of observation are: 
- The gross or less specific (versus fine or with highly specificity) selection of 
families with collagen IV-related nephropathy (AS or TBMN); 
- The study of COL4A5, COL4A4 and COL4A3 genes in all, but three, of the 65 
selected families (Figure 3).  
In three probands without a pathogenic COL4A5 mutation, it was decided not to 
perform the molecular analysis of COL4A3 and COL4A4 within this research project, 
as: (i) in one family, there was insufficient available clinical data (family 59); (ii) in two 
families, clinical manifestations were not characteristic of AS (family 27 and 58). 
 
 
 
Figure 3. Research study flowchart. 
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1.1. Units of analysis 
To operationalize the impact of the genotype (exposure) on the phenotype 
(outcome) of Portuguese families with collagen IV-related nephropathies, one unit of 
analysis of the phenotype, one unit of analysis of the genotype and one unit of 
analysis of the genotype-phenotype correlation were determined. 
The elected phenotypic unit of analysis was the individual. The levels of analysis 
of the phenotype are the function and, when available, the structure of three main 
organs affected by pathogenic COL4A5, COL4A4 and COL4A3 mutations – kidney, 
ear and eye. 
The selected genotypic unit of analysis was the disease causing mutation. The 
levels of analysis chosen, or the scales of molecular unit of analysis, are the mutation 
status and the type of the mutation. Mutation statuses are hemizygous, homozygous, 
compound heterozygous and heterozygous. Mutations types were previously 
proposed to be aggregated in two or more groups: type M – moderate – versus type 
MS – moderate/severe – versus type S – severe (Gross, 2002), truncating versus 
non-truncating (Hertz, 2009). Other levels of analysis may be the exon, intron or 
region (5’ versus 3’) in the gene where the mutation occurred, the class of aminoacid 
that was changed, the domain of the protein the mutation affected, etc. 
The selected unit of analysis to characterize the phenotypic effect of each 
mutation was the group of patients with similar genetic background, i.e. identical 
mutation status or identical mutation type, as mutations in the three know genes that 
cause AS are usually private, i.e. unique to a single family.  
The major benefit of using a group of patients with identical mutation status or 
identical mutation type as a unit of analysis is because it corresponds to the cohort of 
patients that express the phenotypic effect of a specific mutation. Additionally, by 
identifying a first patient in a family, and usually the more severely affected, it is 
relatively easy to localize, contact and characterize other family members carrying 
the same pathogenic mutations. Family members are generally motivated to have the 
cause of the disease confirmed by a genetic test and to understand the inheritance 
pattern and transmission risks of the disease in the family. The limitation of choosing 
families as units of analysis is the expected intra-familial and inter-familial variability 
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and the possibility that it may not be feasible to enroll several patients by family to 
increase the number of observations of the phenotype of a particular pathogenic 
mutation. Consequently, there is the risk that, if only one member of a family is 
studied, an outlier may be characterized, not being sufficient to adequately 
characterize the phenotypic effect of the mutation. 
The levels of analysis of the genotype-phenotype correlation are the function 
and, when available, the structure of three main organs affected by pathogenic 
COL4A5, COL4A4 and COL4A3 mutations – kidney, ear and eye – by mutation 
status or mutation type. 
 
1.2. Units of observation 
The unit of observation about which data were collected to characterize the unit of 
analysis was the individual, including both affected and non-affected family members 
of each family. At a molecular level, the affected individual is the “perfect” proxy for 
the family, because it is expected that all affected family members will carry the same 
mutation(s). At the phenotypic level, the benefit of collecting data on the individual as 
a proxy for the clinical characterization of the family is to identify and increase the 
number of observed outcomes occurring as the result of a single mutation (and many 
times unique, i.e. not previously identified or reported). Consequently, it will enable: 
- Observation of the phenotypic effect of hemizygous or heterozygous 
pathogenic COL4A5 or COL4A5_COL4A6 mutations; 
- Observation of the phenotypic effect of truncating and non-truncating 
pathogenic COL4A5 mutations; 
- Observation of the phenotypic effect of homozygous, compound heterozygous 
or heterozygous COL4A3 or COL4A4 mutations. 
In each individual, data were collected on renal function and ultrastructure, 
audiologic function and ophthalmologic structure and function. 
 
1.3. Nature of data 
The qualitative data collected in the research study included words (interviews, 
hospital clinical files and questionnaires), drawings (pedigrees), images (audiograms) 
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and photographs (renal biopsies, skin biopsies, OCT). Molecular data was also 
classified qualitatively (mutation type, mutation status). 
The quantitative data collected in the research project included age of 
participants, biochemical analytes in blood (plasma creatinine concentration, pCr) 
and urinalysis results (red blood cells (RBC) count and urine, protein excretion), and 
the estimated glomerular filtration rate (eGFR). 
Ultimately, the research was quantitative, because, independently of the nature of 
the data collected, the analyses involved statistic treatment of data. 
 
 
1.4. Origin of data 
The primary data of the research project included (Figure 4): 
- results of blood and urine laboratory analyses; 
- images of audiologic exams (tonal and high frequency audiograms); 
- photographs obtained during ophthalmologic examination; 
- photographs of the GBM ultrastructure obtained on electron microscopy 
examination of kidney biopsies; 
- mutations identified in each patient, i.e. data that were collected by 
implementation of the molecular genetics analysis of COL4A5 gene and by 
purchasing the molecular genetic testing of COL4A3 and COL4A4 from DNA 
diagnostic laboratories in the United Kingdom and Germany.  
Expected benefits of the primary data were to review, catalogue and organize the 
clinical data according to the criteria chosen in the research project, and to describe 
novel pathogenic COL4A5, COL4A4 and COL4A3 mutations in a population that had 
never been genetically screened for collagen IV-related nephropathies.  
The secondary data (data that were originally collected elsewhere) included: 
- data collected on patient’s interviews; 
- data collected from the patient’s medical records, namely clinical diaries, pre-
dialysis medical reports, referral information; 
- data provided through a two-phase questionnaire filled by each patient’s 
assistant physician. 
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Expected benefits of secondarily collected data were the reduction of costs and 
time savings; limitations are those inherent to retrospective data collection, including 
incompleteness and dispersal. 
 
 
Figure 4. Overview of the molecular (exposures) and clinical (outcomes) variables. 
 
2. Study design 
 
An observational (descriptive) study followed by an analytic study was the 
selected research strategy. A retrospective multicentric cohort study was considered 
the most efficient to satisfactorily reach the established aims, which were to identify 
pathogenic COL4A5, COL4A4 and COL4A3 mutations, to perform the clinical 
characterization and to investigate the genotype-phenotype correlations in 
Portuguese individuals with clinical diagnosis of AS or TBMN. Multicentric enrolment, 
enabling the study of a random sample of patients from the whole country (or at least 
from several districts and different medical care settings) would enhance the 
generalizability (external validity) of the study. The retrospective nature of the study 
design was appropriate for a disease of low prevalence (Levy and Feingold 2000), 
with outcomes that progress during decades. Furthermore, follow-up time, effort and 
economic resources were effectively saved. 
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2.1. Clinical data collection and analysis 
Both clinical data collection techniques and data analyses techniques were 
selected for this specific research strategy to meet the required scientific quality 
criteria. 
 
Clinical data: Collection techniques 
The clinical data collection techniques adopted in this research were: (i) 
clinical interviews with the patient and, when required, with family members (CHSJ, 
Porto, and University Hospitals, Coimbra); (ii) review of medical records (CHSJ, 
Porto, and University Hospitals, Coimbra); (iii) questionnaires with data retrieved from 
interviews and clinical files (Protocol P1); (iv) photographs of ultrastructure of GBM 
obtained by electron microscopy and of immunohistochemistry analysis of glomerular 
and EBM obtained by light microscopy. 
The photographic and clinical archives of the kidney biopsy databases of the 
Pathology Department of CHSJ (Porto) and of the Unit of Renal Morphology of Curry 
Cabral Hospital (Lisboa) – which are the only two sites performing electron 
microscopy of kidney biopsies in Portugal –, were systematically reviewed in 
collaboration with their curator nephrologists, Dr. Susana Sampaio and Dr. Fernanda 
Carvalho, respectively. By this approach, a total of 26 patients from 22 unrelated 
families were eventually enrolled in the study cohort through the CHSJ. From 22 
patients there were electron microscopy photographs of kidney biopsies available for 
review, allowing to characterize in detail the ultrastructural GBM pathology. In all 
biopsied patients, light microscopy examination had disclosed only non-specific 
features. In addition, electron microscopy photographs of the kidney biopsies of two 
patients enrolled through sites in the Lisbon region were reviewed at the Curry 
Cabral Hospital. 
Questionnaires were requested at two different time points: (i) a first 
standardized questionnaire was fulfilled at enrollment; (ii) a customized second 
questionnaire, containing questions regarding incomplete answers or fields left blank 
in the first questionnaire, was fulfilled at a later time, with the objective of updating or 
detailing the clinical evaluation of participants, and reduce the missing data, since 
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some patients had renal, audiological and/or ophthalmical investigation requested 
after the enrollment in the research project. The structured questionnaires on each 
patient’s phenotype was completed and retrieved by the participant’s nephrologist 
and/or geneticist. 
 
Clinical data: Analysis techniques 
The data selected to answer the research question #2, i.e. to define the natural 
history of the disease in the study cohort were: (i) pedigree analysis (including family 
history of hematuria, ESRD or SNHL), which enabled inference of the inheritance 
pattern in each family; (ii) clinical and laboratory manifestations of renal disease, 
CKD progression and need for RRT, as evaluated by urinalysis (for ascertainement 
of occurrence and age at diagnosis of hematuria and proteinuria), blood analysis 
(serial pCr measurements for ascertainement of occurrence and age at diagnosis of 
CKD), assessement of blood pressure (for ascertainement of occurrence and age at 
diagnosis of hypertension), as well as age at onset of RRT; (iii) renal pathology, as 
specifically described by ultrastructural examination of kidney biopsies 
(ascertainement of occurrence and age at diagnosis of the typical GBM features of 
AS – thinning, thickening, lamellation and electron-dense bodies); (iv) history of 
hearing loss and of specialized otolaryngology investigation, namely the occurrence 
of self-perceived hearing loss and age at self-perception of hearing loss, and whether 
confirmation and characterization of SNHL by audiogram was obtained (following 
bilaterally normal otoscopic and tympanogram examinations); (v) presence of typical 
ocular signs, as specifically diagnosed by ophthalmoscopy, fundoscopy and OCT 
(ascertainement of occurrence and age at diagnosis of anterior lenticonus, dot-and-
fleck maculopathy and cataracts) (Supplementary table S1 of manuscript 1). 
The CKD-EPI equation (Levey, Stevens et al. 2009) or the four variable MDRD 
equation (Levey, Bosch et al. 1999) (calculators accessed online at http://mdrd.com/) 
were used, as appropriate, to compute eGFR from each available pCr value. 
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2.2.   Molecular data collection and analysis 
 
Molecular data: Collection techniques 
The molecular data obtained in this study were generated by the following 
laboratory approaches: (i) polymerase chain reaction (PCR); (ii) direct DNA Sanger 
sequencing by capillary electrophoresis; (iii) multiplex ligation-dependent probe 
amplification (MLPA); (vi) fragment length analysis; (v) high-resolution X 
chromosome-specific microarray-based comparative genomic hybridization (array-
CGH); (vi) quantitative PCR (qPCR). The molecular genetic analysis of the COL4A5 
gene was developed in the Department of Genetics of the Faculty of Medicine of the 
University of Porto (Porto, Portugal) (Protocol P2). Distinct methods were applied for 
identification of different types of mutation in COL4A5 gene: PCR amplification and 
direct sequencing of genomic DNA for detection of point mutations and MLPA for 
detection of large rearrangements. The molecular genetic analyses of the COL4A3 
and COL4A4 genes were performed in the DNA Laboratory, GSTS Pathology, Guy’s 
& St Thomas’ Hospital Foundation Trust (London, UK), in collaboration of with Hellen 
Storey and Prof. Frances Flinter, and in the Center for Nephrology and Metabolic 
Diseases (Weisswasser, Germany), in collaboration of Dr. Mato Nagel. The high-
resolution array-CGH and qPCR were performed at the Human Genome Laboratory 
from the Department of Human Genetics of the VIB Center for the Biology of Disease 
(Leuven, Belgium), under the supervision of Prof. Guy Froyen. 
 
Molecular data: Analysis techniques 
The molecular data analysis techniques adopted to answer the research 
question #1 are the following theoretical knowledge and bioinformatic tools: (i) the 
pathogenicity of previously described pathogenic variants was supported by clinical 
and molecular data from the literature; (ii) the pathogenicity of the previously 
unreported variants was presumed from the type of mutation, and was also 
supported by intrafamilial genotype-phenotype correlations, following genotyping of 
at-risk first degree relatives of the probands, as well as the absence of the DNA 
sequence variant in 150 X-chromosomes of Portuguese healthy controls or in more 
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than 8,000 alleles from more than 4000 European-Americans unrelated individuals 
listed on the Exome Variant Server (Exome Variant Server); (iii) the pathogenicity of 
the previously unreported nonsense, splicing and frameshift variants was presumed 
from the type of mutation, with such mutations regarded as disease-causing; (iv) the 
possible impact of novel point mutations upon the structure and function of the 
corresponding protein was predicted in silico with the bioinformatic tools 
“MutationTaster” (http://www.mutationtaster.org/), “MutPred” 
(http://mutpred.mutdb.org/), “PolyPhen-2” (http://genetics.bwh.harvard.edu/pph2/) 
and SNPs&GO (http://snps.biofold.org/snps-and-go/snps-and-go.html) (Calabrese, 
Capriotti et al. 2009; Adzhubei, Schmidt et al. 2010; Thusberg, Olatubosun et al. 
2011; Adzhubei, Jordan et al. 2013); (v) the NNSPLICE software 
(http://www.fruitfly.org/seq_tools/splice.html) was used to predict the effect of intronic 
variants on mRNA splicing; (vi) to confirm whether the mutation identified in the 
proband was inherited or de novo, molecular testing of the proband’s parents was 
performed, whenever possible; (vii) genotyping using four microsatellite polymorphic 
markers flanking the COL4A5 gene (DXS1120, DXS1105, DXS1210, DXS456) was 
performed to track its inheritance across the generations of the pedigree available for 
study and to test whether two apparently unrelated families with a same COL4A5 
mutation shared a common haplotype. 
Although it had been initially planned to perform mRNA extraction and cDNA 
synthesis, as a confirmatory method of the presumably pathogenic splicing effect of 
variants in the nucleotide sequence on the aminoacid sequence of the COL4A5, 
COL4A4 and COL4A3 proteins, this method was replaced by bioinformatic tools 
analysis (Thusberg, Olatubosun et al. 2011). Besides the consistency of prediction 
pathogenic mutations in the genomic DNA into proteins, the use of bioinformatic tools 
was also justified to additionally overcome the refusal of patients to undergo skin or 
kidney biopsy and save time and financial resources required to implement and 
perform the analysis of mRNA. 
 
2.3. Genotype-phenotype correlation: Analysis techniques 
The analysis techniques adopted to determine genotype-phenotype 
associations were: (i) quasi-statistics (interpretation of frequencies); (ii) bivariate 
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statistical analysis (two variables). The predictor (independent) variable selected for 
the genotype-phenotype correlation analyses was the mutation status: hemizygosity, 
homozygosity, compound heterozygosity and heterozygosity. Pathogenic COL4A5 
mutations were also divided into two groups, according to its type: non-truncating 
mutations (glycine substitutions, in-frame mutations, splice acceptor mutations) and 
truncating mutations (nonsense mutations, frameshift mutations, splice donor 
mutations, and large rearrangements). Clinical data were censored at the date the 
last information collection. Nominal and numeric dependent variables included in the 
four main groups of outcomes – (i) of renal function; (ii) of renal structure; (iii) 
audiological; (iv) ophthalmological – were analyzed using non-parametric tests: 
Mann-Whitney test for comparison of continuous unpaired data, Fisher’s exact test 
and chi-square test for comparison of proportions between the two independent 
groups and log rank test for comparison of time to an event between two groups. Chi-
square for trend was used to test for the presence of a trend in the 
COL4A5/COL4A4/COL4A3 mutation detection rate as related to the number of 
diagnostic criteria identified in each patient. The 95% confidence intervals (95%CI) 
for prevalence estimates were computed by the modified Wald method (Agresti and 
Coull 1998). The data were analyzed using the following statistics software 
packages: IBM® SPSS® Statistics version 21 (SPSS IBM; New York, NY, U.S.A) and 
GraphPad Prism® version 5 (GraphPad Software, Inc.; La Jolla, CA, U.S.A.). 
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Chapter 3 Results 
 
In the first part of this chapter, the results of the patient enrollment 
process are presented and discussed. The second part consists of the scientific 
manuscripts that have been generated by this research project. Manuscript #1 
reports the results of the comprehensive mutational screening of COL4A5 that 
was carried out as first tier approach to genetic diagnosis in all probands with a 
clinical diagnosis or suspicion of AS, who belonged to families in whom X-linked 
inheritance could not be excluded by pedigree analysis. Manuscript #2 
describes a novel genotype-phenotype correlation identified in a family with 
ATS-DL, raising the question that this disorder may not be a contiguous gene 
deletion syndrome, as it is usually described. Manuscript #3 reports the results 
of the mutational analyses of COL4A3 and COL4A4 genes by Sanger 
sequencing, in patients without a pathologic COL4A5 mutation identified on the 
first tier genetic study, or who belonged to families with unequivocal evidence of 
autosomal inheritance of kidney disease. 
 
1. Cohort assembly: Results of the recruitment process 
 
Nationwide patient enrollment through public hospitals 
In order to guarantee the largest possible nationwide enrollment of 
patients, 28 nephrology departments and two medical genetics departments of 
29 public hospitals – located in fifteen of the eighteen districts of mainland 
Portugal and in the two autonomous Atlantic islands regions of Azores and 
Madeira –, were formally invited to participate in this study. Kidney patients 
living in the three mainland districts where the local hospitals do not have 
nephrology services are referred to hospitals in neighboring districts but, for the 
purpose of this study, the geographic origin of each enrolled patient was defined 
as the district of residence. 
Overall, 51 family probands and 102 at-risk relatives were eventually 
enrolled in this study through 11 nephrology departments and two medical 
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genetics departments of 12 public hospitals, located in 11 of the mainland 
districts and in the autonomous region of Madeira. (These data are summarized 
in Table VI; see also the Supplementary figure S3 of manuscript #1). Of note, 
the two medical genetics departments contributed with 25 probands and 53 at-
risk relatives, an observation that underscores the importance of the 
collaboration between nephrologists and clinical geneticists for effective delivery 
of comprehensive medical care to patients and families with hereditary kidney 
diseases, such as the collagen IV-related nephropathies. 
As shown in Table VI, the major single institutional contributors to the 
enrollment of cases in the study cohort were the Department of Human 
Genetics and the Department of Nephrology of CHSJ. The CHSJ is a large 
tertiary care and university hospital whose catchment area for those two 
specialties is the northwest region of Portugal, comprising part of the district of 
Porto and the districts of Braga and Viana do Castelo, with a global resident 
population of about 2,500.000 people. Twenty three probands were enrolled 
through the clinic of hereditary kidney diseases of the Department of Human 
Genetics, and respectively the peritoneal dialysis and the kidney transplant 
clinics of the Department of Nephrology further contributed with 2 and 3 
probands. 
As summarized in Table VII, the nephrology departments of three major 
hospitals – in Lisbon (Curry Cabral Hospital), Porto and Azores –, originally 
expressed their interest in participating in this study but ultimately did not refer 
any patients for genetic analyses. Some patients with AS followed at the Curry 
Cabral Hospital had been previously enrolled in the ECASCA study and did not 
consent to participate in this research project. Eight of the invited nephrology 
departments (29%) replied that they were not currently caring for any patients 
with a diagnosis of AS and other 5 (18%) did not formally reply to the invitation, 
three of them having later informed the research team that they had no patients 
diagnosed with AS. In the southern districts of Portalegre, Beja and Évora there 
were no patients diagnosed with AS known to nephrologists of the local public 
hospitals.  
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Table VI. Number of participants enrolled in public hospitals, by geographic district (n=153). 
District Hospital Local researcher Probands Family 
members 
Total of 
participants 
Vila Real Hospital São Pedro, Vila Real Dr. Rui Castro 5 12 17 
Braga Hospital de Braga Dr. Carlos Soares 3 4 7 
Porto Centro Hospitalar de São João, Porto Dr. João Paulo Oliveira 28 48 79 
 Hospitala de Vila Nova de Gaia Dr. Joaquim Seabra 3 0  
Coimbra Hospitais da Universidade de Coimbra Dr. Jorge Pratas e Sousa,  
Dr. Luís Freitas 
2 10 12 
Viseu Hospital de São Teotónio, Viseu Dr.ª Tânia Couto Sousa,  
Dr. Jesus Garrido 
1 0 1 
Castelo Branco Hospital Amato Lusitano, Castelo Branco Dr. Rui Alves Filipe 1 0 1 
Lisboa Hospital Santa Maria, Lisboa Dr. António Gomes da Costa 1 1 18 
 Hospital Dona Estefânia, Lisboa Dr.ª Márcia Rodrigues 2 14  
Setúbal Hospital Garcia de Orta, Almada Dr. Fernando Teixeira e Costa 1 3 4 
Faro Hospital de Faro Dr.ª Elsa Morgado 1 2 3 
R.A. Madeira Hospital dos Marmeleiros, Funchal Dr. José Augusto Araújo 3 8 11 
Total 
  51 102 153 
R.A.: autonomous region. 
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Table VII. Invited non-participating hospitals in the research study, by geographic district (n=17).  
District Hospital Local Contact Patients with Alport syndrome 
Bragança Hospital de Bragança Dr.ª Fátima Ramos Unknown (no reply) 
Braga Hospital de Fafe Dr. Joaquim Pinheiro Unknown (no reply) 
Porto Hospital de Santo António, Porto Dr.ª Manuela Almeida Yes (number not determined) 
 Instituto Português de Oncologia, Porto Dr. Alfredo Loureiro None 
 Hospital Pedro Hispano, Matosinhos Dr. José Maximino None 
Aveiro Hospital Infante D. Pedro, Aveiro Dr.ª Carmen do Carmo None 
Coimbra Hospital dos Covões, Coimbra Dr. Armando Carreira None 
Santarém Hospital de Santarém Dr. João Bispo Unknown (no reply) 
 Hospital Rainha Santa Isabel, Torres Novas Dr. Sequeira Andrade Unknown (no reply) 
Lisboa Hospital Curry Cabral, Lisboa Dr. Fernando Nolasco Yes (number not determined) 
 Hospital Santa Cruz, Carnaxide Dr. José Diogo Barata Unknown (no reply) 
 Hospital Professor Doutor Fernando Fonseca, Amadora/Sintra  Dr. Luís Incháustegui None 
Setúbal Hospital de São Bernardo, Setúbal Dr. José Vinhas Unknown (no reply) 
Portalegre Hospital Dr. José Maria Grande, Portalegre Dr. António Sousa None 
Beja Hospital José Joaquim Fernandes, Beja Dr. Carlos Pires None 
Évora Hospital Espírito Santo, Évora Dr. João Aniceto None 
R.A. Açores Hospital de Santo Espírito, Angra do Heroísmo Dr.ª Lurdes Dias Yes (number not determined) 
R.A.: autonomous region. 
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Enrollment of patients from hemodialysis clinics 
For a disease like AS, progressing to ESRD at relatively early ages in a 
substantial proportion of patients, it is expected that a large fraction of them be 
on RRT at any point in time. In Portugal, about 64% of the more than 17,500 
patients on RRT are on hemodialysis; only about 6.6% of the patients on dialytic 
RRT are on peritoneal dialysis (http://www.spnefro.pt/comissoes_gabinetes/ 
Gabinete_registo_2012/registo_2012.pdf); and only 10.7% of the patients on 
chronic hemodialysis are cared for in public hospitals, the remainder being 
treated at private for-profit dialysis facilities. Therefore, despite the risk of 
ascertainement bias towards more severe AS clinical phenotypes, case 
identification through private hemodialysis clinics would be an important step in 
the research plan, to ensure a thorough nationwide ascertaiment of families. To 
this end, the two major networks of hemodialysis clinics operating in Portugal – 
Diaverum and NephroCare / Fresenius Medical Care – were formally invited to 
collaborate. In addition, the Portuguese Society of Nephrology (SPN) publicized 
this research project on their internet site. Of the two hemodialysis networks, 
only NephroCare ultimately approved their participation in the study. Taking into 
consideration the geographic distribution of the hemodialysis clinics of the two 
networks, the non-participation of Diaverum may have affected a thorough 
ascertainment of AS patients in the central-western region of the country. On 
the other hand, an AS patient on chronic hemodialysis at a Diaverum facility in 
Lisbon, self-referred to the research team after having read the announcement 
posted at the SPN website and was enrolled as the proband of her family.  
The results of patient enrollment through hemodialysis clinics are 
summarized in Table VIII: a total of 14 family probands were identified in 12 
dialysis clinics, from northern and central mainland districts. The importance of 
having involved dialysis companies in this study is evident in the following 
results: (i) the probands of all the families identified in the districts of Santarém 
and Guarda were enrolled through NephroCare dialysis centers; (ii) even in 
districts where affected families had been identified through public hospitals, 
additional probands were enrolled through private hemodialyis clinics; (iii) 
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several affected relatives of probands enrolled through public hospitals were 
recruited in private hemodialysis clinics; (iv) no patients diagnosed with AS were 
receiving dialysis treatment in the southern districts of Portalegre, Beja and 
Évora, confirming the findings in the local public hospitals.  
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Table VIII. Number of participants enrolled in hemodialysis clinics, by geographic district (n=25). 
District Dialysis Clinic Local researcher Probands Family members Total 
Braga Nephrocare, Braga Dr. António Castro Henriques 1 1  2 
Porto Uninefro, Santo Tirso Dr.ª Isabel Tavares 2 0  4 
 Diaverum, Paredes Dr.ª Ana Oliveira / Dr.ª Liliana Pinho 0 2   
Coimbra Nephrocare, Coimbra Dr. Jorge Pratas e Sousa 0 1  1 
Viseu Nephrocare, Viseu Dr. Rui Alves / Dr. Carlos Miguel Almeida Botelho 1 0  1 
Guarda Nephrocare, Guarda Dr.ª Tânia Couto Sousa / Dr. Bernardo Faria 1 4  5 
Castelo Branco Nephrocare, Covilhã Dr. José Montalban / Dr.ª Ana Bernardo 1 0  1 
Santarém Nephrocare, Santarém Dr. Fernando Neves / Dr. Adelino Carvalho 3 1  6 
 Nephrocare, Montijo Dr. Francisco Teixeira de Sousa / Dr.ª Joana Felgueiras 1 1   
Lisboa Nephrocare, Lumiar Dr. Pedro Ponce 1 0  5 
 Nephrocare, Restelo Dr.ª Maria Augusta Gaspar / Dr. Luís Filipe Carvalho 2 1   
 Diaverum, Lumiar Dr.ª Cristina Pinto Abreu 1 0   
Total 
  14 11  25 
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2. Clinical and molecular characterization of patients with 
clinical diagnosis or suspicion of Alport syndrome in 
Portugal 
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2.1. Patients with pathogenic COL4A5 and COL4A6 mutations 
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2.1.1. Collagen type IV-related nephropathies in Portugal: 
spectrum of pathogenic COL4A5 mutations and clinical 
characterization of 22 families (Manuscript 1) 
 
 
Manuscripts 1 and 3 were submitted simultaneously to the Journal of Medical 
Genetics, on the 11th April 2014 (Manuscript 1 ID: jmedgenet-2014-102471). 
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ABSTRACT 
Background 
Alport syndrome (AS) is a disorder of basement membranes caused by mutations in 
the genes encoding the α3 (COL4A3), α4 (COL4A4) or α5 (COL4A5) chains of 
collagen IV. Organ-selective expression of those α(IV)-chains explains the AS 
phenotype including hematuria, chronic renal failure (CRF), sensorineural hearing 
loss (SNHL) and ocular abnormalities. Mutations in the X-linked COL4A5 gene have 
been identified in 80-85% of the families (XLAS).  
Patients and Methods 
Sixty-five apparently unrelated families with clinical diagnosis of AS were enrolled in 
this study, aiming to describe the genetic pathology of AS in Portugal.  COL4A5 
molecular analysis was carried out by Sanger sequencing and multiplex-ligation 
probe amplification in 60 probands who showed X-linked or unclear inheritance 
patterns.  
Results 
Twenty-two out of the 60 probands (37%) had a pathogenic COL4A5 mutation, of 
which 12 (57%) are novel and 9 (43%) were previously described. Two families 
shared a missense mutation, with identical microsatellite haplotypes. In two probands 
(9%), the COL4A5 mutation proved to be de novo. Males had more severe and 
earlier renal and extrarenal complications, but microscopic hematuria was a constant 
finding irrespective of patient gender. Truncating mutations were associated with a 
younger age of onset of SNHL in males, and with a higher risk of CRF and SNHL in 
females.  
Discussion 
Diagnosis of XLAS was genetically confirmed in a lower than expected proportion of 
Portuguese families. Conclusive interpretation of these data requires reliable 
information about the prevalence of autosomal AS, due to pathogenic COL4A3 or 
COL4A4 mutations, in the remaining families.  
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INTRODUCTION 
The eponym Alport syndrome (AS) refers to a heterogeneous group of progressive 
familial hematuric nephropathies caused by pathogenic mutations in any of the α5, 
α4 or α3 type IV collagen chains.(Kashtan 1993-2013; Kashtan 1999; Kashtan 2001; 
Tryggvason and Patrakka 2009; Kruegel, Rubel et al. 2013) Since these α(IV)-chains 
are the major components of the protein scaffold of the mature glomerular basement 
membrane (GBM) in the human kidney,(Hudson, Tryggvason et al. 2003; 
Khoshnoodi, Pedchenko et al. 2008) genetic defects that either impair their synthesis 
or extracellular assembly in specific collagenous networks ultimately lead to chronic 
kidney disease (CKD),(Cosgrove 2012; Kruegel, Rubel et al. 2013) by compromising 
the normal role of the GBM as a specialized plasma filtration barrier. The structural 
abnormalities of the GBM observed on electron microscopy (EM), particularly the 
thickening, splitting and fragmentation of the lamina densa, are an important 
diagnostic clue of AS.(Haas 2009) Overall, about 0.6% of the patients with end-stage 
renal failure (ESRF) starting renal replacement therapy (RRT) in Europe had AS, of 
which 22.8% were females and 6.5% were children aged less than 15 years.(Rigden, 
Mehls et al. 1996) Besides CKD, high-tone sensorineural hearing loss (SNHL) and a 
spectrum of ocular lesions affecting the lens, the retina, and the cornea are 
additional, though less common manifestations of AS.(Crawfurd 1988; Flinter 1997; 
Kashtan 2001; Savige and Colville 2009; Tryggvason and Patrakka 2009; Kruegel, 
Rubel et al. 2013) In patients with hematuria of uncertain etiology, the following set of 
criteria enable the diagnosis AS:(Flinter, Cameron et al. 1988) (i) family history of 
macro/microscopic hematuria and/or of chronic renal failure (CRF); (ii) EM evidence 
of AS on renal biopsy; (iii) high tone SNHL; (iv) characteristic ophthalmological signs 
(anterior lenticonus and/or white macular flecks). When the patient, or the proband 
and other affected family members between them, fulfill at least three of those 
criteria, the clinical diagnosis of AS can be confidently established.  
Type IV collagen is exclusive of basement membranes (BM) and comprises 
six genetically distinct isoforms of α(IV)-chains, designated α1(IV) through α6(IV). 
The α(IV)-chains form three different types of triple-helical protomers – α1:α1:α2(IV), 
α3:α4:α5(IV) and α5:α5:α6(IV) – that combine with each other, giving rise to complex 
collagenous networks that provide structural support to BM and influence cell 
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adhesion, migration, and differentiation.(Hudson, Tryggvason et al. 2003; 
Khoshnoodi, Pedchenko et al. 2008) Whereas the α1:α1:α2(IV) are ubiquitously 
present in all mammalian BM, the two other heterotrimers are selectively expressed 
in different tissues.(Hudson, Tryggvason et al. 2003; Khoshnoodi, Pedchenko et al. 
2008) The presence of α3:α4:α5(IV) in the GBM and in BM of the ear and in the eye 
explains the phenotype of AS. Furthermore, the α3:α4:α5(IV) protomers, which are 
more resistant to increased intraglomerular pressure and to proteolytic degradation, 
gradually replace the α1:α1:α2(IV) heterotrimers in the GBM, after early embryonic 
development. This is a critical step of GBM adaption to the postnatal glomerular 
hemodynamic conditions and to the increased exposure to serum 
proteases.(Hudson, Tryggvason et al. 2003; Khoshnoodi, Pedchenko et al. 2008) 
The human α(IV)-chain genes (COL4A1 through COL4A6) have similar genomic 
structures and are arranged pairwise in head-to-head orientation, COL4A1-COL4A2 
on the long arm of chromosome 13, COL4A3-COL4A4 on the long arm of 
chromosome 2 and COL4A5-COL4A6 on the long arm of chromosome 
X.(Khoshnoodi, Pedchenko et al. 2008)  
About 80-85% of AS families reportedly have the classical X-linked form of the 
disease (XLAS; MIM#301050), caused by COL4A5 mutations.(Kashtan 1999; 
Kashtan 2001; Tryggvason and Patrakka 2009; Kruegel, Rubel et al. 2013) XLAS is 
characterized by more severe phenotype and worse prognosis in males.(Jais, 
Knebelmann et al. 2000; Jais, Knebelmann et al. 2003) The remainder of cases, 
which are due to mutations in COL4A43 and/or COL4A4, are inherited as autosomal 
recessive (ARAS; MIM#2013780) or autosomal dominant (ADAS; MIM#104200) 
disorders. In families with ARAS, males and females are equally affected and the 
kidney disease is similar to that observed in males with XLAS.(Tryggvason and 
Patrakka 2009) ADAS is usually quoted as the rarest form of AS,(Rumpelt 1980; 
Kashtan 1999; Kashtan 2001; Tryggvason and Patrakka 2009) comprising less than 
5% of the patients, but this concept has been recently challenged.(Fallerini, Dosa et 
al. 2013) Besides XLAS, mutations affecting COL4A5 also occur in AS with diffuse 
leiomyomatosis (ATS-DL; MIM#308940)(Garcia Torres and Guarner 1983) and in AS 
with mental retardation, midface hypoplasia and elliptocytosis (AMME; 
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MIM#300194),(Jonsson, Renieri et al. 1998) two rare syndromes caused by 
microdeletions involving COL4A5 and adjacent genomic regions.  
More than 700 disease-causing COL4A5 mutations, most of them unique to 
single families, have already been described, and about 400 more are estimated to 
be unpublished.(Savige, Ars et al. 2013) In “The Human Gene Mutation 
Database”(Stenson, Mort et al. 2013) (HGMD®; 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A5, last accessed on March 1, 
2014), missense and nonsense substitutions respectively account for 41.7% and 
6.7% of all the reported COL4A5 mutations; substitutions that affect the normal 
splicing of COL4A5 mRNA account for 16.8%; small insertions, deletions and 
insertions/deletions, involving 20 base pairs (bp) or less, account for 22.2%; deletions 
and insertions/duplications greater than 20 bp and gross complex rearrangements 
account for 12.6%. Glycine substitutions in the conserved Gly-Xaa-Yaa repeat 
sequence of the α5(IV) collagenous domain are the most frequent type of pathogenic 
COL4A5 mutation, variably accounting for 56.2-95.2% of the missense mutations 
identified in several large European(Jais, Knebelmann et al. 2000; Hanson, Storey et 
al. 2011) and North-American(Bekheirnia, Reed et al. 2010) cohorts. Between 14.3-
26.1% of the pathogenic COL4A5 mutations are nonsense substitutions or small 
frameshifting deletions or insertions that result in premature stop codons. In 
hemizygous males, large deletions and truncating mutations are associated with 
earlier progression to ESRF, higher risk of developing hearing loss before age 30 
years and higher probability of expressing anterior lenticonus.(Jais, Knebelmann et 
al. 2000; Gross, Netzer et al. 2002; Bekheirnia, Reed et al. 2010) Mutations located 
closer to the 5’ end of the gene are also associated with more severe renal 
phenotype.(Bekheirnia, Reed et al. 2010) Contrastingly, no significant genotype-
phenotype correlations could be identified in heterozygous females.(Jais, 
Knebelmann et al. 2003)  
In males with XLAS,(Jais, Knebelmann et al. 2000) the presenting clinical 
manifestation was hematuria in 81% and isolated proteinuria in 12.5%; during the 
course of the disease, a single or recurrent episodes of gross hematuria occurred in 
62% of the patients and proteinuria was found in 95%; and all patients who had a 
kidney biopsy examined by EM showed either typical or suggestive ultrastructural 
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GBM abnormalities. Between 88.5-94% of the patients had positive family history, 
with 76-84% of the families reporting history of ESRF.(Jais, Knebelmann et al. 2000; 
Bekheirnia, Reed et al. 2010; Hanson, Storey et al. 2011) The prevalence of 
extrarenal diagnostic criteria of AS ranged between 67-89% for clinical hypoacusia 
and/or audiologically confirmed SNHL and 30-40% for ocular lesions (lenticonus 
and/or maculopathy and/or congenital or early onset cataract).(Jais, Knebelmann et 
al. 2000; Bekheirnia, Reed et al. 2010; Hanson, Storey et al. 2011) At least 85% of 
the females with XLAS have microscopic hematuria.(Crawfurd 1988; Flinter 1997; 
Kashtan 2001) Since microscopic hematuria may be intermittent, repeat testing may 
be necessary before expression of the disease can be excluded, especially in a 
female. At age 40 years, the probability of having ESRF or deafness is, respectively, 
90% and 80% in males and 12% and 10% in females.(Jais, Knebelmann et al. 2000; 
Jais, Knebelmann et al. 2003) Overall, 30% of the heterozygous females develop 
ESRD by age 60 years and an additional 10% progress to ESRD during the next two 
decades of life.(Jais, Knebelmann et al. 2003)  
Data about the genetics of AS in Portugal are scarce and result of a small 
contribution to an European Concerted Action.(Jais, Knebelmann et al. 2000; Jais, 
Knebelmann et al. 2003) Our major goals were to describe the genetic pathology and 
genotype-phenotype correlations in a large cohort of Portuguese families with AS, 
identified through systematic ascertainment all over the country.  
 
PATIENTS AND METHODS 
Enrollment of Patients and Families 
Between 1/January/2009 and 30/June/2012, patients with clinical diagnosis of AS 
who were residing in Portugal and consented to participate, as well as their affected 
or at-risk relatives who accepted or requested genetic evaluation, were enrolled in 
this study. In order to ensure the broadest possible geographic catchment area, all 
nephrology departments and two major medical genetics departments from 29 public 
hospitals throughout the country, as well as the two biggest private dialysis clinics 
networks operating in Portugal, were formally invited to participate, and the study 
was publicized through the internet site of the Portuguese Society of Nephrology.  
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As operationally defined herein, “genetic probands” were the first patient of 
each apparently unrelated family who was enrolled in this study and underwent 
molecular genetics analysis. The clinical diagnosis of AS in genetic probands was 
based on the set of criteria proposed by Flinter and colleagues,(Flinter, Cameron et 
al. 1988) for patients with hematuria of unknown etiology. The diagnosis of AS was 
considered clinically “established” if the genetic proband, or the genetic proband and 
other affected family members between them, fulfilled at least three of the diagnostic 
criteria. Genetic probands presenting with less than three diagnostic criteria were 
considered to have a “probable” diagnosis of AS, being also eligible for mutational 
analysis. The observation of typical ultrastructural GBM abnormalities on kidney 
biopsy was regarded as highly suggestive of the diagnosis of AS.(Hanson, Storey et 
al. 2011)  
The study protocol and informed consent documents were reviewed and 
approved by the Health Ethics Commission of São João Hospital Centre (CHSJ, 
Porto; Portugal).  
Clinical questionnaire and definitions 
Specific clinical data from each participant, as well as the relevant details of their 
family histories, were collected by means of a standardized questionnaire. Clinical 
outcomes assessed in the questionnaire and the corresponding definition and 
measurement method are described in Supplementary table S1. Baseline clinical 
assessment was performed at enrollment by the referring physician, either a 
nephrologist or a clinical geneticist. Additional data were retrospectively collected by 
review of archive medical records and pathology reports. In some cases, information 
on the family history was completed by interviewing patient’s relatives.  
Molecular genetics analyses 
Genomic DNA of the participants was extracted from whole blood samples using a 
commercial kit (Citomed; Lisbon, Portugal), and aliquots kept refrigerated at 4ºC until 
used for molecular analysis. Blood sampling from patients on hemodialysis was done 
at the beginning of a dialysis session, before the administration of heparin. Blood 
samples drawn at the central laboratory (Genetics Department; Faculty of Medicine, 
University of Porto – FMUP; Portugal) were processed for DNA extraction within 24 
hours; blood samples drawn at other sites were sent to the central laboratory by 
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priority mail, at room temperature, and processed for DNA extraction no later than 72 
hours following blood collection.  
In the genetic probands, all 53 exons of COL4A5 as well as their 
corresponding intronic flanking regions were polymerase chain reaction (PCR)-
amplified using previously described intronic primers and conditions (see 
Supplementary table S2).(Martin, Heiskari et al. 1998) PCR products were 
automatically sequenced in forward and reverse directions in an ABI Prism® 310 
Genetic Analyzer (Applied Biosystems; Foster City, CA, USA), using the BigDye® 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems), and the corresponding 
electropherograms were visually checked for sequence variants. Subsequent 
screening for a known mutation in affected or at-risk probands’ relatives was 
performed by direct analysis of relevant exon.  
The GenBank® identifier NM_000495.3 (National Center for Biotechnology 
Information; Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov/nuccore/), 
corresponding to transcript variant 1 of COL4A5, that lacks the two alternatively 
spliced exons located within intron 41, was used for reporting the COL4A5 variants. 
In order to facilitate the comparison of our data with those of previous reports, the 
alternatively spliced exons are respectively designated as 41A and 41B, according to 
their original nomenclature.(Guo, Van Damme et al. 1993; Martin and Tryggvason 
2001) Therefore, in comparison to the GenBank® COL4A5 genomic reference 
sequence NG_011977.1, where all the exons are numbered sequentially, the exon 
identifiers beyond exon 41 differ by two, the last one being numbered 51 instead of 
53.  
The SALSA P191-B1/192-B1 Alport Multiplex Ligation-dependent Probe 
Amplification (MLPA) commercial kit (MRC-Holland; Amsterdam, The Netherlands), 
which includes probes for 48 of the 53 exons of COL4A5 and for the first three exons 
of COL4A6 (originally designated 1’, 1 and 2(Sugimoto, Oohashi et al. 1994)), was 
used to detect large deletions/duplications involving COL4A5 and the 5’ region of 
COL4A6. The MLPA assay was performed according to the recommendations of the 
manufacturer (available at http://www.mrc-holland.com).  
“The Human Gene Mutation Database” (HGMD®; accessed at 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A5), The “Leiden Open Variation 
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Database” (accessed at 
https://grenada.lumc.nl/LOVD2/COL4A/variants.php?action=search_unique&select_d
b=COL4A5), and the Alport (COL4A5) Mutation Database of the ARUP Scientific 
Resource for Research and Education, University of Utah, USA (accessed at 
http://www.arup.utah.edu/database/Alport/Alport_display.php) were last checked on 
the March 1, 2014 for previous reports of the COL4A5 sequence variants identified in 
this study.  
Novel DNA sequence variants were considered pathogenic if: (i) the same 
DNA variant was carried by affected relatives of the proband but was not identified in 
first degree at-risk relatives with no evidence of AS; (ii) the DNA sequence variant 
was not detected in a control sample of X-chromosomes (n=235); (iii) exonic single 
nucleotide substitutions were predicted to be disease-causing by in silico analyses 
(see Table I for details); (iv) intronic or exonic single nucleotide substitutions that 
might affect mRNA splicing were predicted to be pathogenic by in silico analyses 
(see Table I for details).  
In apparently sporadic cases, parental genotyping was carried out, whenever 
possible, to confirm whether the COL4A5 mutation identified in a proband was 
inherited or de novo. In cases where the same mutation was identified in apparently 
unrelated probands, the microsatellite polymorphic markers DXS1120, DXS1105, 
DXS1210, DXS456, flanking the COL4A5-COL4A6 genes, were used for haplotype 
analysis as previously described.(Srivastava, McMillan et al. 1999; Tazon-Vega, Ars 
et al. 2007)  
Whenever the comprehensive mutational analyses of COL4A5 did not reveal a 
known or presumed pathogenic mutation, the patient was enrolled in a second tier 
study screening for COL4A3 and COL4A4 mutations. Scanning for mutations in the 
latter two genes was additionally performed in patients with novel COL4A5 variants 
of uncertain pathogenicity.  
Gender comparisons and genotype-phenotype correlation analysis 
For this purpose, the COL4A5 mutations were classified as non-truncating or 
truncating, as formerly proposed.(Gross, Netzer et al. 2002) Demographic and 
clinical data were censored at the time they were collected for each patient and the 
relevant outcomes were compared between genders and between carriers of 
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truncating or non-truncating mutations within each gender. In order to minimize the 
ascertainment bias, comparisons were made in a larger “phenotyping cohort”, 
including not only the genetic probands (“genotyping cohort”) but also their affected 
first or second degree relatives either previously identified or prospectively diagnosed 
on family screening. Parametric and non-parametric statistics were used, as 
appropriate, for comparisons of demographic variables and clinical outcomes. The 
data were analyzed with the IBM SPSS Statistics software version 21 (IBM 
Corporation; Armonk, NY, USA).  
 
RESULTS 
Sixty-five unrelated genetic probands with clinical diagnosis of AS were enrolled in 
this study from all over the country (Supplementary figure S3). Comprehensive 
molecular analyses of COL4A5 was carried out in 33 males (median age: 38 years) 
and 26 females (median age: 36 years) but was limited to the relevant exon in a 5-
year-old boy in whom a pathogenic missense COL4A5 had already been identified as 
part of his clinical diagnostic workup. In the remainder five cases, the family history 
was indicative of autosomal inheritance and mutational analysis of COL4A5 was 
skipped [manuscript submitted to the JMG simultaneously]. In addition to hematuria, 
respectively 5 (8%), 19 (29%), 28 (43%) and 13 (20%) probands fulfilled four, three, 
two and one diagnostic criteria.  
COL4A5 gene mutations 
Twenty-two out of the 60 probands (37%) had a pathogenic mutation in COL4A5, of 
which 12 (57%) are novel and 9 (43%) have been previously described (Table 
I).(Knebelmann, Breillat et al. 1996; Renieri, Bruttini et al. 1996; Martin, Heiskari et al. 
1998; Plant, Green et al. 1999; Wang, Wang et al. 2005; Bekheirnia, Reed et al. 
2010; Wang, Zhao et al. 2012; Sa, Fieremans et al. 2013) Eighty percent of the 
probands who presented with all four diagnostic criteria, but only 1/3 of those who 
presented with two or three criteria, had a pathogenic mutation in COL4A5 
(Supplementary tables S4 and S5). Missense substitutions (7/21; 33%), all of them 
involving glycine residues, were the most common type of mutation. The c.4342G>C 
(p.Gly1448Arg) missense mutation was identified in two apparently unrelated 
families, living in the same geographic area. As the microsatellite risk haplotype was 
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the same in both families (Supplementary figure S6), and additionally included an 
intragenic single nucleotide polymorphism (SNP) in exon 23 (c.1584A>G), the two 
families probably share a common ancestor. Other types of pathogenic COL4A5 
mutations identified in our cohort were nonsense mutations (n=2), acceptor splice 
site mutations (n=2), donor splice site mutations (n=4), small deletions (n=2) and 
large deletions (n=4). It is of note that exon 47 harbored two distinct point mutations; 
that the acceptor splice site of intron 30 harbored 2 distinct small deletions; and that 
the breakpoint of two deletions confined to COL4A5 were located to intron 1. The 
COL4A5 mutation was proven to be de novo by parental genotyping in 2 out of 13 
(15%) genetic probands. Since the remainder 9 probands had family history of major 
AS manifestations, we assume that pathogenic COL4A5 mutations occurred de novo 
in 9% of probands from this cohort.  
Identification of the disease-causing mutation in the genetic probands allowed 
confirmation of the diagnosis of XLAS in an additional 43 patients of the 22 families, 
increasing the size of the phenotyping cohort to 65 patients – 30 males (46%) and 35 
females (54%), with mean ages at genotyping respectively of 36±16.8 and 42±14.8 
years (Supplementary tables S7, S8, S9 and S10). 
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Table I. Pathogenic COL4A5 mutations identified in 22 families with clinical diagnosis of collagen type IV-related nephropathy. 
Type of 
mutation 
Exon / 
/ Intron 
Nucleotide change Predicted effect  
on the protein 
Family  
(ID#) 
[Reference] or original report // Annotations 
and comments 
Missense 
 
E8 c.458G>A p.(Gly153Asp) 53 [(Bekheirnia, Reed et al. 2010)] // (a) (b) (c) 
 
E13 c.715G>A p.(Gly239Arg) 23 [(Wang, Zhao et al. 2012)] // (a) (b) (c) (§) 
 
E18 c.1009G>A p.(Gly337Ser) 48 Novel // (a) (b) (c) (§) (^) 
 
E24 c.1718G>A p.(Gly573Asp) 57 [(Martin, Heiskari et al. 1998)] // (a) (b) (c) 
 
E25 c.1844G>A p.(Gly615Glu) 49 Novel // (a) (b) (c) (§) (^) 
 
E31 c.2633G>T p.(Gly878Val) 50 [(Plant, Green et al. 1999)] // (a) (b) (c) 
 
E47 c.4342G>C p.(Gly1448Arg) 7, 11 Novel // (a) (b) (c) (§) (^) 
Nonsense 
 
E33 c.2815G>T p.(Glu939*) 26 Novel // (a) (§) 
 
E47 c.4444C>T p.(Gln1482*) 6 LOVD@ // (a) (§) 
Splicing 
 
I19 c.1165+1G>A 
 
60 [(Renieri, Bruttini et al. 1996)] // (a) 
 
I20 c.1339+6C>G 
 
3 Novel // (a) (d) (§) 
 
I46 c.4297+1G>A 
 
31 [(Wang, Wang et al. 2005)] // (a) 
 
I49 c.4803+1G>A 
 
45 [(Knebelmann, Breillat et al. 1996)] // (a) 
Small deletions 
 
E10 c.590delC p.(Pro197Glnfs*6) 15 Novel // (a) (§) 
 
E30 c.2423delG p.(Gly808Aspfs*11) 1 Novel // (a) (§) 
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 I30/E31 c.2510(-1)_2525del(15bp)Δ  34 Novel 
Large deletions 
 E1-13 delE1_13 (+delE1_3,COL4A6)  33 [(Sa, Fieremans et al. 2013)] (Novel) 
 
E2-29 delE2_29 
 
41 [(Sa, Fieremans et al. 2013)] (Novel) 
 
E2-51 delE2_51 
 
19 [(Plant, Green et al. 1999; Sa, Fieremans et al. 2013)] // (^^) 
 E31 c.2510_2554del(45bp)ΔΔ  28 Novel 
 
E43-45 delE43_45 
 
18 Novel 
 
Mutations were classified according to the Human Gene Mutation Database nomenclature [www.hgmd.cf.ac.uk/ ]. Nonsense point mutations, frameshifting 
mutations and exonic deletions were considered pathogenic.  
@
 Mutation reported at the LOVD – Leiden Open Variation Database [accessed at 
https://grenada.lumc.nl/LOVD2/COL4A/variants.php?select_db=COL4A5&action=search_all&search_Variant%2FDNA=c.4444C>T].  
Bioinformatic predictions of pathogenicity for missense non-synonymous mutations, splice site intronic mutations and short (<12 nucleotides) 
microdeletions: 
(a) MutationTaster [www.mutationtaster.org/];  
(b) PolyPhen-2 [genetics.bwh.harvard.edu/pph2/ ];  
(c) SIFT [sift.jcvi.org];  
(d) Human Splicing Finder [http://www.umd.be/HSF/].  
(§) Sequence variation not identified in 234 control X-chromosomes.  
(^) Pathogenic mutations reported at the same codons:  
(i) p.(Gly337Asp) / c.1010G>A, reported at the Leiden Open Variation Database [LOVD; accessed at 
https://grenada.lumc.nl/LOVD2/COL4A/variants.php?select_db=COL4A5&action=search_all&search_Variant%2FDNA=c.1010G>A];  
(ii) p.(Gly615Arg) / c.1843G>C, reported by Wang et al, 2012(Wang, Zhao et al. 2012);  
(iii) p.(Gly1448Ser) / c.4342G>A, reported by Wang et al. 2005(Wang, Wang et al. 2005). 
(^^) Plant et al. 1999(Plant, Green et al. 1999) also reported large deletions encompassing exons 2_51 but their exact breakpoints were not determined. 
Δ
 GGTTTACATCATGGAATA.  
ΔΔ GTTTACATGGAATACCAGGAGAGAAGGGGGATCCAGGACCTCCTG (p.delGLHGIPGEKGDPGPP): the first nucleotide involved in this deletion is the 
first nucleotide of exon 31.  
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Inter-gender comparisons of clinical outcomes 
Microscopic hematuria was detected in all the 65 patients of the XLAS phenotyping 
cohort (Table II). History of macroscopic hematuria was significantly more common in 
males than females (62% vs 17%; p=0.002). Proteinuria was more frequently 
reported in males than females, but the difference did nor reach statistical 
significance (96.2% vs 79%; p=0.067). Although the proportion of patients with 
history of hypertension also did not differ significantly between males and females 
(73% vs 53%; p=0.112), the median age at onset of hypertension was significantly 
lower in the male patients (20 vs 34 years; p=0.002). Eighty-six percent of the male 
patients and 62% of the females developed CRF (p=0.029). CRF was diagnosed in 
males at a significantly lower age than in females (21 vs 32 years; p=0.038). At 
diagnosis of CRF, eGFR was significantly lower in males (40 vs 61 ml/min/1.73m2; 
p=0.003). While 77% of male patients with CRF had already started RRT, only 17% 
of females with CRF were on RRT (p<0.001). Six males and three females in the 
XLAS phenotyping cohort had EM photomicrographs of kidney biopsies available for 
review. All of them showed the typical ultrastructural features of AS, i.e. alternate 
thinning and thickening of the GBM with splitting and/or reticulation of the lamina 
densa, enclosing electron-lucent areas that contain round electron-dense bodies with 
diameters of up to 90 nm. Subjective hearing loss was more often reported (87% vs 
46%; p=0.001) in males than in females. Likewise, anterior lenticonus and dot-and-
fleck retinopathy were more frequently diagnosed in the males (p=0.013 and 
p=0.129, respectively). ATS-DL was diagnosed in a single family, in association with 
a large deletion involving COL4A5, but not the COL4A6 gene.(Sa, Fieremans et al. 
2013) 
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Table II. Phenotypic comparisons between hemizygous males and heterozygous 
females for pathogenic COL4A5 mutations (n=65). 
 Hemizygotes 
(n=30) 
Heterozygotes 
(n=35) 
p-value 
  N  N  
PHENOTYPE 
Age at enrolment (median (interquartile range)) 33.5 (18.5) 30 42 (14.8) 35 0.088  
History of renal abnormalities 
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
61.9 
5 (4) 
13/21 
11 
17.4 
3 (11.5*) 
4/23 
3 
0.002  
0.501  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
12.5 (20.3) 
25/25 
22 
100.0 
21 (26.5) 
35/35 
28 
a 
0.219 
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
96.2 
18 (22.5) 
25/26 
21 
78.8 
24 (19) 
26/33 
23 
0.067  
0.508  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
73.1 
20 (11.5) 
19/26 
12 
52.9 
34 (22.3) 
18/34 
16 
0.112  
0.002  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
86.2 
21 (10) 
40 (35) 
25/29 
16 
13 
61.8 
32 (17.5) 
61 (26.3) 
21/34 
20  
20 
0.029  
0.038  
0.003  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
76.7 
23 (19.5) 
9 (6) 
23/30 
21 
12 
17.1 
40 (14) 
6 (1) 
6/35 
6 
5 
<0.001  
0.272  
0.019  
GBM ultrastructural abnormalities 
Age at kidney biopsy (median (interquartile range)) 20 (14.5) 6 24 (11*) 3 0.933  
Thinning (%) 100.0 6/6 100.0 3/3 a 
Thickening (%) 100.0 6/6 100.0 3/3 a 
Lamellation (%) 100.0 6/6 100.0 3/3 a 
Electrondense bodies (%) 100.0 6/6 100.0 3/3 a 
Hearing loss 
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
86.7 
15 (30) 
26/30 
15 
45.5 
39 (19) 
15/33 
9 
0.001  
0.142  
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
94.1 
27.5 (18) 
16/17 
16 
91.3 
41 (10) 
21/23 
13 
0.053  
0.030  
Ocular abnormalities 
Anterior lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
33.3 
19 (12) 
5/15 
5 
0.0 
- 
0/18 
- 
0.013  
- 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
50.0 
25 (19) 
10/20 
8 
26.3 
44 (22) 
5/19 
5 
0.129  
0.180  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
46.2 
30 (35.8) 
6/13 
6 
15.0 
56 (56*) 
3/20 
3 
0.107  
0.263  
Other abnormalities 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
3.3 
24 (0*) 
1/30 
1 
5.7 
18 (0*) 
2/35 
1 
1.000 
0.317 
GENOTYPE      
Truncating mutation (%) 47 14/30 37.1 13/35 0.437  
SD: standard deviation.  CKD: chronic kidney disease.  eGFR: estimated glomerular filtration rate. GBM: 
glomerular basement membrane. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. * The range is 
indicated instead of the interquartile range. a Statistics not computed because the proportions in the comparison 
groups are the same. 
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Genotype-phenotype correlations 
Among males, no statistically significant differences were found between patients 
with truncating and non-truncating COL4A5 mutations in the prevalence of the major 
renal manifestations of AS, or of their natural histories as captured by age or severity 
of CRF at diagnosis (Supplementary table S11). Although the prevalence of SNHL 
was not statistically different in the two groups, subjective hearing loss was reported 
by patients with truncating mutations at a much younger age than by those with non-
truncating mutations (7 vs 36 years; p<0.001). While the difference in the 
prevalences of anterior lenticonus in patients with truncating and non-truncating 
mutations who underwent formal ophthalmological examination did not reach 
statistical significance (50% vs 14%; p=0.282), dot-and-fleck retinopathy was 
identified in a significantly higher proportion of patients with truncating mutations 
(75% vs 13%; p=0.020).  
Among females, CRF was diagnosed in 92.3% of those with truncating 
COL4A5 mutations but only in 43% of those with non-truncating mutations (p=0.005) 
(Supplementary table S12). However, the age at diagnosis of CRF did not differ 
significantly (32 vs 31 years; p=0.684) and the proportion of patients who needed 
RRT was similar in the two groups (15% vs 18%; p=1.000). Patients with truncating 
mutations reported subjective hearing loss more frequently than those with non-
truncating mutations (69% vs 30%; p=0.027) and SNHL was also confirmed by tonal 
audiogram at a significantly younger age in the former group of patients (38 vs 47 
years; p=0.003). Irrespective of the type of mutation, ocular involvement was 
diagnosed in only a small minority of females with AS.  
 
DISCUSSION 
Herein, we report the clinical characterization, the molecular pathology and the 
genotype-phenotype correlations observed in 22 Portuguese families with genetically 
confirmed XLAS, identified by mutational screening of a nationwide cohort of 65 non-
related probands in whom the diagnosis of AS was considered clinically established 
or probable, according to standard clinical and pathologic criteria.(Flinter, Cameron et 
al. 1988)  
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A pathogenic COL4A5 mutation was identified in only 34% (22/65) of families. 
This prevalence is within the 30-67% range reported in several large studies that 
have used single-strand conformation polymorphism (SSCP) analysis to screen for 
COL4A5 mutations,(Hertz 2009) but is significantly lower than the 82% rate reported 
with PCR amplification and direct DNA sequencing of the promoter and all the exons 
of COL4A5.(Martin, Heiskari et al. 1998) Such a result cannot be attributed to 
limitations of the laboratory methods that we have used to scan for mutations, as the 
sensitivity of MLPA combined with direct sequencing to identify COL4A5 mutations is 
higher than 95%(Hanson, Storey et al. 2011) while that of SSCP is estimated to be 
around 80%.(Grompe 1993) Although we did not scan for promoter and deep intronic 
mutations, missing COL4A5 mutations at those locations is an unlikely 
explanation(King, Flinter et al. 2006) for the lower than expected prevalence of XLAS 
observed in the Portuguese families.  
The wide variety of different types of pathogenic COL4A5 mutations identified 
in this study is further evidence of the effectiveness of our laboratory approach, and 
their relative frequencies did not significantly differ from those reported to the 
HGMD®. Surprisingly, a large deletion confined to COL4A5 was identified in a family 
with ATS-DL, challenging an established concept of genotype-phenotype 
correlation.(Sa, Fieremans et al. 2013) Pathogenic COL4A5 mutations were novel in 
57% of families (12/21) and occurred de novo in 15% (2/13) of the probands, which is 
within the expected 10-15% range.(Kashtan 2001) With the exception of a glycine 
substitution (p.Gly1448Arg) shared by two apparently unrelated families from 
neighboring villages, all other pathogenic COL4A5 mutations identified in our cohort 
were exclusive of single families. These findings show that mutation panels designed 
for the genetic diagnosis of AS should be based on population-specific data.4  
The detection rates of pathogenic COL4A5 mutations in probands with 
complete clinical assessment (n=22) that fulfilled one, two, three, or four diagnostic 
criteria were, respectively, 0.0%, 25.0%, 14.3% and 80.0%. The corresponding 
figures reported for British patients (n=101) were 9.5%, 48.5%, 82.1%, and 
81.3%,(Hanson, Storey et al. 2011) which differ significantly from our own results 
only for patients fulfilling three diagnostic criteria. Since the extrarenal manifestations 
of AS seem to be relatively rare in patients with autosomal forms of the 
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disease,(Tryggvason and Patrakka 2009) a possible explanation for that difference 
might be the higher prevalence of ADAS or ARAS in Portuguese families. Indeed, 
preliminary results of second-tier mutational screening of COL4A3 and COL4A4 
[manuscript submitted to the JMG simultaneously] suggest that the proportion of 
XLAS in Portuguese families with AS is significantly lower than the 80-85% generally 
referred in the literature.(Kashtan 1999; Tryggvason and Patrakka 2009; Kruegel, 
Rubel et al. 2013) These data are much in agreement with those of a recent Italian 
study(Fallerini, Dosa et al. 2013) reporting the diagnosis of XLAS in only 65% of 48 
families with genetically confirmed AS, by unbiased simultaneous next generation 
sequencing (NGS) of COL4A5, COL4A3 and COL4A4. In keeping with the above 
argument, more than half of the Italian patients that presented with only one or two 
diagnostic criteria of AS had a pathogenic mutation identified by NGS.(Fallerini, Dosa 
et al. 2013)  
The clinical manifestations of renal disease observed in our phenotyping 
cohort did not substantially differ from the classical descriptions of the 
XLAS.(Kashtan 1999; Tryggvason and Patrakka 2009) Microscopic hematuria was 
the most consistent diagnostic clue, being present in all cases, irrespective of 
gender. Although history of macroscopic hematuria was much more frequent in 
males, the first episode typically occurred before school age in both boys and girls. 
Proteinuria was also highly prevalent in males and females but its diagnosis usually 
followed the detection of hematuria by several years. The risks of developing 
progressive CRF and of needing RRT were considerably higher in males; 
nevertheless, CRF was diagnosed in 62% of the heterozygous females, at young 
adult age in many cases. Only two-thirds of the patients in our genotyping cohort had 
undergone audiological assessment and only approximately 58% had been referred 
for specialized ophthalmological examination. These data show that formal screening 
for the extrarenal signs of AS is frequently overlooked in clinical practice.  
Because of the genetic heterogeneity and variable clinical expression of AS, 
and the incomplete penetrance of XLAS in females, clinicians should take a detailed 
three-generation family history in order to try to recognize a pattern of inheritance, 
before initiating genetic testing for AS.(Hanson, Storey et al. 2011) Particularly in 
females, the diagnosis of microscopic hematuria requires repeated urinalysis. Not 
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screening for SNHL by audiogram, and for the typical ocular lesions by slit-lamp 
ophthalmological examination, are common errors in clinical practice that should be 
avoided. Indeed, failure to comprehensively assess patients for the clinical diagnostic 
criteria of AS may be one of the reasons for missing the diagnosis in some cases, for 
uninformative family histories and erroneous estimates of genetic risks, and for false 
assumptions of de novo mutations.  
In contrast with results of previous studies,(Jais, Knebelmann et al. 2000; 
Gross, Netzer et al. 2002; Bekheirnia, Reed et al. 2010) we did not identify any 
significant differences on the prevalence or severity of expression of renal disease 
between males carrying truncating or non-truncating COL4A5 mutations, although 
they had a more severe extrarenal phenotypes. On the other hand, the higher 
prevalence of CRF and of hearing loss in females with truncating COL4A5 mutations 
observed in our cohort was not apparent in the largest study of females with XLAS 
reported so far.(Jais, Knebelmann et al. 2003) However, the relative small size of our 
study cohort should caution about the generalization of the present findings.  
Genetic testing in AS is useful for confirming a clinical diagnosis, informing 
genetic counseling, and facilitating both prenatal and pre-implantation 
diagnosis.(Bekheirnia, Reed et al. 2010) The identification of a pathogenic COL4A5 
mutation is the most specific diagnostic criterion of XLAS, avoiding more invasive 
and complex diagnostic procedures as kidney or skin biopsy.(Kashtan 1993-2013) In 
addition, the type of mutation is of help in the estimation of the clinical 
prognosis.(Jais, Knebelmann et al. 2000; Gross, Netzer et al. 2002; Bekheirnia, Reed 
et al. 2010) However, molecular genetic analysis by Sanger sequencing of all 53 
COL4A5 exons and their flanking intronic sequences is an expensive, time-
consuming process and several weeks are usually needed to complete a 
diagnosis.(Artuso, Fallerini et al. 2012) The recently available, high-throughput NGS 
methods for DNA sequencing are cheaper and have much lower turn-around times 
than the conventional Sanger method. High-throughput DNA sequencing methods 
are most useful for the molecular diagnosis of genetically heterogeneous disorders, 
and NGS may soon become the first-tier genetic test in cases where AS is clinically 
suspected, particularly in populations where the prevalence of XLAS is not much 
higher than that of the autosomal forms.(Fallerini, Dosa et al. 2013) In those families 
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where the causative COL4A5 mutation is already known, genetic testing of at-risk 
persons is much less expensive, allows the accurate assessment of individual 
genetic risks and provides a tool for pre-symptomatic diagnosis, which is particularly 
valuable in females, and for the selection of potential family donors for kidney 
transplantation.(Gross, Weber et al. 2009; Kashtan 2009) Moreover, early 
confirmation of the diagnosis of XLAS offers the opportunity to optimize treatment 
outcomes, since pharmacologic blockade of the renin–angiotensin–aldosterone 
system with angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers proved effective in delaying the progression of CRF in both males and 
females.(Gross, Licht et al. 2012; Temme, Peters et al. 2012)  
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Supplementary table S1. Outcome variables, definitions, measurement of outcomes, diagnostic methods, degree of evidence and time 
of collection of clinical variables. 
 Outcomes Definition of outcomes Measurement of outcomes Diagnostic 
evaluation  
Degree of 
evidence 
Time of 
diagnosis  
Birth District District of Portugal where the patient was born Portuguese districts None I, CF, Q – 
Residence District District of Portugal where the patient lived at the 
date of enrollment 
Portuguese districts None I, CF, Q – 
Affected relatives Family history of hematuria, CRF or hearing loss Exams required to evaluate the 
renal, audiologic and ocular 
involvement 
 
 
Pedigree I, CF, Q At enrollment 
Retrospectively 
Renal anomalies           
History of 
macroscopic 
hematuria 
Presence of red blood cell (RBC) in urine visible 
to the eye, as “cola-colored” urine. 
Occurrence of outcome 
(Yes/No) 
Age at first event (in years) 
Urinalysis I, CF, Q Retrospectively 
History of 
microscopic 
hematuria 
≥3 RBC visible per high power field under light 
microscopy examination of the centrifuged urine 
sediment or an equivalent value per microliter 
when assessed by flow cytometry 
Occurrence of outcome 
(Yes/No) 
Age at first event (in years) 
Urinalysis:  
- RBC count 
Urinalysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
History of 
proteinuria 
Urinary protein excretion ≥300 mg/day or a 
urinary protein to creatinine ratio ≥300 mg/g, in 
morning spot samples. The highest recorded 
level of 24-hour proteinuria was graded as 
follows: ≤500 mg/day; 500–1000 mg/day; 1000–
3500 mg/day; ≥3500 mg/day. 
Occurrence of outcome 
(Yes/No) 
Age at first event (in years) 
Degree of proteinuria (mg/day or 
mg/g) at diagnosis/most recent 
Highest recorded level of 
proteinuria 
 
Urinalysis:  
- Protein count  
Urinalysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
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 Outcomes Definition of outcomes Measurement of outcomes Diagnostic 
evaluation  
Degree of 
evidence 
Time of 
diagnosis  
History of 
hypertension 
Systolic blood pressure ≥140 mmHg and/or 
diastolic blood pressure ≥90 mmHg. Patients 
undergoing chronic anti-hypertensive 
medication were also considered to have 
hypertension, irrespective of their blood 
pressure levels. 
Occurrence of outcome 
(Yes/No) 
Age at first event (in years) 
Therapy with anti-hypertensive 
medication (Yes/No) Age at 
onset of anti-hypertensive 
medication (in years) 
Blood pressure 
measurement 
I, CF, Q Retrospectively 
At enrollment 
During the study 
History of CRF 
(≥ stage 2 CKD) 
Plasma creatinine (pCr) level ≥1.2 mg/dl in 
males and ≥0.9 mg/dl in females.*  
Plasma creatinine level (mg/dl) 
CKD stage (≥2, according to the 
KDOQI clinical guidelines) 
Blood analysis:  
- Plasma 
creatinine level 
Blood analysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
History of 
advanced CRF 
(≥ stage 3 CKD) 
Plasma creatinine level >1.5 mg/dl in males and 
>1.2 mg/dl in females. 
Plasma creatinine level (mg/dl) 
CKD stage (3 to 5, according to 
the KDOQI clinical guidelines) 
Blood analysis:  
- Plasma 
creatinine level 
Blood analysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
Estimated 
glomerular 
filtration rate 
(eGFR)  
eGFR computed from pCr values, namely at the 
diagnosis of CRF and advanced CRF (eGFR at 
diagnosis of stage 2 and stage 3 CKD).** 
eGFR (ml/min/1.73 m2) CKD 
stage (≥2, according to the 
KDOQI clinical guidelines) 
Blood analysis:  
- Plasma 
creatinine level 
Blood analysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
History of renal 
replacement 
therapy (RRT) 
First procedure of renal replacement function 
(hemodialysis, peritoneal dialysis or renal 
transplantation), performed when the GFR 
reached <15 ml/min 
Need of RRT (Yes/No) Age at 
onset of first RRT (in years)  
Plasma creatinine level at onset 
of first RRT (mg/dl)  
eGFR at onset of first RRT 
(ml/min/1.73 m2) 
Blood analysis:  
- Plasma 
creatinine level 
Blood analysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
Time between 
onset of first RRT 
and first kidney 
transplant 
Time from the date of onset of first RRT 
(dialysis) and first kidney transplant 
Time (in months) None I, CF, Q 
 
Retrospectively 
At enrollment 
During the study 
Last available pCr 
(eGFR) 
eGFR calculated from the last measurement of 
plasma creatinine level of the participant, to 
evaluate his/her CKD stage** 
eGFR (ml/min/1.73 m2) CKD 
stage (≥2, according to the 
KDOQI clinical guidelines) 
Blood analysis:  
- Plasma 
creatinine level 
Blood analysis 
report 
I, CF, Q 
Retrospectively 
At enrollment 
During the study 
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 Outcomes Definition of outcomes Measurement of outcomes Diagnostic 
evaluation  
Degree of 
evidence 
Time of 
diagnosis  
Typical 
ultrastuctural GBM 
abnormalities 
Characteristic ultrastructural GBM abnormalities 
of Alport syndrome, namely thinning, thickening, 
lamellation and electron-dense particles in GBM 
lacunae 
Age at kidney biopsy (in years)  
GBM thinning (Yes/No) GBM 
thickening (Yes/No)  
GBM lamellation (Yes/No)  
Electron-dense particules in 
GBM lacunae (Yes/No) 
Kidney biopsy 
with electron 
microscopy 
examination 
Pathology 
database: - 
Electron 
microscopy 
photographies 
Kidney biopsy 
report (CF), Q 
Retrospectively 
Typical hearing loss (HL) 
History of self-
noticed HL 
Self-perception of HL and approximated age at 
onset of self-noticed HL 
Self-noticed HL (Yes/No)  
Age at onset of self-noticed HL 
(in years) 
None I, CF, Q  Retrospectively 
Diagnosis of HL Diagnosis of HL and its characterization by 
audiogram, including uni- or bilateral HL, type of 
HL and degree of HL. The degree of HL was 
classified using standardized hearing loss 
categories, according to the WHO classification 
(Danermark, Cieza et al. 2010), as follows: dB 
HL < 26 (normal); 26 ≤ dB HL < 40 (Mild HL); 
41 ≤ dB HL < 60 (Moderate HL); 61 ≤ dB 
HL < 80 (Severe HL); 80 < dB HL (Profound 
HL). 
Diagnosis of HL (Yes/No)  
Type of HL  
Degree of HL:  
- Pure tone average (PTA): 
average of the three thresholds 
(in decibels, dB) at 500 Hz, 1000 
Hz and 2000 Hz 
- Average of high frequencies: 
average of the two thresholds (in 
decibels, dB) at 4000 Hz and 
8000 Hz  
Age at the first and the most 
recent audiometric evaluations 
(in years) 
Pure tone 
audiogram 
High frequency 
audiogram 
Audiogram Retrospectively 
At enrollment 
During the study 
Typical ocular abnormalities 
History of anterior 
lenticonus, 
retinopathy and 
History of and age at diagnosis of anterior 
lenticonus, dot-and-fleck maculopathy, retinal 
atrophy and cataracts 
Anterior lenticonus (Yes/No)  
Dot-and-fleck maculopathy 
(Yes/No) 
Biomicroscopy
Funduscopy  
OCT 
Biomicroscopy 
photography 
Fundus 
Retrospectively 
At enrollment 
During the study 
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 Outcomes Definition of outcomes Measurement of outcomes Diagnostic 
evaluation  
Degree of 
evidence 
Time of 
diagnosis  
cataracts Retinal atrophy (Yes/No) 
Cataracts (Yes/No) 
Age at the first and the most 
recent ophthalmological 
assessment (in years) 
photography 
I, CF, Q 
Other clinical outcomes 
Abnormal type IV 
collagen 
expression in EBM 
Abnormal epidermal basement membrane 
(EBM) reactivity to a monoclonal antibody 
directed against the α5(IV) chain 
Complete absence, 
discontinuous or presence of 
staining of the EBM with a 
monoclonal antibody directed 
against the collagen α5(IV) 
chain  
Skin biopsy 
with 
immunohistoch
emical 
analysis of the 
type IV 
collagen 
expression in 
the EBM 
EBM 
photography 
Retrospectively 
During the study 
History of diffuse 
leiomyomatosis 
Gastrointestinal, tracheobronchial and female 
genital manifestations 
Histologic diagnosis Endoscopic 
ultrasonograph
y with 
esophageal 
biopsy 
Pathology 
report 
I, CF, Q 
Retrospectively 
At enrolment 
During the study 
History of 
intellectual 
impairment 
Level of education and employment Number of year in school 
Degree completed  
Job 
None I, CF, Q Retrospectively 
At enrolment 
During the study 
Typical 
dysmorphic face 
Craneofacial dysmorphy described in patients 
with AMME complex (Meloni et al., 2002) 
Mild midface hypoplasia  
Anteverted nares  
Flat nasal bridge Downward 
slanting palpebral fissures 
Peripalpebral fullness Facial 
hypotonia 
Physical 
examination 
Facial 
photography 
I, CF, Q 
Retrospectively 
At enrollment 
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I: Patient interview. 
CF: Patient clinical file: consultation registry, pre-dialysis medical report, referral information. 
Q: Questionnaire filled by assistant physician. 
OCT: Optical Coherence Tomography. 
*These pCr cut-off values were selected to be roughly equivalent to the upper limits of eGFR for the diagnosis respectively of stage 2 and stage 3 
chronic kidney disease (CKD), in patients with kidney damage, over the age of 18 years, according to the Kidney Disease Outcomes Quality Initiative 
(KDOQI) clinical practice guidelines for CKD evaluation, classification and stratification of the National Kidney Foundation (NKF; New York, NY, USA) 
(http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class_g1.htm). 
**The eGFR was computed from pCr values using the calculators available online at the NKF website 
(http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm), as appropriate. [Online calculator used at the NKF website: CKD-EPI Creatinine 
equation 2009] 
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Supplementary table S2. Primer sequences, annealing temperatures and product size for PCR amplification of the COL4A5 gene.† 
 
Exons Foward Primers (5’ to 3’) Reverse Primers (5’ to 3’) Annealing 
temperature 
PCR 
Product size 
1 AAGCCTCACTGTCCCTCTC AAAGGAAGATAAAGGGACCC 60ºC 296 bp 
2 GATTGTTGATTTCAGTTGAGCTGT CTTAAGTACTGAGATAGAAGCTC 51ºC 248 bp 
3 TCTCAACCATGCCTGTGCTTG TGATGTGACACCTAGTCCCAC 60ºC 229 bp 
4 TCACAGATGTTTACAGTAGTTTAAA GGTCTTTTCCAATTGTCTCAT 57ºC 237 bp 
5(F)/6(R) GAACAATGAGTAGTAATAAATAGTG TTGTCAAGTATACTACCCAAGAT 52ºC 373 bp 
7(F)/8(R) GGAAAGTGAAGGCTAATGAAC ATTATCCTATTGAAGTTGCCAGC 52ºC 644 bp 
9 GCCTAATCTTTTAGTACATCTC GTACTAAAGGTTGAGGGAT 52ºC 275 bp 
10 GGCGACACAAGTGAGACTTT GAATGTTGAGAATGCATTATGTTTTC 52ºC 248 bp 
11(F)/13(R) AATACTATTTTGATGGGCTTT TATACATTGTGATGTGATTAC 52ºC 628 bp 
14(F)/16(R) CTCCAGCTCTAACCATGTTG TTTTGTCATACTGCTTCTCT 55ºC 726 bp 
17 GAAGACAATCTTTGGAG TAACTCAAGCCTGGGAGAA 52ºC 201 bp 
18 TGGAAAGTTTCTCTTATATTC TGTGTTCTATCAAGAAAGAG 48ºC 224 bp 
19 CAGGAGAACAAGGCTTTTCTTCTTTGCA
TT 
ACATGGATTAGTAAGGATGC 52ºC 248 bp 
20(F)/21(R) GAAGATCTTATCATTATCTAATG GTCTTGGGGTATGACCAT 51ºC 793 bp 
22 GTGGAAATGCTGTCCCTTAG CATTCTAAAAGTATAAGCTCAAC 52ºC 266 bp 
23(F)/24(R) TCAAAGCTTACGTTATTGTGT GGTGTTTATCTCAGCATCAG 55ºC 726 bp 
25 GAAGAACTATTTATGGCTATATCC TTGGCTACTCATGGCTTCC 57ºC 350 bp 
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Exons Foward Primers (5’ to 3’) Reverse Primers (5’ to 3’) Annealing 
temperature 
PCR 
Product size 
26(F)/27(R) AGACCTTTAGTTGAGTAAATAC CATGATGTTATTCTCTCATAAA 52ºC 757 bp 
28 ACATCTTACTGTTGTCACTAAGC GTCTTTACTATAAATATACAGATAAC 52ºC 334 bp 
29 CGGCATTAAATTCTCTGT GTTTCCAGTTAATTGGGC 57ºC 333 bp 
30 TTCTTGCTGAATGAATGC TCACTTTATTGATGAGCTAAC 55ºC 300 bp 
31 TTAGGTCTGTTATCTACAGGG GAATTATCTACCAGAGTCGTATTAG 48ºC 347 bp 
32 AGTTTTCTGGTTGACATCTTAAAA TATTCTGTACTGACATAAAGC 55ºC 249 bp 
33 ATATGCATTAATCTTTGATGGA ATAAGTCACTTTTCATGC 48ºC 293 bp 
34 CTTATAGTTTAACACTTGAGTAG GAATTCAGTGTCAGCTAAGCA 52ºC 243 bp 
35(F)/36(R) GACTATCCATTCCCATGAAACCAG AAAACTTAGGAATGAGCATAG 50ºC 800 bp 
37 ATTTACATCAAGTACTTACTGGAG AGTCTGCCAAATAAGAAGCTGC 53ºC 337 bp 
38 GTTCTTCACTGTTTCTATGCT AATGTTCACAGCTGAACATGA 48ºC 279 bp 
39 GAAGGGAGCATATGGAAG CAAGTTAAATTCAACACAG 50ºC 233 bp 
40 AGTTTGTATTATCCACTTGAGT GTAAAAGGTGGAGATGGAAAA 48ºC 191 bp 
41 ATTGCCCTAATGTATGTGAATAGC CAAGCTATTTACTTGTAAGAAGTTAT 50ºC 441 bp 
41A CTTTTTGTTAATGATGACAT ACAGAAACACTGGGTTCTACA 55ºC 232 bp 
41B CTTCTGTATGGTTCTGTTTGC TTGCATTTCTCTTATCACACAC 55ºC 269 bp 
42 GAAGATGACTGATATTTTAAAAG GAATTCACATTTTGAATACA 50ºC 286 bp 
43(F)/44(R) AGTTTGACTCTAGAAATAGTGC GCATCTAAGTATCAGGTATAAC 50ºC 433 bp 
45 GTCCTGAACTTAGGTCACTTT GCACATGTATCCCAGAAAT 55ºC 228 bp 
46 CTTATGTCTCCTAGATCTGTC ATCTCACAGCTCTAAGTGGAG 55ºC 263 bp 
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Exons Foward Primers (5’ to 3’) Reverse Primers (5’ to 3’) Annealing 
temperature 
PCR 
Product size 
47 ATGAGGTCATAATGTTTTGTC CACTTTGGCCAAGGCTACTC 55ºC 386 bp 
48 TTGAAAGGCTGTTTGCTATTG ACCTAGGAGGAATATCATCAG 55ºC 364 bp 
49 ATCGGCTTCCATACTAAGAAG GCAAATGACAGGGATTCCTC 55ºC 304 bp 
50 GATTTGAATTTGGCCAAGCTC CATTTGTTGAGGATAAACCAT 55ºC 366 bp 
51 GTCACCAAGAGAGCTACTTAACAC CATTGACGGCAGCAGTAGTAAAG 55ºC 303 bp 
 
†
 Cycling conditions (adapted from (Martin, Heiskari et al. 1998)) were: initial denaturation for 5 minutes at 94ºC, followed by 35 
cycles of denaturation at 94ºC for 60 seconds, annealing for 60 seconds, and extension at 72ºC for 90 seconds, ending with a final 
extension at 72ºC for 10 minutes. 
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Supplementary figure S3 
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Supplementary figure S3. Map of Portugal showing the boundaries of each of the 
14 continental districts (white background) and the two autonomous Atlantic islands 
regions. The names and geographic locations (black squares) of the respective 
capital cities are shown only for those where probands enrolled in this study were 
resident (numbers in parenthesis). Fifty-one (78.5%) of the 65 probands were 
enrolled through 11 nephrology and two genetics services of public hospitals, and 14 
(21.5%) were enrolled through 12 outpatient dialysis clinics. Of the 16 nephrology 
departments of public hospitals that did not enroll patients, four did not reply to the 
invitation to participate, two declined to participate and ten responded they had no 
patients with the clinical diagnosis of Alport syndrome. Nationwide case 
ascertainment through public hospitals and private dialysis clinics minimized the 
negative impact that the nonparticipation in this study of some public hospitals might 
have had upon the catchment of affected families in some regions of the country. 
Indeed, several families could have been redundantly identified by different patients, 
at different stages of kidney disease, through different sites. The average proband 
catchment, per 100,000 inhabitants, was 0.62 in the continental districts and 1.12 in 
the Madeira Islands. The geographic distribution of the 65 probands by area of 
residence broadly paralleled the Portuguese population density, when comparing the 
coastal, densely populated, and the inland, scarcely populated, regions. Possible 
explanations for the lower than expected catchment in a few of the highly populated 
central-western districts, including in the capital Lisbon district, are the 
nonparticipation in this study of a private dialysis clinics network that is the major 
provider of dialysis care in some of those districts, and the exclusion of four families 
with X-linked Alport syndrome that had been previously enrolled in the European 
Community Alport Syndrome Concerted Action. In contrast, the disproportionately 
higher number of families identified in the northwestern districts of Braga and Porto 
most probably reflects the long-term activity of an outpatient clinic dedicated to 
hereditary kidney disorders operating in a major academic hospital in Porto.  
 
 
 
114 
 
 
 
Supplementary table S4. COL4A5 mutation detection rate per number of diagnostic criteria met, among probands tested for 
COL4A5, with complete and incomplete clinical evaluation (n=60). 
Diagnostic criteria COL4A5 molecular study 
      
FH AC OC UC 
Probands with  
a pathogenic 
mutation identified 
Probands without  
a pathogenic 
mutation identified 
Total 
number of 
probands 
Mutation 
detection 
rate 
Mutation detection 
rate per number of 
diagnostic criteria 
1 criterion FH 9 
   
4 5 9 44% 33% 
  AC 
 
1 
  
0 1 1 0% (4/12) 
  OC 
  
0 
 
0 
  UC 
   
2 0 2 2 0% 
2 criteria FH 
 
14 
  
8 6 14 57% 38% 
  
  
1 
 
0 1 1 0% (10/26) 
  
   
7 1 6 7 14% 
  AC 
  
1 
 
0 1 1 0% 
  
   
3 1 2 3 33% 
  OC 
   
0 0 
3 criteria FH AC 
  
9 
 
2 7 9 22% 24% 
  
   
5 1 4 5 20% (4/17) 
  FH OC 
   
0 0 
  AC OC 
   
3 1 2 3 33% 
4 criteria FH AC OC 
   
5 4 1 5 80% 80% (4/5) 
FH: family history. 
AC: audiologic criteria; hearing loss, with and without confirmation by audiogram. 
OC: ophthalmologic criteria; ocular signs, including anterior lenticonus, cataracts and retinopathy. 
UC: ultrastructural criteria; characteristic glomerular basement membrane changes on electron microscopy examination of kidney biopsy, including 
thinning, thickening, lamellation and presence of electron-dense bodies. 
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Supplementary table S5. COL4A5 mutation detection rate per number of diagnostic criteria met, among probands tested for 
COL4A5, with complete clinical evaluation (n=22). 
    Diagnostic criteria COL4A5 molecular study    
    
FH AC OC UC 
Probands with  
a pathogenic 
mutation identified 
Probands without  
a pathogenic 
mutation identified 
Total 
number of 
probands 
Mutation 
detection 
rate 
Mutation detection 
rate per number of 
diagnostic criteria 
1 criterion FH     0 
   
0 0% 
  AC     
 
0 
  
0 (0/2) 
  OC     
  
0 
 
0 
  UC     
   
2 0 2 2 0% 
2 criteria FH     
 
0 
  
0 25% 
        
  
0 
 
0 (2/8) 
        
   
5 1 4 5 20% 
  AC     
  
0 
 
0 
        
   
3 1 2 3 33% 
  OC     
   
0 0 
3 criteria FH AC   
  
0 
 
0 14% 
        
   
4 0 4 4 0% (1/7) 
  FH   OC 
   
0 0 
    AC OC 
   
3 1 2 3 33% 
4 criteria FH AC OC 
   
5 4 1 5 80% 80% (4/5) 
FH: family history. 
AC: audiologic criteria; hearing loss, with and without confirmation by audiogram. 
OC: ophthalmologic criteria; ocular signs, including anterior lenticonus, cataracts and retinopathy. 
UC: ultrastructural criteria; characteristic glomerular basement membrane changes on electron microscopy examination of kidney biopsy, including thinning, 
thickening, lamellation and presence of electron-dense bodies. 
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Supplementary figure S6 
 
 
Supplementary figure S6. Pedigrees of families 7 and 11, with X-linked 
Alport syndrome segregating with the COL4A5 mutation p.Gly1448Arg, in 
exon 47, showing the individual haplotypes for a set of four polymorphic 
microsatellite markers adjacent to the COL4A5 and COL4A6 genes. The 
numbers indicate the size of each allele, in base pairs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
 
Supplementary table S7. Correlation between genotype and phenotype in Portuguese male patients with truncating COL4A5 
mutations (n=14). 
a In brackets, the age at diagnosis or at last screening, in years. b In brackets, the age at start of hemodialysis (HD), peritoneal dialysis (PD) or of kidney 
transplant (Tx). c In brackets, the age at kidney biopsy. d In brackets, the age at skin biopsy. < Before the age indicated within brackets. CKD: chronic kidney 
disease. pCr: plasma creatinine level, in micromol/L. Conversion of micromoles/L (SI units) into mg/dL may be performed, dividing SI units by the conversion 
factor 88.4. eGFR: estimated glomerular filtration rate, in mL/min/1.73m2. GBM: glomerular basement membrane. EBM: epidermal basement membrane. ND: 
effect on splicing not determined by mRNA analysis. Genetic probands are indicated in bold. 
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Supplementary table S8. Correlation between genotype and phenotype in Portuguese male patients with non-truncating COL4A5 
mutations (n=16). 
 
NA: Data not available. a In brackets, the age at diagnosis or at last screening, in years. b In brackets, the age at start of hemodialysis (HD), peritoneal dialysis 
(PD) or of kidney transplant (Tx). c In brackets, the age at kidney biopsy. d In brackets, the age at skin biopsy. < Before the age indicated within brackets. 
CKD: chronic kidney disease. pCr: plasma creatinine level, in micromol/L. Conversion of micromoles/L (SI units) into mg/dL may be performed, dividing SI 
units by the conversion factor 88.4. eGFR: estimated glomerular filtration rate, in mL/min/1.73m2. GBM: glomerular basement membrane. EBM: epidermal 
basement membrane. ND: effect on splicing not determined by mRNA analysis. Genetic probands are indicated in bold. 
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Supplementary table S9. Correlation between genotype and phenotype in Portuguese female patients with truncating COL4A5 
mutations (n=13). 
NA: Data not available. a In brackets, the age at diagnosis or at last screening, in years. b In brackets, the age at start of hemodialysis (HD), peritoneal dialysis 
(PD) or of kidney transplant (Tx). c In brackets, the age at kidney biopsy. d In brackets, the age at skin biopsy. < Before the age indicated within brackets. CKD: 
chronic kidney disease. pCr: plasma creatinine level, in micromol/L. Conversion of micromoles/L (SI units) into mg/dL may be performed, dividing SI units by 
the conversion factor 88.4. eGFR: estimated glomerular filtration rate, in mL/min/1.73m2. GBM: glomerular basement membrane. EBM: epidermal basement 
membrane. ND: effect on splicing not determined by mRNA analysis. Genetic probands are indicated in bold. 
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Supplementary table S10. Correlation between genotype and phenotype in Portuguese female patients with truncating COL4A5 
mutations (n=13). 
 
a In brackets, the age at diagnosis or at last screening, in years. b In brackets, the age at start of hemodialysis (HD), peritoneal dialysis (PD) or of kidney 
transplant (Tx). c In brackets, the age at kidney biopsy. d In brackets, the age at skin biopsy. < Before the age indicated within brackets. CKD: chronic kidney 
disease. pCr: plasma creatinine level, in micromol/L. Conversion of micromoles/L (SI units) into mg/dL may be performed, dividing SI units by the conversion 
factor 88.4. eGFR: estimated glomerular filtration rate, in mL/min/1.73m2. GBM: glomerular basement membrane. EBM: epidermal basement membrane. ND: 
effect on splicing not determined by mRNA analysis. Genetic probands are indicated in bold. 
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Supplementary table S11. Phenotypic comparisons between hemizygous 
males with truncating and non-truncating pathogenic COL4A5 mutations 
(n=30). 
 Truncating 
(n=14) 
Non-truncating 
(n=16) 
p-value 
  N  N  
PHENOTYPE 
     
Age at enrollment (median (interquartile range)) 28 (11.8) 14 41 (19) 16 0.046  
History of renal abnormalities 
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
50.0 
3.5 (10.5) 
4/8 
4 
69.2 
5 (3) 
9/13 
7 
0.646   
0.527  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
15 (13) 
12/12 
9 
100.0 
8 (27.5) 
13/13 
13 
a 
0.969  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
16.5 (13) 
13/13 
10 
92.3 
23 (26) 
12/13 
11 
1.000  
0.172  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
91.7 
20 (5) 
11/12 
5 
57.1 
20 (19) 
8/14 
7 
0.081  
0.417  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
100.0 
18 (7) 
23 (39) 
13/13 
8  
7 
75.0 
26 (10) 
41.5 (35) 
12/16 
8  
6 
0.107  
0.204  
0.224  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
78.6 
21.5 (12) 
9 (2.3) 
11/14 
10 
6 
75.0 
25 (28) 
10.5 (10) 
12/16 
11 
6 
1.000  
0.512  
0.936  
GBM ultrastructural abnormalities 
Age at kidney biopsy (median (interquartile range)) 18 (14*) 3 28 (12*) 3 0.025  
Thinning (%) 100.0 3/3 100.0 3/3 a  
Thickening (%) 100.0 3/3 100.0 3/3 a  
Lamellation (%) 100.0 3/3 100.0 3/3 a  
Electrondense bodies (%) 100.0 3/3 100.0 3/3 a  
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
100.0 
7 (6.3) 
14/14 
8 
75.0 
36 (27) 
12/16 
7 
0.103  
<0.001 
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
100.0 
19 (15) 
8/8 
8 
88.9 
33 (15.8) 
8/9 
8 
1.000  
0.027  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
50.0 
19 (14) 
4/8 
4 
14.3 
24 (0*) 
1/7 
1 
0.282  
0.806  
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
75.0 
24 (14) 
9/12 
7 
12.5  
46 (0*) 
1/8 
1 
0.020  
0.112  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
50.0 
22 (23.3) 
4/8 
4 
40.0 
56.5 (21*) 
2/5 
2 
1.000  
0.049  
Other abnormalities 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
7.1 
24 (0*) 
1/14 
1 
0.0 
-  
0/16 
- 
0.467  
- 
SD: standard deviation.  CKD: chronic kidney disease.  eGFR: estimated glomerular filtration rate. GBM: 
glomerular basement membrane. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The 
range is indicated instead of the interquartile range. aStatistics not computed because the proportions in 
the comparison groups are the same. 
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Supplementary table S12. Phenotypic comparisons between heterozygous 
females with truncating and non-truncating pathogenic COL4A5 mutations 
(n=35). 
 Truncating 
(n=13) 
Non-truncating 
(n=22) 
p-value 
  N  N  
PHENOTYPE 
Age at enrollment (median (interquartile range)) 43 (16) 13 41.5 (22) 22 0.720  
History of renal abnormalities 
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
22.2 
1.75 (2.5*) 
2/9 
2 
14.3 
12 (-) 
2/14 
1 
1.000  
0.225  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
26 (37) 
13/13 
12 
100.0 
21 (20.5) 
22/22 
16 
a  
0.271  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
92.3 
19.5 (29.3) 
12/13 
10 
70.0 
27 (13) 
14/20 
13 
0.202  
0.717  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
53.8 
35 (22.3) 
7/13 
6 
52.4 
32.5 (26) 
11/21 
10 
0.934  
0.578  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
92.3 
32 (14) 
60 (33) 
12/13 
11 
11 
42.9 
31 (21.5) 
65 (23) 
9/21 
9 
9 
0.005  
0.684  
0.939  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
15.4 
38.5 (15*) 
5 (0*) 
2/13 
2 
1 
18.2 
40 (11.8) 
6 (0.8) 
4/22 
4 
4 
1.000  
0.707  
0.114  
GBM ultrastructural abnormalities 
Age at kidney biopsy (median (interquartile range)) 20.5 (7*) 2 28 (0*) 1 0.225  
Thinning (%) 100.0 2/2 100.0 1/1 a  
Thickening (%) 100.0 2/2 100.0 1/1 a  
Lamellation (%) 100.0 2/2 100.0 1/1 a  
Electrondense bodies (%) 100.0 2/2 100.0 1/1 a  
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
69.2 
34.5 (21.3) 
9/13 
6 
30.0 
46 (7*) 
6/20 
3 
0.027  
0.407  
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
81.8 
37.5 (14.5) 
9/11 
8 
50.0 
47 (20.5) 
5/10 
5 
0.183  
0.003  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/8 
- 
0.0 
- 
0/10 
- 
a  
b 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
40.0 
37 (22.3*) 
4/10 
4 
11.1 
49 (0*) 
1/9 
1 
0.303  
0.156  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
11.1 
20 (0*) 
1/9 
1 
18.2 
66 (20*) 
2/11 
2 
1.000  
0.157  
Other abnormalities 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
15.4 
18 (0*) 
2/13 
1 
0.0 
- 
0/22 
- 
0.131 
- 
SD: standard deviation.  CKD: chronic kidney disease.  eGFR: estimated glomerular filtration rate. GBM: 
glomerular basement membrane. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The 
range is indicated instead of the interquartile range. aStatistics not computed because the proportions in 
the comparison groups are the same.  
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2.1.2. Deletion of the 5’exons of COL4A6 is not needed for the 
development of diffuse leiomyomatosis in Alport syndrome 
patients (Manuscript 2) 
 
Published in J Med Genet. 2013 Nov;50(11):745-53. 
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ABSTRACT 
Background 
Alport syndrome (AS), a hereditary type IV collagen nephropathy, is a major 
cause of end-stage renal disease in young people. About 85% of the cases 
are X-linked (ATS), due to mutations in the COL4A5 gene. Rarely, families 
have a contiguous gene deletion comprising at least exon 1 of COL4A5 and 
the first exons of COL4A6, associated with the development of diffuse 
leiomyomatosis (ATS-DL). We report three novel deletions identified in 
families with AS, one of which challenges the current concepts on genotype-
phenotype correlations of ATS/ATS-DL.  
Methods 
In the setting of a multicentric study aiming to describe the genetic 
epidemiology and molecular pathology of AS in Portugal, three novel COL4A5 
deletions were identified in two families with ATS and in one family with ATS-
DL. These mutations were initially detected by PCR and MLPA, and further 
mapped by high-resolution X chromosome-specific oligo-array and PCR.  
Results 
In the ATS-DL family, a COL4A5 deletion spanning exons 2 through 51, but 
not extending to COL4A6, segregated with the disease phenotype. A COL4A5 
deletion encompassing exons 2 through 29 was identified in one of the ATS 
families. In the second ATS family, a deletion of exon 13 of COL4A5 through 
exon 3 of COL4A6 was detected.  
Conclusions 
These observations suggest that deletion of the 5’ exons of COL4A6 and of 
the common promoter of the COL4A5 and COL4A6 genes is not essential for 
the development of leiomyomatosis in patients with ATS, and that 
COL4A5_COL4A6 deletions extending into COL4A6 exon 3 may not result in 
ATS-DL.  
 
Key words 
Alport syndrome, leiomyomatosis, COL4A5, COL4A6.  
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BACKGROUND 
X-linked Alport syndrome (MIM#301050; ATS) is a childhood onset 
progressive glomerulopathy with high frequency sensorineural hearing loss 
(SNHL) and typical ocular signs.(Kruegel, Rubel et al. 2013) Electron 
microscopy (EM) examination of kidney biopsies of ATS patients, which 
remain a crucial diagnostic test for the disease,(Cosgrove 2012) shows 
characteristic changes of the glomerular basement membrane (GBM), 
including irregular thinning, thickening and splitting. These abnormalities are 
thought to be an expression of the higher susceptibility of the GBM to 
proteolytic degradation,(Khoshnoodi, Pedchenko et al. 2008) in all forms of 
Alport syndrome (AS). ATS is fully penetrant and consistently severe in 
hemizygous males, most of whom have reached end-stage renal disease 
(ESRD) by the age of 30 years, but has lower penetrance and is clinically less 
severe in heterozygous females.  
In rare families, ATS is associated with diffuse leiomyomatosis 
(MIM#308940; ATS-DL). Diffuse leiomyomatosis (DL) is a benign neoplastic 
condition characterized by aberrant proliferation of well differentiated smooth 
muscle cells, involving the gastrointestinal, tracheobronchial and female 
genital tracts.(Garcia Torres and Guarner 1983) DL of the oesophagus is a 
constant finding in families with ATS-DL, being the initial clinical manifestation 
in most patients, frequently mimicking achalasia.(Cochat, Guibaud et al. 1988; 
Bourque, Spigland et al. 1989) In contrast to sporadic oesophageal 
leiomyomata, which form circumscribed and often solitary nodules, these 
patients have diffuse thickening of the esophageal musculature, particularly of 
the lower third. Histologically, there is extensive replacement of the normal 
fibre pattern by irregular, plexiform fibres with whorl formation.(Heidet, Boye et 
al. 1998) The gender-related penetrance and severity of the renal, 
audiological and ocular manifestations of ATS-DL are similar to those 
described in ATS. In ATS-DL, however, the esophageal involvement is 
identically severe in both genders, even in females with no evidence of renal 
disease, including microscopic hematuria.(Dahan, Heidet et al. 1995)  
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ATS is caused by mutations in the COL4A5 gene (MIM*303630),(Barker, 
Hostikka et al. 1990) the gene encoding the alpha-5 chain of collagen type IV 
(α5(IV)), which is a major structural component of the mammalian 
GBM.(Khoshnoodi, Pedchenko et al. 2008) So far, more than 700 different 
pathogenic mutations confined to COL4A5 have been described in affected 
individuals (Human Gene Mutation Database®; 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A5, last accessed on 
March 9, 2014). In males, large deletions, nonsense and frameshift mutations 
that lead to truncated proteins and/or mutations located closer to the 5’ end of 
the gene were shown to correlate with a younger age of onset of chronic 
kidney disease (CKD) and a higher risk of developing SNHL and specific 
ocular changes, as compared with other types of COL4A5 mutations. In 
females, no clear-cut genotype-phenotype correlations have ever been 
established.(Jais, Knebelmann et al. 2003) COL4A5 is paired head-to-head 
with COL4A6 (MIM*303631), at chromosome location Xq22.3, sharing a 
bidirectional promoter.(Khoshnoodi, Pedchenko et al. 2008) COL4A6 encodes 
the alpha-6 chain of collagen type IV (α6(IV)), which assembles with two 
α5(IV) chains in long triple helical molecules. These α5(IV)/α5(IV)/α6(IV) 
heterotrimers are present in the basement membrane (BM) of the skin, 
smooth muscle, and of the Bowman’s capsule and distal tubules in the kidney, 
but not in the GBM.(Ninomiya, Kagawa et al. 1995; Peissel, Geng et al. 1995) 
Absence of α6(IV) in the GBM explains why mutations confined to COL4A6 
would not cause ATS.  
A contiguous gene deletion involving the 5’ exons of COL4A5 and 
COL4A6 was identified in all patients with ATS-DL reported so far.(Antignac, 
Zhou et al. 1992; Zhou, Mochizuki et al. 1993; Renieri, Bassi et al. 1994; 
Dahan, Heidet et al. 1995; Heidet, Cohen-Solal et al. 1997; Van Loo, 
Vanholder et al. 1997; Heidet, Boye et al. 1998; Ueki, Naito et al. 1998; Segal, 
Peissel et al. 1999; Guillem, Delcambre et al. 2001; Mothes, Heidet et al. 
2002; Wang, Ding et al. 2002; Anker, Arnemann et al. 2003; Thielen, Barker 
et al. 2003; Sugimoto, Yanagida et al. 2005; Oohashi, Naito et al. 2011; 
Uliana, Marcocci et al. 2011) Deletion of a 4.2 kb critical region containing 
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exon 1 of COL4A5, exons 1’, 1 and 2 of COL4A6 and the common promoter 
region that regulates the expression of the two adjacent genes, is thought to 
be required for the development of DL.(Thielen, Barker et al. 2003) With the 
exception of a single family,(Uliana, Marcocci et al. 2011) deletions extending 
beyond exon 3 of COL4A6 were associated with ATS only.(Heidet, Dahan et 
al. 1995; Heidet, Cohen-Solal et al. 1997) To the best of our knowledge, 
mutations involving only COL4A5 or COL4A6 have not been found in patients 
with ATS-DL.  
Herein, we report the clinical and molecular characterization of three 
Portuguese families with ATS or ATS-DL bearing deletions of COL4A5. 
Remarkably, the family with ATS-DL had a deletion confined to COL4A5, an 
observation that questions the current genotype-phenotype correlation 
paradigm in this disorder.  
 
METHODS 
Probands and their relatives were enrolled in a multicentric study aiming 
to describe the phenotype and identify the genotype of families with AS in 
Portugal. Written informed consent was obtained from all patients. Current as 
well as retrospective clinical and laboratory data were collected at enrolment, 
concerning typical renal, audiological and ophthalmologic manifestations of 
AS.  Chronic kidney disease (CKD) was defined according to the National 
Kidney Foundation clinical practice guidelines 
(http://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class_g1.htm
) and the glomerular filtration rate was estimated by a standard equation 
(http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm). Clinically 
relevant gastrointestinal tract symptoms were investigated as appropriate. 
Upper gastrointestinal workup of the proband of family 1 was detailed 
elsewhere.(Sousa, Figueiredo et al. 2013) 
For the purpose of inclusion in this report, we selected “large” COL4A5 
deletions, defined as those involving at least 50 kb and/or 10 exons. 
GenBank® reference sequences NG_011977.1 and NG_012059.2 
(http://www.ncbi.nlm.nih.gov/nuccore/) were used as the reference nucleotide 
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sequences of COL4A5 and COL4A6, respectively. In order to facilitate the 
comparison of our data with previous reports of deletions involving the 
COL4A5 and COL4A6 genes, COL4A6 exons are numbered according to the 
original description of the two alternative promoters,(Sugimoto, Oohashi et al. 
1994) where exon 1' corresponds to exon 1 of reference sequence 
NG_012059.2, exon 1 to exon 2, exon 2 to exon 3, and so forth. Similarly, due 
to the existence of two alternatively spliced exons within intron 41 of the 
COL4A5 gene, which have been termed 41A and 41B,(Guo, Van Damme et 
al. 1993; Martin and Tryggvason 2001) the sequential exon numbers in 
reference sequence NG_011977.1 differ from the original numbering beyond 
exon 41. For this reason, the last COL4A5 exon herein numbered 51 
corresponds to exon 53 in the GenBank® sequence.  
Genomic DNA was extracted from peripheral blood leukocytes using a 
commercial kit (Citomed; Lisbon, Portugal). PCR amplification of all exons 
and adjacent intronic regions of the COL4A5 gene was performed in affected 
males, using previously described primers and conditions.(Martin, Heiskari et 
al. 1998) Exon 1 of the COL4A5 gene, exons 1’, 1, 2, 3 and 4 of the COL4A6 
gene, and their intervening common promoter region, were amplified using 
the PCR primers and conditions described in supplementary table S1. 
Amplified regions were sequenced with an ABI Prism® 310 Genetic Analyzer 
(Life Technologies; Foster City, CA), using the BigDye® Terminator v3.1 
Cycle Sequencing kit (Life Technologies). Deletions of the COL4A5 coding 
region and deletions of exons 1’, 1 and 2 of COL4A6 were further investigated 
using the SALSA P191/P192 Alport Multiplex Ligation-dependent Probe 
Amplification (MLPA) commercial kit (MRC-Holland; Amsterdam, The 
Netherlands). The MLPA assay was performed according to the 
manufacturer's protocol, available at the MRC-Holland internet site 
(http://www.mrc-holland.com). The extension of deletions in family 1 was 
determined by microarray-based comparative genomic hybridization (array-
CGH), using a high-resolution custom-designed X chromosome-specific 244k 
oligo-array (Agilent; Santa Clara, CA), as described elsewhere.(Froyen, Van 
Esch et al. 2007) Confirmation and mapping of the deletions was achieved by 
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standard PCR assay. Iterative rounds of PCR were performed at both the 
proximal and distal breakpoints to narrow down the breakpoint regions, using 
the primer pairs indicated in Supplementary table S2. Breakpoint positions are 
reported according to the most recently updated human genome reference 
sequence at the UCSC Genome Bioinformatics Site (http://genome.ucsc.edu/) 
(hg19; Feb 2009). Carrier status analysis was performed by quantitative PCR 
(qPCR) using the SYBRgreen relative quantitation method on a LC480 
apparatus (Roche; Basel, Switzerland), as described previously.(Vandewalle, 
Van Esch et al. 2009) Primer sequences used for the qPCR assays can be 
obtained upon request. In order to track its inheritance across the three 
generations of the pedigree available for study, the risk haplotype of the ATS-
DL family was characterized with four microsatellite polymorphic markers 
flanking the COL4A5 gene (DXS1120, DXS1105, DXS1210, 
DXS456).(Srivastava, McMillan et al. 1999; Tazon-Vega, Ars et al. 2007) 
 
RESULTS 
Clinical Investigation 
The demographic and clinical features of patients are summarised in 
table 1. 
Family 1 
Family 1 includes two siblings and their mother affected with ATS-DL 
(figure 1-A). AS was diagnosed in the proband (III-1) when he was five years 
old, based on typical EM findings on a kidney biopsy (figure 2) obtained in the 
work-up of persistent urinary abnormalities. High frequency SNHL was first 
documented at age six years. The patient started haemodialysis for renal 
replacement therapy (RRT) at age 20, eventually receiving a kidney transplant 
six months later. Typical AS retinopathy was diagnosed at age 26. 
At age 25, due to persistent upper gastrointestinal symptoms, including 
long-standing odynophagia, dysphagia to solids and liquids, regurgitation, and 
retrosternal and epigastric pain, the proband underwent a barium 
oesophagography, an oesophagogastroduodenoscopy and a stationary 
manometry, whose results were consistent with the diagnosis of achalasia. 
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Unsuccessful standard surgical treatment for achalasia with Heller myotomy 
and Dor fundoplication prompted further evaluation by computer tomography 
(CT), which showed prominent circumferential thickening of the distal two-
thirds of the oesophagus and of the cardia (figure 3). Endoscopic ultrasound 
imaging confirmed the marked increase in the thickness of the esophageal 
wall, most prominently of the second endosonographic layer, suggesting the 
involvement of the muscularis mucosa, and endoscopic tunnel biopsies were 
diagnostic of leiomyomatosis (figures 4-A,B). As the patient suffered from 
bronchial asthma since early childhood, a positron emission tomography 
(PET)–CT was performed to screen for pulmonary involvement by DL. It 
showed abnormal uptake of the radiotracer by the distal oesophagus, right 
colon and rectum. A colonoscopy to exclude colon cancer was normal and a 
rectal biopsy showed abundant smooth muscle cells but the tissue sample 
was too superficial to allow the histological diagnosis of leiomyomatosis. In 
the patient’s clinical setting, these results were interpreted as suggestive of 
colonic and rectal involvement by DL. 
The proband’s mother (II-2) has bilateral high frequency SNHL and 
microscopic hematuria. She reported to have had surgeries for “achalasia” at 
ages 18 and 22. At age 30, hysterectomy, right adnexectomy and left 
salpingectomy were performed due to diagnostic hypothesis of uterine 
fibromyoma and right adnexal mass. At age 36, she underwent total 
colectomy with proctectomy for the treatment of severe long-standing 
constipation, which was attributed to aganglionic megacolon. Gross 
examination showed an irregularly dilated colon, reaching a maximum 
diameter of 15cm, and a strikingly dilated rectum, reaching a maximum 
diameter of 8 cm, with a markedly thickened muscular layer. Histologically, 
however, the diagnostic hypothesis of aganglionic megacolon was not 
confirmed. After the diagnosis of ATS-DL in the son, microscopic examination 
of the same fragments was performed, which showed, not only the presence 
of ganglion cells in the submucosa and muscle layer, but also the proliferation 
of well-differentiated smooth muscle cells in the muscularis mucosa and 
muscularis propria of the colon and rectum, confirming the diagnosis of DL 
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(figure 5). A barium oesophagography obtained at the age of 44, for the 
investigation of recurrent complaints of dysphagia for solids and liquids, 
showed significantly delayed progression of the barium swallows along the 
distal two thirds of the oesophagus, especially of the liquid boluses, resulting 
in their accumulation in mid-oesophagus. Endoscopic ultrasound imaging 
additionally revealed thickening of the distal oesophagus, particularly of the 
second layer. In view of the patient’s clinical and family history, these findings 
were considered to be highly suggestive of esophageal leiomyomatosis, and 
further invasive diagnostic procedures were avoided.  
The proband’s sister (III-3) presented with recurrent macroscopic 
hematuria and persistent urinary abnormalities in the first year of life, and 
eventually reached CKD stage 3 at age 19 years. She has a long-standing 
history of severe constipation, with a normal colonoscopy result before the 
diagnosis of ATS-DL was suspected. At age 20, due to sporadic symptoms of 
dysphagia, she underwent a barium esophagography which was consistent 
with esophageal leiomyomatosis. In addition, she has microcephaly, moderate 
intellectual disability and dysmorphic facial features, which have been 
attributed to a de novo 13q34 terminal deletion syndrome.  
The proband’s maternal grandmother (I-2) reported history of sporadic 
microscopic hematuria, hypertension, SNHL and bilateral cataracts. The 
proband’s brother (III-2), maternal aunt (II-3) and maternal uncle (II-4) are 
asymptomatic and have no evidence of CKD.  
Family 2 
In family 2, a 34 years old male and his mother were diagnosed with 
ATS (figure 1-B). Urinary abnormalities and CKD were detected in the 
proband (III-1) at age 15 years, on the diagnostic investigation of progressive 
SNHL, which had been first noticed when he was eight years old. AS was 
clinically suspected but a kidney biopsy was not conclusive. Bilateral cataracts 
were detected at age 25. The patient reached ESRD at age 30. The 
proband’s mother (II-2) has CKD stage 3. No other cases of ESRD are known 
in this family.  
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Family 3 
Family 3 includes mother and son with ATS (figure 1-C). The proband 
(II-2) is a female who started RRT at age 46. Urinary abnormalities had been 
present since early childhood. Pure-tone audiometry screening, performed at 
enrolment for the present study, revealed moderate SNHL on the right ear. 
Her 18-year-old son (III-1) has persistent urinary abnormalities and bilateral 
moderate SNHL since early childhood, and a right cataract was diagnosed at 
age 5 years. Neither the proband nor her son reported symptoms that might 
be suggestive of DL.  
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Table 1. Demographic, clinical and genetic characterization of three Alport syndrome families with COL4A5 deletions. 
Family 1 2 3 
Patient Proband  (III-1) 
Sister  
(III-3) 
Mother  
(II-2) 
Grandmother  
(I-2) 
Proband  
(III-1) 
Mother  
(II-2) 
Proband  
(II-2) 
Son  
(III-1) 
Genotype 
Mutation del ex.2_51 [COL4A5] del ex.2_29 [COL4A5] del ex.1_13 [COL4A5] /  
    
  
  
 
  
/ del ex.1_3 [COL4A6] 
Mutation status hemizygous heterozygous heterozygous no deletion hemizygous heterozygous heterozygous hemizygous 
Clinical history and phenotype 
Gender, age at enrollment in years M, 26y F, 20y F, 45y F, 69y M, 34y F, 60y F, 47y M, 18y 
History of macroscopic hematuriaa Yes [2] Yes [<1] No NA Yes [15] NA No No 
History of microscopic hematuriaa Yes [2] Yes [<1] Yes [43] Yes [66] Yes [15] Yes [60] Yes [3] Yes [5] 
History of proteinuriaa Yes [7] Yes [<1] No No Yes [15] Yes [NA] Yes [3] Yes [5] 
Degree of proteinuria (mg/day) at 
diagnosis / most recenta 256 [7] / - - / 250 [19]
+
 - - NA - / 340 [60] NA NA 
History of hypertensiona Yes [NA] No No Yes [NA] Yes [20] Yes [50] Yes [35] No 
History of CKD stage 3 or highera Yes [NA] Yes [19] No No  Yes [15] Yes [60] Yes [38] NA 
pCr (eGFR) at diagnosis of CKD stage 3 NA 124 (48)  -  - NA 97 (51) 106 (50) NA 
History of renal replacement therapyb HD [20], Tx [21] No No No 
HD [30], Tx 
[33] No HD [46] No 
Last available pCr (eGFR)†,a 97 (81) [26] 124 (48) [19] 62 (91) [44] 71 (77) [66] NA 97 (51) [60] - 44 (217) [11] 
Kidney biopsyc Yes [5]* No No No Yes [NA] No No Yes [NA] 
Sensorineural hearing loss‡,a Yes [6] Yes [16] Yes [40] Yes [67] Yes [8] No Yes [46] Yes [6] 
Ocular signsa Yes [26] Yes [20] Yes [45] Yes [NA] Yes [25] NA NA Yes [5] 
Diffuse leiomyomatosisa Yes [25] ** Yes [19] ~ Yes [<18] *** No No No No No 
NA: Data not available.  a In brackets, the age at diagnosis or at last screening, in years.  b In brackets, the age at start of haemodialysis (HD) or of kidney 
transplant (Tx).  c In brackets, the age at kidney biopsy.  < Before the age indicated within brackets. †For patients not on HD.  ‡ SNHL confirmed by 
audiogram in all affected patients.  +Under treatment with an angiotensin-converting-enzyme inhibitor.  * GBM changes shown in figure 2.  pCr: plasma 
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creatinine level, in micromol/L (to convert into mg/dL divide by 88.4).  eGFR: estimated glomerular filtration rate, in mL/min/1.73m2. ** DL diagnosis 
histologically confirmed (see  figure 4); *** DL diagnosis histologically confirmed (see  figure 5);  ~ DL diagnosis clinically suspected. 
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Molecular Investigation 
In the proband (III-1) of family 1, a COL4A5 hemizygous deletion 
spanning exons 2 to 51 was detected by PCR and confirmed by MLPA 
analysis. No point mutations were detected in exon 1 of COL4A5, in exons 1’, 
1, 2, 3 and 4 of COL4A6, nor in the shared promoter region. High-resolution 
X-chromosome array-CGH showed that there were no additional genes 
included in the deletion (Supplementary figure S1). For junction analysis, 
breakpoint mapping was first performed by iterative rounds of PCR. When 
breakpoint regions were <3 kb, a PCR with forward primer set 2 combined 
with reverse primer set 7 (Supplementary table S2) was done yielding a 4 kb 
PCR product specific for the patient (Supplementary figure S2-A). A nested 
PCR was then performed using the complementary sequences from reverse 
primer set 2 and forward primer set 7 to yield a band of approximately 3 kb, 
which was subsequently sequenced (Supplementary figure S2-B). The 
COL4A5 deletion was mapped precisely to chrX:107,773,340-107,950,610, 
with the proximal breakpoint located in intron 1, 9.5 kb proximal to exon 2, at 
the end of a MA3-LINE1 repeat, and the distal breakpoint located 10 kb distal 
to the last exon 51, within a MB5-LINE1 repeat. As both breakpoints locate in 
different subfamilies of LINE1 repeats (MA3 and MB5) with no significant 
homology, this junction did not likely result from non-allelic homologous 
recombination (NAHR) (Supplementary figure S2-C). Mapping the breakpoint 
to the nucleotide level however, cannot exclude the occurrence of additional, 
but subtle rearrangements in COL4A5 or COL4A6. Regular PCR and high-
resolution X-oligo-array demonstrated that at least all other exons flanking this 
deletion are neither deleted nor duplicated in the proband of family 1. 
Moreover, qPCR at five different loci within COL4A6 intron 2 and one in exon 
3 all revealed the expected copy number of 1.00 showing that intron 2 does 
not contain any copy number variations larger than 25 kb. The MLPA and 
qPCR assays showed that the proband’s mother (II-2) and sister (III-3) were 
heterozygous for the same deletion but that it was not present in the 
unaffected proband’s brother (III-2), maternal aunt (II-3) and maternal uncle 
(II-4). Of note, this deletion was also not detected by MLPA in peripheral 
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blood genomic DNA of the proband’s maternal grandmother (I-2), who has 
several clinical manifestations that might fit in the diagnosis of AS. Since 
haplotype analysis showed that she transmitted the same haplotype both to 
her affected daughter (II-2) and unaffected son (II-4) (Supplementary figure 
S3), it might be speculated that instead the COL4A5 rearrangement having 
occurred de novo in her daughter, this woman is a mosaic carrier of the 
COL4A5 deletion in her gonads and other ectodermal tissues affected in AS. 
In family 2, a deletion of exons 2 to 29 of the COL4A5 gene was 
detected by PCR and confirmed by MLPA in the proband (II-1). The proximal 
breakpoint was mapped in intron 1 in a 700 bp region 24.5 kb distal to 
COL4A5 exon 1 (chrX:107,707,634-107,708,329), which contains a ME1-
LINE1 repeat. The distal breakpoint was mapped within a region of 2.9 kb in 
intron 29 (chrX:107,856,319-107,858,111) also including a LINE1 of the ME1 
subfamily. Although we were unable to obtain the junction sequence, the most 
likely mechanism for this rearrangement is NAHR between LINE1 repeats. His 
mother (II-2) carries the same COL4A5 deletion, as shown by MLPA.  
In family 3, a deletion of exons 1 to 13 of COL4A5 and of exons 1’, 1 and 
2 of COL4A6, was identified by MLPA in the female proband (II-2). The 
deletion also includes exon 3 of COL4A6, as confirmed by PCR in her 
affected son (III-1). Since COL4A6 exon 4 was retained, the proximal 
breakpoint of this deletion locates in intron 3 of COL4A6. As demonstrated by 
PCR in the son, the shared promoter region of both genes was also deleted.  
 
DISCUSSION 
We report the detailed molecular characterization of three deletions 
involving the COL4A5 gene identified in Portuguese patients presenting with 
ATS or ATS-DL. The ATS families carried either a 149 kb deletion 
encompassing exons 2 to 29, or a contiguous gene deletion that included 
exons 1 to 13 of COL4A5 and exons 1’ to 3 of COL4A6. According to current 
paradigms of genotype-phenotype correlation in ATS, these two genetic 
defects are fully consistent with the patients’ clinical phenotypes. Surprisingly, 
however, in the family manifesting ATS-DL, molecular analyses revealed a 
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177 kb deletion involving exons 2 to 51 of COL4A5, which would not be 
expected to cause DL. Direct sequencing of genomic DNA excluded the 
presence of single nucleotide or of any other small variants in exon 1 of 
COL4A5, in the intergenic common promoter region and in exons 1’, 1, 2, 3 
and 4 of COL4A6. Although we did not perform pulsed field gel 
electrophoresis (PFGE) for long range mapping and detection of more 
complex rearrangements, a technique formerly used by other investigators to 
characterize large COL4A5 (Vetrie, Boye et al. 1992) or COL4A5_COL4A6 
deletions (Heidet, Dahan et al. 1995; Heidet, Cohen-Solal et al. 1997; 
Guillem, Delcambre et al. 2001; Mothes, Heidet et al. 2002), cloning the 
junction clearly demonstrated that the deletion in this family was a simple 
rearrangement, with no inversion or insertion at the deletion breakpoints. It 
was also demonstrated by high-resolution array-CGH that exons and genes 
flanking the COL4A5 deletion were neither deleted nor duplicated. Although 
qPCR at several locations within COL4A6 intron 2 showed the expected copy 
number at all the tested loci, it does not formally exclude the presence of a 
second, smaller rearrangement between the qPCR probed regions. Such a 
rearrangement might be of pathogenic importance as COL4A6 intron 2 is 
thought to constitute the proximal boundary of the critical region for the 
development of DL in patients with ATS.(Thielen, Barker et al. 2003)  
Until now, approximately 30 families with ATS-DL were found to carry 
deletions comprising the 5’ regions of COL4A5 and COL4A6, all of them 
including the 4.2 kb critical region (figure 6). (Antignac, Zhou et al. 1992; 
Zhou, Mochizuki et al. 1993; Renieri, Bassi et al. 1994; Dahan, Heidet et al. 
1995; Heidet, Dahan et al. 1995; Heidet, Cohen-Solal et al. 1997; Heidet, 
Boye et al. 1998; Ueki, Naito et al. 1998; Segal, Peissel et al. 1999; Guillem, 
Delcambre et al. 2001; Mothes, Heidet et al. 2002; Wang, Ding et al. 2002; 
Anker, Arnemann et al. 2003; Thielen, Barker et al. 2003; Sugimoto, Yanagida 
et al. 2005; Oohashi, Naito et al. 2011; Uliana, Marcocci et al. 2011) In 
contrast, contiguous COL4A5_COL4A6 deletions extending upstream beyond 
exon 3 of COL4A6,(Heidet, Dahan et al. 1995; Heidet, Cohen-Solal et al. 
1997) or encompassing the entire COL4A5 and COL4A6 genes,(Thielen, 
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Barker et al. 2003) were identified in patients with ATS who did not develop 
DL. Furthermore, intragenic COL4A5 deletions of at least one exon have been 
described in more than 30 ATS families but none of these patients developed 
DL, including two cases who had deletions that also involved exons 2 to 51 of 
COL4A5.(Plant, Green et al. 1999) These observations led to the postulate 
that the contiguous deletion of the 5’ exons of COL4A5 and COL4A6, with the 
proximal breakpoint located within the intron 2 of COL4A6, was the critical 
genetic defect underlying ATS-DL.(Zhou, Mochizuki et al. 1993; Antignac, 
Knebelmann et al. 1994; Heidet, Dahan et al. 1995; Segal, Peissel et al. 1999; 
Zheng, Harvey et al. 1999; Thielen, Barker et al. 2003).  
Contiguous COL4A5_COL4A6 deletions remove the intergenic 
bidirectional promoters that drive the transcription of the two 
genes,(Sugimoto, Oohashi et al. 1994; Sund, Maeshima et al. 2005) thereby 
preventing their normal transcription and expression. Both the α5(IV) and 
α6(IV) collagen chains are absent in the BM of esophageal leiomyomata 
removed from patients with ATS-DL.(Heidet, Cai et al. 1997) Lack of 
expression of α5(IV) and α6(IV) in the tumour BM has also been 
demonstrated in sporadic esophageal leiomyomata, in association with a 
somatic deletion of the 5’ ends of COL4A5 and COL4A6, mimicking the 
germline mutation in ATS-DL.(Heidet, Boye et al. 1998) These findings 
suggest that the mechanisms leading to smooth muscle cell proliferation are 
similar in the hereditary and sporadic leiomyomata, strengthening the case for 
the pathogenic role of the specific contiguous gene deletion in ATS-
DL.(Heidet, Boye et al. 1998) Unfortunately, the expression status of α6(IV) 
collagen chains in the normal esophageal smooth muscle basement 
membranes of ATS patients who do not have deletions extending into 
COL4A6, is not known.(Miner 1999) However, absence of α6(IV) chains from 
other α6(IV)-containing BM, including of the dermal-epidermal junction and/or 
of the kidney Bowman’s capsule and distal tubules, has been observed in 
patients with ATS-DL (Segal, Peissel et al. 1999) or with ATS.(Ninomiya, 
Kagawa et al. 1995; Peissel, Geng et al. 1995; Hino, Takemura et al. 1996; 
Naito, Kawai et al. 1996; Sasaki, Zhou et al. 1998) This suggests that the 
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α6(IV) chain cannot assemble into BM without the α5(IV) chain,(Miner 1999) 
an assumption supported by experimental data in the canine model of X-
linked AS.(Zheng, Harvey et al. 1999) These dogs carry a nonsense point 
mutation in COL4A5 that is sufficient to prevent incorporation of the collagen 
α6(IV) chain into smooth muscle BM, independent of a reduction in α6(IV) 
mRNA levels. However, the lack of the α6(IV) chain does not result in any 
obvious complications in the affected animals, particularly the development of 
leiomyomata. This implies that the absence of the α6(IV) chain, alone or in 
combination with absence of the α5(IV) chain, is not enough to cause DL, and 
that some other mechanisms, other than expression of α6(IV) and its 
incorporation into BM, are pathogenically relevant in this disease.(Zheng, 
Harvey et al. 1999)  
Several hypotheses have been proposed to explain the apparent 
requirement for the proximal breakpoint of deletions associated with ATS-DL 
to be located within COL4A6 intron 2: (i) gain of function of COL4A6 conferred 
by deletions at that position, in a manner abrogated by more extensive 
deletions,(Heidet, Cohen-Solal et al. 1997) due to activation of a cryptic 
promoter, resulting in the transcription of sequences that are normally not 
expressed,(Heidet, Dahan et al. 1995) or formation of pathogenic fusion 
transcripts;(Thielen, Barker et al. 2003) (ii) loss of an unspecified gene or of 
its regulatory elements within intron 2 of COL4A6 that might be involved in the 
regulation of smooth muscle cell proliferation;(Heidet, Dahan et al. 1995; Ueki, 
Naito et al. 1998) and finally (iii) alteration of the chromatin structure, 
influencing the expression of neighboring genes by an epigenetic 
mechanism.(Thielen, Barker et al. 2003) The detection of a COL4A6 transcript 
that included exon 4, but not exon 3, in an esophageal tumour sample of a 
patient with ATS-DL,(Heidet, Dahan et al. 1995) lends support to the 
hypothesis that an abnormal COL4A6 mRNA transcript or truncated α6(IV) 
collagen chain might be involved in the pathogenesis of DL. The epigenetic 
model assumes that the critical ATS-DL region may contain a silencer 
element(s) for establishment of repressed chromatin, or act as a 
transcriptional insulator of genes involved in the pathogenesis of DL.(Thielen, 
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Barker et al. 2003) However, none of these hypotheses is entirely satisfactory 
(Uliana, Marcocci et al. 2011) and the molecular mechanisms of the smooth 
muscle overgrowth in ATS-DL patients remains to be elucidated.  
Since the α5(IV) collagen chain has binding sites for numerous 
components of the extracellular matrix (ECM) and interacts with multiple 
integrin and non-integrin cell receptors,(Khoshnoodi, Pedchenko et al. 2008) it 
is also possible that the absence or the presence of abnormal α5(IV) chains in 
the BM induces changes in the structure or function of other ECM 
component(s) and/or of cell surface receptors. As a result, degradation of the 
physical support for ECM components provided by the BM type IV collagen 
network, and the deregulation of the tissue-specific ECM-cell interactions that 
coordinate intracellular signalling essential for cell growth and proliferation, 
might favour the development of the leiomyomata.(Zhou, Mochizuki et al. 
1993; Heidet, Cai et al. 1997; Heidet, Boye et al. 1998; Thorner, Heidet et al. 
1998) Further studies are needed to test these assumptions.  
The recent report of a deletion extending proximally into the intron 3 of 
COL4A6 in a family with ATS-DL,(Uliana, Marcocci et al. 2011) although 
leading to reconsider the location of the centromeric limit of the critical region 
for DL, would still be compatible with a putative pathogenic role for the 
truncated COL4A6 mRNA lacking the first three exons. Indeed, it might be 
speculated that a truncated COL4A6 transcript causes the development of 
leiomyomatosis by a dominant activating effect,(Heidet, Boye et al. 1998) 
while the complete absence of a COL4A6 transcript does not. This hypothesis 
implies the presence of a cryptic promoter within the ~90 kb large intron 3 of 
COL4A6. Therefore, mapping the breakpoint sites in intron 3 in those few 
reported cases with contradictory phenotypic outcomes (Heidet, Dahan et al. 
1995; Heidet, Cohen-Solal et al. 1997; Wang, Ding et al. 2002; Uliana, 
Marcocci et al. 2011) might provide additional proof for the existence of such 
a cryptic promoter.  
Our finding of a deletion confined to COL4A5 segregating with ATS-DL 
further challenges the current paradigm of genotype-phenotype correlation in 
this disorder, showing that contiguous deletion of the COL4A5_COL4A6 
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common promoter region and the 5’ exons of COL4A6 is not an absolute 
requisite for the development of DL in ATS patients. The fact that DL 
developed in family 1, carrying a COL4A5 deletion with proximal breakpoint 
very close to exon 2, while it did not develop in family 2, carrying a COL4A5 
deletion with proximal breakpoint much closer to exon 1, might indicate the 
presence of a regulatory domain within the large intron 1 that could affect the 
expression of a transcript involved in DL. Mapping the breakpoints of other 
similar COL4A5 deletions, like those reported by Plant and colleagues (Plant, 
Green et al. 1999) will be most important to test for this hypothesis. On the 
other hand, failure to identify more ATS-DL patients with deletions confined to 
COL4A5 may be due to the rarity of this disease and the difficulty in 
recognizing its clinical manifestations, in the context of more common 
differential diagnoses.  
 
CONCLUSIONS  
This is the first report on a family with ATS-DL carrying a deletion 
confined to COL4A5, suggesting that the deletion of the 5’ exons of COL4A6 
and of the common COL4A5_COL4A6 promoter region is not essential for the 
development of DL in patients with ATS. Deletion breakpoint mapping might 
prove essential to pinpoint the underlying molecular mechanism resulting in 
ATS-DL.  
Given the implications of the recognition of genotype-phenotype 
correlations in ATS-DL for diagnosis and genetic counselling, the following 
practical points are worth emphasising: (i) clinicians should be aware of the 
full spectrum of ATS-DL manifestations, as its diagnosis requires a high 
suspicion index; (ii) leiomyomatosis is often severely symptomatic, both in 
males and females with ATS-DL, before patients develop advanced CKD; (iii) 
besides the esophageal involvement mimicking achalasia, ATS-DL may 
present with megacolon secondary to colon and anorectal involvement 
(Guillem, Delcambre et al. 2001; Claus, Geboes et al. 2008); (iv) the 
diagnosis of ATS-DL should be considered in any female with gastrointestinal 
and gynaecological manifestations suggestive of DL, even without any clinical 
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or laboratory evidence of nephropathy, due to the risk of ATS-DL in male 
offspring; and finally (v) the inclusion of primers for the exons 3 and 4 of 
COL4A6 in the MLPA commercial kits for ATS is justified for a comprehensive 
molecular diagnosis.   
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Figures 
 
Figure 1 
 
 
 
Figure 1. Pedigrees of family 1 (A), family 2 (B), and family 3 (C). 
 
 
 
Figure 2 
 
 
 
Figure 2. Electron microscopy of the kidney biopsy of the proband of family 1 
performed at 5 years, showing the typical glomerular basement membrane 
lesions of Alport syndrome: alternating thinning and thickening, splitting, and 
electron-dense bodies surrounded by a lucent halo. 
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Figure 3 
 
 
 
Figure 3. Axial section of the lower half of the thorax from the proband of 
family 1 (III-1), obtained during arterial and venous phases of a computer 
tomography scan, showing “isodense to muscle”, homogeneous and 
circumscribed wall thickening of the distal segment of the oesophagus with 
luminal gas bubble relatively centred and symmetrical. 
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Figure 4 
 
 
 
Figure 4. A – Light microscopy of the esophageal biopsy of the proband of 
family 1 performed at 25 years, showing muscle cell proliferation arranged in 
intersecting bundles (H&E (hematoxylin and eosin); x200). B – 
Immunohistochemistry of the esophageal biopsy of the proband of family 1 
showing desmin-positive, DOG1 (“Discovered on GIST-1”)-negative spindle 
cells (desmin; x300). 
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Figure 5 
 
 
 
Figure 5. Light microscopy of sections from the colon (A,B,C) and rectum 
(D,E,F) of the proband’s mother of family 1, obtained after total colectomy with 
protectomy, performed at 36 years. A – Proliferation of smooth muscle cells in 
the muscularis mucosa and markedly thickened circular muscle layer of the 
colon (H&E (hematoxylin and eosin); x40). B –Poorly delineated smooth 
muscle proliferation of the muscular longitudinal layer and ganglion cells from 
the myenteric plexus of the colon [detail from the white box is magnified in C] 
(H&E; x40). C – Well-differentiated smooth muscle cells, which lost their usual 
parallel orientation (H&E; x100). D – Thickened muscularis mucosa under 
vertically oriented mucosal crypts of the rectum (H&E; x100). E – Smooth 
muscle cell proliferation of the muscularis propria and presence of ganglion 
cells from the myenteric plexus of the rectum, excluding Hirschsprung disease 
[detail from the white box is magnified in F] (H&E; x40). F – Interlacing 
bundles of smooth muscle cells infiltrating the myenteric plexus (H&E; x100). 
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Figure 6 
 
 
Figure 6. Schematic overview of the most currently reported deletions within 
COL4A5 in ATS or ATS-DL patients. The 400 kb region (107.45 Mb to 107.85 
Mb; UCSC Hg19) at Xq22.3 containing the complete COL4A5 (exon 1 to 51) 
and part of the COL4A6 (exon 1 to 3) genomic organization is shown above. 
The seven deletions of which the junctions were mapped and sequenced are 
shown first followed by 29 deletions for which only the breakpoints were 
mapped.  Horizontal grey bars indicate regions that were demonstrated as 
deleted while the grey lines represent the regions in which the breakpoints 
must be located. The first or last exon that is deleted is given by its number, 
which is placed at the beginning or end of each grey bar, respectively. For 
each deletion, it is mentioned whether it concerns ATS patients (underlined, 
highlighted in grey) or ATS-DL patients (no highlight), followed by the 
reference in which the patient(s) was described. The deletions identified in our 
three families are highlighted in a box labelled ‘this study’. 
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Supplementary Material 
 
Supplementary table S1. Primer sequences, annealing temperatures and product sizes for PCR amplification of the common promoter 
region of the COL4A5 and COL4A6 genes, the exon 1 of COL4A5 and exons 1’, 1 and 2 of COL4A6. 
 
 
Forward primer Reverse primer 
Annealing 
temperature 
PCR product 
size 
References 
COL4A5 exon 1 † 5’-AAGCCTCACTGTCCCTCTC-3’ 5’-AAAGGAAGATAAAGGGACCC-3’ 60oC 296 bp Adapted from (Martin, Heiskari et al. 
1998) 
COL4A5-COL4A6 
intergenic region † 5’-AAATTCCCGGCTGGCTCTA-3’ 5’-CAGGGAGCACCGACCAAAA-3’ 58
oC 621 bp 
(Sugimoto, Oohashi et al. 1994; Mothes, 
Heidet et al. 2002) 
COL4A6 exon 1’ † 5’-CCAGACTAGTTGACTGAGC-3’ 5’-CCCTAAGTATCTCCACAGC-3’ 58oC 1150 bp Primers designed for this study 
COL4A6 exon 1 and 2 † 5’-GGCAGCTGAATCGATATCTC-3’ 5’-CTCGTGGTGAAACTCTCTGC-3’ 60oC 1218 bp Primers designed for this study 
COL4A6 exon 3 †† 5'-TGAGAAAGGAGCGAGAGT-3’ 5'-GGGAGGGAAGAATCAAGT-3’ 58oC 360 bp Primers designed for this study 
COL4A6 intron 3 †† 5'-GGAAAAGTGTTGAAAGGG-3’ 5'-GATAATGAAAGAGAAGGTGG-3’ 58oC 437 bp Primers designed for this study 
COL4A6 exon 4 †† 5'- CACTCCTTCTGTCCACCT -3’ 5'-CCTGGCACCAAACTACTC-3’ 58oC 274 bp Primers designed for this study 
†
 Cycling conditions were: initial denaturation for 5 minutes at 94ºC, followed by 35 cycles of denaturation at 94ºC for 60 seconds, 
annealing for 60 seconds, and extension at 72ºC for 90 seconds, ending with a final extension at 72ºC for 10 minutes.  
††
 Cycling conditions were: initial denaturation for 5 minutes at 94ºC, followed by 35 cycles of denaturation at 94ºC for 30 seconds, 
annealing for 30 seconds, and extension at 72ºC for 40 seconds, ending with a final extension at 72ºC for 10 minutes. 
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Supplementary table S2. PCR primers to map the breakpoint regions in the proband of family 1. 
N° Amplicon location a Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Size 
(bp) 
Present b 
Mapping the proximal breakpoint in COL4A5 intron 1 
1 107,761,475 - 107,761,850 GTCCCATTTCACTATTTCC TCCCATATGTTTTTTCCCC 376 yes 
2 107,770,364 - 107,770,677     CCCATGTTGTGTCGATTTA AAGTGAGATAGGGTGAAAG 314 yes 
3 107,773,302 - 107,773,649     AAACATCCTACCCAACAAC TTGCCTGTTCACTCTGAT 348 no 
4 107,775,848 - 107,776,325     GGGAAAAGAAGCAGTCAAA TTAGGTCAGGGTTGCATT 478 no 
Mapping the distal breakpoint downstream of COL4A5 
5 107,946,359 - 107,946,617     TAGAGAGGCAGGAAAGGT TGAGTAGGAGAAGGAAGTGT 259 no 
6 107,948,701 - 107,949,182     TGGGGTGTTGATTTGTTG TTGTGCACTTGGATTAGG 482 no 
7 107,951,237 - 107,951,625     CTGTCCTGGGCTTTTATTT CCCATCGCCACAAAAAAA 389 yes 
8 107,953,812 - 107,954,214 GAAGAATAGATGCACTGGAA GGGAGCGGAAAATGGAGA 403 yes 
 
a Positions based on UCSC Hg 19. 
b The column ‘Present’ indicates whether a PCR fragment was obtained (yes) or not (no).  
The proximal breakpoint is located in a 2.7 kb region between positions 107,770,677 and 107,773,302.  
The distal breakpoint is located in a 2.0 kb region between positions 107,949,182 and 107,951,237.
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Supplementary figure S1 
 
 
 
Supplementary figure S1. X chromosome-specific exome array-CGH data of 
the COL4A6-COL4A5 region at Xq22 for the proband III-1 of family 1, 
diagnosed with ATS-DL. The deletion (shaded area) includes exon 2 to exon 51 
of COL4A5. Locations of probes are: last normal: 107,570,227; first deleted: 
107,669,482; last deleted: 107,827,516; and first normal: 107,859,356. 
Therefore, the proximal breakpoint region is located in intron 1 and is 9.5 kb 
proximal to exon 2 while the distal breakpoint region is situated between the last 
exon of COL4A5 and the IRS4 gene, being located 10 kb distal to the last exon 
51. The genomic positions indicated here are based on UCSC Hg18. 
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Supplementary figure S2 
 
 
 
Supplementary figure S2. Junction analysis of COL4A5 deletion in family 1. A. 
Agarose gel analysis showing the results of the PCR with forward primer 2 
combined with reverse primer 7 (Supplementary table S2). For the patient (Pat) 
a 4 kb PCR product was obtained, which was absent in the control (Co). M is 
the 100 bp DNA ladder. B. Agarose gel image with the 3 kb junction DNA 
fragment. Nested PCR on PCR products obtained in A was done with the 
complementary sequences of reverse primer 2 and forward primer 7. C. 
Junction sequence from the nested PCR band. Both proximal (upper) and distal 
(lower) regions are located within LINE1 sequences. However, the proximal 
breakpoint is within a MA3 subtype while the distal one is located in a MB5 
subtype thereby having no homology, excluding NAHR. No microhomology is 
found at the junction. Mismatches at the proximal and distal regions are 
highlighted in grey. Positions of the break sites are indicated and are based on 
UCSC Hg19. 
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Supplementary figure S3 
 
Supplementary figure S3. Pedigree of family 1 with haplotypes for 
polymorphic markers adjacent to COL4A5-COL4A6 genes (DXS1120, 
DXS1105, DXS1210, DXS456). Numbers indicate lengths of PCR products in 
base pairs (bp) for different alleles of the chosen microsatellites. 
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2.2. Patients with pathogenic COL4A3 and COL4A4 mutations 
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2.2.1. Collagen type IV-related nephropathies in Portugal: spectrum 
of pathogenic COL4A3 and COL4A4 mutations and clinical 
characterisation of 25 families (Manuscript 3) 
 
Manuscripts 1 and 3 were submitted simultaneously to the Journal of 
Medical Genetics, on the 11th April 2014 (Manuscript 3 ID: jmedgenet-
2014-102472). 
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ABSTRACT 
Background 
Pathogenic mutations in the COL4A3/COL4A4 genes are responsible for the 
autosomally inherited collagen IV-related glomerular basement membrane 
(GBM) nephropathies, including the recessive (ARAS) and dominant (ADAS) 
forms of Alport syndrome (AS) and thin basement membrane nephropathy 
(TBMN). The purpose of this study was to identify pathogenic COL4A3/COL4A4 
mutations in unrelated Portuguese patients (n=40) with clinical suspicion of 
ARAS/ADAS/TBMN, and assess relevant genotype-phenotype correlations.  
Methods 
Mutation scanning of COL4A3/COL4A4 was performed by Sanger sequencing 
of all exons and splice site regions. In 35 cases where X-linked AS (XLAS) 
could not be excluded by pedigree analysis, prior comprehensive mutational 
analysis of COL4A5 had not shown any pathogenic mutations. Clinical 
phenotypes were compared between the apparently homozygous/compound 
heterozygous and the apparently heterozygous patients.  
Results 
Seventeen novel and four previously reported pathogenic COL4A3/COL4A4 
mutations were identified in 62.5% (25/40) of the probands. Regardless of the 
mutated gene, all patients with ARAS manifested chronic renal failure (CRF) 
and hearing loss, whereas only a minority of the apparently heterozygous 
patients had CRF or extrarenal symptoms. CRF was diagnosed at a 
significantly younger age in patients with ARAS. Overall, a pathogenic 
COL4A3/COL4A4/COL4A5 mutation was identified in >50% of patients with 
fewer than three diagnostic criteria of AS.  
Discussion 
The occurrence of pathogenic COL4A3/COL4A4 mutations in Portuguese 
patients with AS was higher, while the prevalence of XLAS was lower than 
expected. In such epidemiological context, next-generation sequencing of all 
three genes simultaneously may be the most cost-effective first-tier approach to 
the diagnosis of collagen IV-related GBM nephropathies. 
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INTRODUCTION 
Alport syndrome (AS) is a hereditary glomerulopathy associated with 
sensorineural hearing loss (SNHL) and ocular anomalies, caused by mutations 
in the genes encoding the α3 (COL4A3), α4 (COL4A4) and α5 (COL4A5) 
chains of collagen type IV.(Kashtan 1999; Kashtan 2001; Tryggvason and 
Patrakka 2009) Although rare in the general population,(Levy and Feingold 
2000) AS is one of the most common genetic disorders leading to advanced 
chronic renal failure (CRF) and end-stage renal disease (ESRD) in teenagers 
and young adults. Overall, AS was the primary renal disease in 0.56% of all 
patients commencing renal replacement therapy (RRT) in Europe, but 
accounted for 1.61% of the children requiring RRT before 15 years of 
age.(Rigden, Mehls et al. 1996) Pathogenic mutations in the COL4A5 gene, 
mapping at chromosome location Xq22.3, cause X-linked AS (XLAS; 
MIM#301050), which is identified in approximately 80-85% of the 
families.(Kashtan 2001; Tryggvason and Patrakka 2009) Pathogenic mutations 
in either the COL4A3 or COL4A4 genes, mapping at chromosome location 
2q36.3, cause the autosomally inherited forms of AS: recessive AS (ARAS; 
MIM#203780), which accounts for about 15% of the reported families, and 
dominant AS (ADAS; MIM#104200), which so far has been described in a small 
number of kindreds.(Kashtan 2001; Tryggvason and Patrakka 2009)  
Familial persistent or recurrent hematuria, without significant proteinuria or 
extrarenal complications, is associated with heterozygosity for pathogenic 
mutations in the COL4A3 or COL4A4 genes in up to 60% of the 
families.(Lemmink, Nillesen et al. 1996; Badenas, Praga et al. 2002) Usually 
detected during childhood, this dominantly inherited condition is characterized, 
on electron microscopy (EM) examination of kidney tissue, by diffuse thinning of 
the glomerular basement membrane (GBM) to about half its normal 
thickness.(Rogers, Kurtzman et al. 1973; Yoshikawa, Matsuyama et al. 1988; 
Tiebosch, Frederik et al. 1989) Although commonly referred to as “benign 
familial hematuria” (BFH; MIM#141200), such term is a misnomer because a 
significant proportion of affected individuals develop proteinuric chronic kidney 
disease (CKD) and eventually need RRT later in life.(van Paassen, van Breda 
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Vriesman et al. 2004; Voskarides, Damianou et al. 2007; Pierides, Voskarides 
et al. 2009; Temme, Peters et al. 2012) For this reason, “thin basement 
membrane nephropathy” (TBMN) has been proposed as a better descriptor for 
this disorder, reflecting the underlying ultrastructural abnormality.(Savige, Rana 
et al. 2003) The lack of clinical or genetic markers to predict the natural history 
of renal disease in heterozygote carriers of pathogenic mutations in COL4A3 or 
COL4A4 prompted the recommendations for comprehensive family screening 
and periodic surveillance of affected individuals for signs of disease 
progression.(Frasca, Onetti-Muda et al. 2005; Marcocci, Uliana et al. 2009; 
Temme, Peters et al. 2012) Furthermore, such patients should be counseled 
about the possibility of having children affected with ARAS, particularly if the 
partner is consanguineous.(Frasca, Balestra et al. 2008) Likewise, patients with 
ARAS should recognize that their own progeny, as well as other first-degree 
relatives, may develop TBMN and, more rarely, even progressive CKD. 
The spectrum of clinical manifestations associated with pathogenic 
mutations in the COL4A3 and COL4A4 genes, ranging from isolated hematuria 
to progressive CKD with ESRD, together with the mutations in the COL4A5 
gene causing XLAS, demonstrate the importance of these type IV collagen 
chains for the integrity of kidney structure and function, and led to the 
nosological concept of collagen IV-related GBM nephropathies.(Kashtan 2001; 
Longo, Porcedda et al. 2002) Genetic heterogeneity and clinical variability 
complicate the differential diagnosis of the various collagen IV-related GBM 
nephropathies, particularly in small pedigrees, as well as in young patients and 
sporadic cases. TBMN and ADAS may be regarded as the two extremes of 
severity of the familial patterns of expression of heterozygous COL4A3 or 
COL4A4 pathogenic mutations. The distinction between ADAS and TBMN is not 
easy, especially in children and young adults. Accurate diagnosis and 
prognostic information may also be difficult with XLAS in families where only 
females are affected.(Longo, Porcedda et al. 2002; Marcocci, Uliana et al. 
2009) ARAS may be easily confused with XLAS in affected males, when the 
family history is uninformative. Immunohistochemical analysis of basement 
membrane expression of type IV collagen in a skin or kidney biopsy may be of 
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help in the differential diagnosis between those conditions.(Kashtan 2001; 
Tryggvason and Patrakka 2009) Comprehensive clinical investigation of 
probands and of their at-risk relatives, including screening for renal and 
extrarenal signs of AS in older family members, along with thorough pedigree 
analysis, are baseline key steps in the diagnostic process of collagen IV-related 
GBM nephropathies and genetic counseling of affected families.(Marcocci, 
Uliana et al. 2009)  
Mutational analyses of the COL4A3 and COL4A4 genes can be used to 
establish the genetic diagnosis of autosomal collagen IV-related GBM 
nephropathies, obviating the need for a kidney biopsy.(Hoefele, Lange-
Sperandio et al. 2010; Deltas, Pierides et al. 2012) Prior identification of the 
disease-causing mutation(s) in the family is usually a prerequisite for 
preimplantation genetic diagnosis (PIGD), for prenatal diagnosis (PND) of at-
risk pregnancies, and for screening at-risk asymptomatic relatives in order to 
identify those who need specific medical follow-up. In very large pedigrees 
where the inheritance pattern is clearly established it may be possible to use 
linkage analysis to track the inheritance of the disease if specific mutation(s) 
cannot be identified. Furthermore, molecular genetic testing is a valuable 
adjunct in the differential diagnosis between collagen IV-related GBM 
nephropathies and other monogenic causes of glomerular hematuria, as well as 
with non-genetic diseases.(Norby and Cosio 2005; Deltas, Pierides et al. 2012; 
Deltas, Pierides et al. 2013)  
The purpose of this study was to estimate the relative prevalence of 
pathogenic COL4A3 and COL4A4 mutations among Portuguese patients with 
diagnoses of collagen IV-related GBM nephropathies, in order to implement a 
cost-effective laboratory approach to their genetic diagnosis in our population.  
 
MATERIAL AND METHODS 
Patients and families 
Between 1/January/2009 and 30/June/2012, in the setting of a nationwide study 
to identify the disease-causing mutations in Portuguese patients with the clinical 
diagnosis of AS, 40 apparently unrelated probands either with no detectable 
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pathogenic mutations in the COL4A5 gene (n=35), as screened by Sanger 
sequencing and multiplex ligation-dependent probe amplification (MLPA; MRC-
Holland), or with family history suggestive of autosomal transmission of kidney 
disease (n=5), were selected for molecular analysis of the COL4A3 and 
COL4A4 genes (Supplementary figure S1). In one of these five probands, direct 
sequencing of COL4A3 and COL4A4 was performed since the proband was a 
young female with AS who had family history of hematuria, but not of CKD. Four 
of these five probands of families with the diagnosis of AS (n=3) or TBMN (n=1), 
who attended the Inherited Kidney Diseases Clinic of São João Hospital Centre 
(CHSJ), Porto, Portugal, were known to carry pathogenic COL4A3 or COL4A4 
mutations, identified through an outsourcing molecular genetics laboratory 
service (GENetic DIAgnostic Network, GENDIA; Antwerp, Belgium).  
Patients were candidate for genetic analyses if they had history of urinary 
anomalies (e.g., intermittent or persistent microscopic hematuria with or without 
proteinuria) of unknown etiology and, at least, one of the other major diagnostic 
criteria of AS (Flinter, Cameron et al. 1988): (i) family history of hematuria, CRF 
and/or hearing loss; (ii) ultrastructural GBM changes, including thinning, 
thickening, splitting and electron-dense bodies inclusion; (iii) bilateral, high 
frequency SNHL; (iv) specific ocular lesion, including anterior lenticonus and/or 
central and peripheral dot-and-fleck retinopathy. CRF was defined as plasma 
creatinine (pCr) ≥1.2 mg/dl in males and ≥0.9 mg/dl in females, and advanced 
CRF was defined as pCr >1.5 mg/dl in males and >1.2 mg/dl in females. These 
cut-off values roughly correspond to the upper limits of the estimated glomerular 
filtration rate respectively of CKD stages 2 and 3, in young adult subjects, 
according to the guidelines for CKD evaluation, classification and stratification 
of the National Kidney Foundation (New York, NY, USA) 
[http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm].  
In order to describe the phenotypic spectrum and the natural history of the 
disease in our cohort, a standardized questionnaire collecting data about the 
diagnostic criteria and other relevant features of AS identified on each patient 
was completed by his/her nephrologist or geneticist [manuscript submitted to 
the JMG simultaneously]. Whenever necessary and possible, retrospective 
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details of individual or familial medical histories were obtained by review of 
archive clinical records. In addition, available audiograms and EM 
photomicrographs of kidney biopsies were systematically rechecked.  
As used herein, the term “proband” refers to the patient who first 
underwent mutational analyses for collagen IV-related GBM nephropathies in 
each family. Regarding the clinical phenotypic description, the diagnosis of AS 
was made strictly in patients or families who manifested three or four diagnostic 
criteria as proposed by Flinter and colleagues (Flinter, Cameron et al. 1988), 
i.e., in patients or families in whom at least one extra-renal criterion had 
manifested. Diagnosis of familial hematuria was made in families in whom 
extra-renal criteria of AS did not manifest, whether or not manifesting 
proteinuria or CRF. The term TBMN was strictly applied to those patients or 
families with microscopic hematuria in whom ultrastructural examination of a 
kidney biopsy showed thin GBM, whether or not manifesting proteinuria or CRF. 
In such families, the diagnosis of TBMN was assumed for all the relatives of a 
biopsied patient who also manifested microscopic hematuria with or without 
additional evidence of renal disease. Regarding the molecular description, the 
diagnosis of ARAS was made in patients presenting with typical manifestations 
of AS who were (apparently) compound heterozygotes or  homozygotes for 
pathogenic COL4A3 and/or COL4A4 mutations, even if not all diagnostic criteria 
of AS had manifested.(Savige, Gregory et al. 2013) When one pathogenic 
COL4A3 or COL4A4 mutation was detected, the phenotype, at the familial level, 
was decisive to interpret the molecular result. The term ‘carrier of ARAS’ was 
used to denote a patient who carried a single pathogenic COL4A3 or COL4A4 
mutation, whose phenotype ranged from absence of microscopic hematuria to 
progressive CRF and ESRD. The term ‘collagen type IV-related GBM 
nephropathy’ was used to refer to a patient or family in whom at least a 
pathogenic COL4A5, COL4A4 or COL4A3 mutation was identified. 
The study was approved by the Health Ethics Commission of CHSJ, and 
patient enrollment for the genetic analyses required written informed consent.  
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Molecular study of the COL4A3 and COL4A4 genes 
Genomic DNA samples of 30 probands without a pathogenic COL4A5 mutation, 
identified in the first-tier molecular genetics diagnostic study, were screened for 
pathogenic mutations in COL4A3 and COL4A4 using tagged primer Sanger 
sequencing, either at the DNA Laboratory, Guy's and St. Thomas' National 
Health Service Foundation Trust, London, United Kingdom (n=18), or at the 
Center for Nephrology and Metabolic Diseases, Weisswasser, Germany (n=12). 
Polymerase chain reaction (PCR) products covering the entire coding sequence 
and the splice regions of the two genes were generated, purified and 
automatically sequenced by capillary electrophoresis, using standard laboratory 
methods and state-of-art equipment and techniques (details provided upon 
request).  
The presence of the COL4A3 and COL4A4 sequence variants identified in 
the probands was confirmed in a second set of sequencing analyses at the 
Department of Genetics, Faculty of Medicine, University of Porto, Porto, 
Portugal. The confirmatory assays were limited to the relevant exons and 
corresponding exon-intron boundaries in each family, and were carried out as 
described in supplementary tables S2 and S3.(Boye, Mollet et al. 1998; Heidet, 
Arrondel et al. 2001) The same laboratory approach was used for screening at-
risk relatives within the affected families.  
Sequence variants were described according to the COL4A3 reference 
sequence NM_000091.4 (http://www.ncbi.nlm.nih.gov/nuccore/NM_000091.4) 
and the COL4A4 reference sequence NM_000092.4 
(http://www.ncbi.nlm.nih.gov/nuccore/NM_000092.4), with the first nucleotide 
position corresponding to the first base of the translation start codon, using the 
nomenclature recommended by the Human Genome Variation Society.(den 
Dunnen and Antonarakis 2000)  
The pathogenicity of the identified variants was presumed from the type of 
mutation – with nonsense mutations, splicing mutations within the consensus 
donor or acceptor splice regions and frameshifting mutations regarded as 
disease-causing –, and supported by the observed genotype-phenotype 
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correlations within the family. The inheritance pattern in each family was 
inferred from pedigree analysis. The possible impact of novel COL4A3 and 
COL4A4 missense point mutations upon the structure and function of the 
corresponding protein and/or mRNA splicing was predicted by in silico analyses 
with several bioinformatic tools (see details in the footer of Table I).  
 
Genotype-phenotype correlations and statistical analyses 
For genotype-phenotype correlation analyses, the study cohort consisted of 
both the probands and their affected and adult unaffected relatives 
prospectively identified on genetic screening. Subjects were divided according 
to their genetic status into a subcohort of homozygotes and compound 
heterozygotes for pathogenic COL4A3 or COL4A4 mutations, clinically 
corresponding to patients with ARAS, and a subcohort of individuals apparently 
carrying a single pathogenic mutation in either COL4A3 or COL4A4, clinically 
corresponding to a wide phenotypic spectrum, including individuals without 
microscopic hematuria and individuals with AS who may have a second yet 
unidentified pathogenic COL4A3 or COL4A4 mutation.  
The chi-square or the Fisher’s exact tests were used as appropriate for 
comparisons of proportions. Survival analysis was used for comparisons of time 
to events. Non-parametric statistical tests were used to compare selected 
continuous clinical outcomes. The chi-square test for trend was used to assess 
the association between the numbers of diagnostic criteria of AS identified in 
each patient and the probability of finding a pathogenic mutation(s) in any of the 
COL4A3/COL4A4/COL4A5 genes. The 95% confidence intervals (95%CI) for 
prevalences were estimated by the modified Wald method.(Agresti and Coull 
1998) The data were analyzed with the statistics software packages PASW® 
Statistics 18 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism® 5.0 
(GraphPad Software, Inc.; La Jolla, CA, USA). 
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RESULTS 
COL4A3 and COL4A4 mutations 
Three previously reported (Heidet, Arrondel et al. 2001; Badenas, Praga et al. 
2002; Wang, Rana et al. 2004) and 10 novel pathogenic mutations scattered 
along the COL4A3 gene, as well as one recurrently described variant 
(Lemmink, Mochizuki et al. 1994; van der Loop, Heidet et al. 2000; Heidet, 
Arrondel et al. 2001; Badenas, Praga et al. 2002; Longo, Porcedda et al. 2002; 
Tazon Vega, Badenas et al. 2003; Wang, Rana et al. 2004) of uncertain 
significance (VUS) (p.Leu1474Pro) and one novel VUS (p.Phe1504Leu), were 
identified in 18 apparently unrelated families (Table I). Of the novel pathogenic 
mutations, five are small duplications or deletions that result in shifting of the 
reading frame and truncated protein translation; two are nonsense mutations; 
two involve critical nucleotides in canonical donor or acceptor splice junctions; 
and one is a glycine-changing missense mutation. All three previously known 
pathogenic mutations were typical glycine substitutions in the collagenous 
domain of the α3-chain. In the Portuguese cohort, one of these mutations 
(p.Gly407Arg) was identified in 8 apparently unrelated pedigrees, but all the 
other were unique to a single family. The p.Leu1474Pro VUS was identified in 
apparent compound heterozygosity with different pathogenic mutations, in two 
female probands. As both of these patients presented with a severe renal 
disease phenotype, with early progression to ESRD, they were included with 
the other homozygotes and compound heterozygotes for the genotype-
phenotype correlation analyses. On the other hand, the p.Phe1504Leu VUS 
was not included in these correlation analyses, since this variant was not 
unequivocally causative of the proband’s phenotype. This variant was detected 
in a female, in whom pathogenic mutations in COL4A5 and COL4A4 were not 
identified, who presented at 27-years-old with persistent microscopic hematuria, 
proteinuria and hypertension, diagnosed while she was pregnant, and whose 
mother, who was said to have had AS, had already deceased. At age 31, 
ultrastructural examination of kidney biopsy revealed GBM of variable 
thickness, with areas of thinning and wrinkling of the membrane, as well as 
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electron-dense bodies, but she did not have typical audiologic or ocular findings 
of AS. 
One previously reported (Lemmink, Nillesen et al. 1996; Tazon Vega, 
Badenas et al. 2003) and 7 novel pathogenic mutations scattered along the 
COL4A4 gene, as well as one recurrently described VUS (p.Gly999Glu),(Buzza, 
Dagher et al. 2003; Wang, Rana et al. 2004; Slajpah, Gorinsek et al. 2007) 
were identified in 9 families (Table II). Of the novel pathogenic mutations, two 
small duplications and one small deletion result in frameshifting and truncated 
protein translation; one is a small in-frame deletion; two involve critical 
nucleotides in canonical donor splice junctions; and one is a glycine-changing 
missense mutation. The previously reported pathogenic mutation was a typical 
glycine substitution in the collagenous domain of the α4-chain. All COL4A4 
mutations were unique to each family. The COL4A4 p.Gly999Glu VUS was 
detected in heterozygosity in a 37-year-old female who had been on RRT since 
the age of 18 years and the sequencing of the COL4A3 and COL4A5 genes did 
not show any additional variants. However, as p.Gly999Glu in COL4A4 seems 
to be of questionable pathogenicity, reaching a polymorphic allelic frequency of 
0.11 in the Slovenian population,(Slajpah, Gorinsek et al. 2007) this proband 
has not been included in the genotype-phenotype correlation analyses. 
Genetic screening of at-risk family members allowed identification of: 23 
relatives of probands with pathogenic COL4A3 mutations, three of whom were 
compound heterozygotes, while 20 were heterozygotes for one pathogenic 
mutation previously found in the proband; and 11 relatives of probands with 
pathogenic COL4A4 mutations, all of whom were heterozygotes for the 
mutation found in the proband. Three of the heterozygote relatives 
(p.Pro135Glnfs*18 and p.Tyr481* in COL4A3; p.Ser1555* in COL4A4), 
including two relatives of patients with ARAS, were totally asymptomatic and in 
6 there was insufficient clinical data to support a clinical diagnosis. These 
subjects were also included in the genotype-phenotype correlation analyses, 
according to their genetic status. In 11 of the families with COL4A3 mutations 
and five of the families with COL4A4 mutations the disease phenotype 
segregated with the identified mutation(s) at least in one relative of the proband. 
170 
 
 
 
None of the novel mutations identified in this study was present in more than 
8,000 alleles from more than 4,000 unrelated European-American individuals 
listed on the Exome Variant Server.(Exome Variant Server) 
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Table I. Pathogenic mutations and allelic variants of unknown significance identified in the COL4A3 gene in Portuguese 
patients with Alport syndrome and Thin Basement Membrane Nephropathy.  
Mutation type Exon or 
Intron 
Nucleotide change Predicted effect on the 
protein 
Bioinformatic 
prediction of 
pathogenicity‡ 
Mutation status Reference# Family 
Missense mutations               
 Exon 19 c.1114 G>C p.(Gly372Arg) Disease causing a, b, c Compound heterozygosity  56 
 Exon 21 c.1219G>C p.(Gly407Arg)  Disease causing a, b, c Compound heterozygosity (Heidet, 
Arrondel et al. 
2001)  
5,9,16,46,54,
55,A3_4 - 
4/1, A3_4 - 
6/1 
     Heterozygosity   
 Exon 28 c.2083G>A p.(Gly695Arg) Disease causing a, b, c Heterozygosity (Wang, Rana 
et al. 2004)  
A3_4 - 5/1 
 Exon 35 c.2954G>T p.(Gly985Val) Disease causing a, b, c Compound heterozygosity (Badenas, 
Praga et al. 
2002) 
56 
Frameshift mutations               
 Exon 2 c.92_95dupGTGT p.(Lys34Leufs*2) Disease causing a Homozygosity  35 
     Heterozygosity   
 Exon 7 c.402delT p.(Pro135Glnfs*18) Disease causing a Compound heterozygosity  9 
     Heterozygosity   
 Exon 26 c.1845dupA p.(Pro616Thrfs*30) Disease causing a Compound heterozygosity  44 
 Exon 28 c.2111delC p.(Pro704Leufs*43) Disease causing a Compound heterozygosity  44 
 Exon 35 c.2914_2915delAG p.(Gly973Argfs*53) Disease causing a Compound heterozygosity  61 
Nonsense mutations               
 Exon 23 c.1443T>A p.(Tyr481*) Disease causing a Homozygosity  61, 62 
     Compound heterozygosity   
 Exon 30 c.2371C>T p.(Arg791*) Disease causing a Compound heterozygosity  38 
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Splice site mutations               
 Intron 33 c.2657-1G>T ND Disease causing d, e, f Compound heterozygosity  63 
 Intron 44 c.3955+1G>C ND Disease causing d, e, f Homozygosity  38, 12 
     Compound heterozygosity   
          Heterozygosity     
Variant of unknown significant             
 Exon 48 c.4421T>C p.(Leu1474Pro) Disease causing a, b, c Compound heterozygosity (Lemmink, 
Mochizuki et 
al. 1994; van 
der Loop, 
Heidet et al. 
2000; Heidet, 
Arrondel et al. 
2001; 
Badenas, 
Praga et al. 
2002; Longo, 
Porcedda et 
al. 2002; 
Tazon Vega, 
Badenas et 
al. 2003; 
Wang, Rana 
et al. 2004)  
55, 63 
 Exon 49 c.4510T>C p.(Phe1504Leu) Disease causing a, b, c Heterozygosity  47 
#
 Mutation previously reported in HGMD (http://www.hgmd.cf.ac.uk/, last accessed on March 1, 2014) and/or  
LOVD (http://www.lovd.nl/3.0/home, last accessed on March 1, 2014). 
‡
 Superscript letters refer to different bioinformatic predictions of pathogenicity: 
a: Predicted by Mutationt@ster (http://www.mutationtaster.org/, last accessed on March 1, 2014). 
b: Predicted by Polyphen 2 (http://genetics.bwh.harvard.edu/pph2/, last accessed on March 1, 2014). 
c: Predicted by SNPs&GO (http://snps-and-go.biocomp.unibo.it/snps-and-go/, last accessed on March 1, 2014). 
d: Predicted by NNSplice (http://www.fruitfly.org/seq_tools/splice.html, last accessed on March 1, 2014). 
e: Predicted by NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/, last accessed on March 1, 2014). 
f: Predicted by Human Splicing Finder (http://www.umd.be/HSF/, last accessed on March 1, 2014). 
ND: effect on splicing not determined by mRNA analysis. 
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Table II. Pathogenic mutations and allelic variants of unknown significance identified in the COL4A4 gene in Portuguese 
patients with Alport syndrome and Thin Basement Membrane Nephropathy.  
Mutation type 
Exon or 
Intron 
Nucleotide change 
Predicted effect on the 
protein 
Bioinformatic 
prediction of 
pathogenicity‡ 
Mutation status Reference# Family 
Missense mutations               
 Exon 30 c.2690G>A p.(Gly897Glu) Disease causing a, b, c Heterozygosity (Lemmink, 
Nillesen et al. 
1996; Tazon 
Vega, 
Badenas et 
al. 2003) 
17 
 Exon 38 c.3506G>T  p.(Gly1169Val) Disease causing a, b, c Heterozygosity  37 
Frameshift mutations               
 Exon 9 c.568_569dupGG p.(Asp191Glyfs*29) Disease causing a Heterozygosity  22 
 Exon 28 c.2216dupC p.(Val741Cysfs*47) Disease causing a Homozygosity  4 
     Heterozygosity   
 Exon 47 c.4664_4665delCT p.(Ser1555*) Disease causing a Heterozygosity  25 
Small (in-frame) deletion               
 Exon 20 c.1323_1340del 
(18bp)† 
p.(Gly442_Pro447del) Disease causing Heterozygosity  8 
Splice site mutations               
 Intron 2 c.71+1G>A ND Disease causing d, e, f Heterozygosity  A3_4 - 2/1 
  Intron 31 c.2860+1G>A ND Disease causing d, e, f Homozygosity   40 
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Variant of unknown significant             
 Exon 33 c.2996G>A p.(Gly999Glu) Disease causing a, b, c Heterozygosity (Buzza, 
Dagher et al. 
2003; Wang, 
Rana et al. 
2004; 
Slajpah, 
Gorinsek et 
al. 2007) 
30 
 
† c.1323_1340delTGGCTTGCCTGGAGCACC 
#
 Mutation previously reported in HGMD (http://www.hgmd.cf.ac.uk/, last accessed on March 1, 2014) and/or  
LOVD (http://www.lovd.nl/3.0/home, last accessed on March 1, 2014). 
‡
 Superscript letters refer to different bioinformatic predictions of pathogenicity: 
a: Predicted by Mutationt@ster (http://www.mutationtaster.org/, last accessed on March 1, 2014). 
b: Predicted by Polyphen 2 (http://genetics.bwh.harvard.edu/pph2/, last accessed on March 1, 2014). 
c: Predicted by SNPs&GO (http://snps-and-go.biocomp.unibo.it/snps-and-go/, last accessed on March 1, 2014). 
d: Predicted by NNSplice (http://www.fruitfly.org/seq_tools/splice.html, last accessed on March 1, 2014). 
e: Predicted by NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/, last accessed on March 1, 2014). 
f: Predicted by Human Splicing Finder (http://www.umd.be/HSF/, last accessed on March 1, 2014). 
ND: effect on splicing not determined by mRNA analysis. 
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Genotype-phenotype correlations 
The diagnosis of ARAS was genetically confirmed in 12 probands and in three 
of their relatives (Supplementary table S4). Five of the probands were 
apparently homozygous for COL4A3 (n=3) or COL4A4 (n=2) mutations, the 
other seven being compound heterozygotes for COL4A3 mutations. In two of 
these 12 families (12 and 35), it was confirmed that both probands’ parents 
were heterozygotes for the pathogenic COL4A3 mutation found in 
homozygosity in the proband. Parental consanguinity was observed in one 
family with a proband who was homozygous for a pathogenic COL4A4 mutation 
(family 40) and in one family in which the proband was a compound 
heterozygote for two pathogenic COL4A3 mutations (family 61). The higher 
prevalence of COL4A3 mutations in probands diagnosed with ARAS was 
statistically significant (p=0.02).  
Apparent heterozygosity for pathogenic COL4A3 (n=7) or COL4A4 (n=6) 
mutations was identified in 13 probands with clinical and/or pathology 
diagnoses of familial hematuria, TBMN or AS (Supplementary table S5) and, in 
the 8 families in whom at least one of the probands’ parents was enrolled, the 
same pathogenic mutation was found to have been inherited from one of the 
parents (families 8, 16, 17, 22, 25, 37, 54, A3/4_2). In some probands with 
heterozygous COL4A3 or COL4A4 mutations who had personal or family 
history of typical extra-renal manifestations of AS, we hypothesize that a second 
pathogenic mutation remained undetected, as it is the case of the proband of 
family 8 who reached ESRD at age 23 and had typical AS maculopathy, and in 
whom direct sequencing of COL4A4 detected a single pathogenic mutation 
(p.Gly442_Pro447del). Moreover, in this proband, pathogenic COL4A5 and 
COL4A3 variants were not found, by direct sequencing of both genes. 
Additionally, we hypothesize that audiological and ocular manifestations, which 
may mimic extra-renal features of AS, may have other distinct causes, which 
should be pursued. The COL4A4 mutation p.Val741Cysfs*47 caused ARAS, in 
homozygosity, and was also found in the 58-year-old heterozygote sister of the 
proband who manifested microscopic hematuria and CKD, concurrently with 
hearing loss.  
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Regarding the severity of the renal disease, six out of seven pathogenic 
COL4A3 mutations and all the six pathogenic COL4A4 mutations identified in 
apparently heterozygous probands were associated with microscopic hematuria 
and proteinuric CKD and, in five probands, even with stage 2 CKD 
(p.(Gly407Arg) in the COL4A3 gene; and p.Gly897Glu, p.Asp191Glyfs*29, 
c.71+1G>A in the COL4A4 gene). The recurrent p.Gly407Arg COL4A3 mutation 
caused ARAS when present together with a second pathogenic mutation and, in 
heterozygotes, was associated with a wide array of age-dependent clinical 
phenotypes, ranging from absence of microscopic hematuria, to isolated 
microscopic hematuria and to ESRD.  
The proportion of probands (as compared with affected relatives of 
probands), was significantly higher in the subcohort of homozygous/compound 
heterozygous patients than in the subcohort of apparently heterozygous 
patients (Table III), but the median ages at enrollment were similar in the two 
subcohorts. Gender distribution also did not significantly differ between the two 
groups. The diagnosis of microscopic hematuria was made at a significantly 
younger median age in the homozygous/compound heterozygous patients (12 
vs. 26 years; p=0.006). As compared with the (apparently) heterozygous 
patients, the prevalence of proteinuria, hypertension and CRF were significantly 
higher in the former, while the median ages at diagnosis were significantly 
lower. Proteinuria and hypertension were diagnosed at median ages of 16 and 
25 years respectively (p=0.002) and of 18 and 42 years (p<0.001) in each of the 
sub-cohorts. CRF was diagnosed at a median age of 20 years in the 
homozygous/compound heterozygous patients and at a median age of 46 years 
(p<0.001) in the (apparently) heterozygous patients. All homozygous/compound 
heterozygous patients, but only 14% of the (apparently) heterozygous patients, 
had already started RRT (p<0.001); however, the difference in the median ages 
at start of RRT between the two groups did not reach statistical significance. 
Significantly more homozygous/compound heterozygous patients reported 
subjective hearing loss. Among patients who underwent formal 
ophthalmological examination, the prevalence of anterior lenticonus and of dot-
and-fleck retinopathy was also significantly higher in this subcohort. Diagnostic 
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kidney biopsies were performed at significantly younger ages in 
homozygous/compound heterozygous patients, but the prevalence of distinctive 
GBM ultrastructural features of AS did not differ between the two groups.  
The overall COL4A3/COL4A4/COL4A5 mutation detection rates in the 24 
probands that had been comprehensively evaluated for all the diagnostic criteria 
of AS, are presented in Table IV. A highly significant linear trend (p<0.01) was 
observed between the number of diagnostic criteria of AS identified in each 
patient and the probability of detecting at least a pathogenic mutation in any of 
the three genes. Of note, the probability of identifying a pathogenic COL4A3, 
COL4A4 or COL4A5 mutation in patients with microscopic hematuria and two 
additional diagnostic criteria of AS was 57%.  
In general, the severity of the clinical expression of AS in the 
homozygous/compound heterozygous patients was comparable with that of 
males with XLAS, both groups showing high rates of ESRD and of SNHL 
manifesting before the fourth decade of life. When the disease expression was 
compared between males and females carrying a COL4A3 or COL4A4 mutation 
in apparent heterozygosity and females with XLAS (i.e., heterozygotes for a 
pathogenic mutation in COL4A5), no major differences were identified except in 
the prevalence of microscopic hematuria, which was a constant finding in XLAS 
females but was not manifested by a significant number of the heterozygotes for 
a pathogenic mutation in COL4A3 or COL4A4 that were prospectively identified 
on family screening.  
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Table III. Descriptive characteristics of Portuguese Alport syndrome patients 
with pathogenic COL4A3 and COL4A4 mutations by mutation status 
(homozygotes and compound heterozygotes versus heterozygotes). 
 Homozygotes and 
Compound 
Heterozygotes 
(n=15) 
Heterozygotes 
(n=44) 
p-
value 
  N  N  
Phenotype      
Index-cases (%) 80 12/15 30 13/44 0.001 
Male gender (%) 53 8/15 32 14/44 0.137 
Age at enrollment (median (interquartile range)) 42 (17) 15 46 (26.8) 44 0.296  
Renal anomalies      
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
55 
8 (15*) 
6/11 
3 
12 
17 (12*) 
3/25 
3 
0.012  
0.343  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100 
12 (14.3) 
9/9 
6 
77 
26 (20.5) 
27/35 
26 
0.175 
0.006  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
100 
16 (13.5) 
12/12 
9 
70 
25 (19.5) 
23/33 
22 
0.042  
0.002  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
92.3 
18 (14.8) 
12/13 
8 
52 
42 (18.5) 
17/33 
13 
0.016  
0.000  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile 
range)) 
100 
20 (10) 
59 (15*) 
14/14 
9 
3 
51 
46 (19.5) 
67 (20) 
18/35 
17  
15 
0.001  
0.000  
0.236  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
100 
23 (12) 
9.5 (3*) 
15/15 
15 
2 
14 
36 (22) 
14 (-) 
5/36 
5 
1 
0.000  
0.042  
0.221  
GBM ultrastuctural anomalies 
Age at diagnosis (median (interquartile range)) 
 
17.5 (7.8) 
 
6 
 
34 (19) 
 
9 
 
0.004  
Thinning (%) 100 5/5 100 8/8 a  
Thickening (%) 100 4/4 100 3/3 a  
Lamellation (%) 100 5/5 60 3/5 0.444 
Electrondense bodies (%) 100 5/5 67 2/3 0.375 
Hearing loss      
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
93.3 
9 (19) 
14/15 
9 
35 
36 (32*) 
12/34 
3 
0.000  
0.086  
Hearing loss confirmed by audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
90 
32 (22) 
9/10 
7 
53 
44 (26.5) 
10/19 
9 
0.098  
0.009  
Ocular anomalies      
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
33 
30 (-) 
3/9 
1 
0 
- 
0/25 
- 
0.014  
- 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
63 
34 (25*) 
5/8 
3 
9.1 
40.5 (35*) 
3/33 
2 
0.003  
0.610  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
83 
42.5 (17*) 
5/6 
2 
12 
58 (15*) 
3/25 
3 
0.002 
0.207 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The range is 
indicated instead of the interquartile range. a Statistics cannot be computed for this variable because the 
proportion in the two groups is a constant. 
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Table IV. COL4A3, COL4A4 and COL4A5 detection mutation rate per number of diagnostic criteria met, among probands 
tested for COL4A3, COL4A4 and COL4A5, with complete clinical evaluation (n=23).  
 
Diagnostic 
criteria met 
COL4A5-
positive 
probands 
(n=7) 
COL4A3 or 
COL4A4-
positive 
probands 
(n=10) 
COL4An-
negative 
probands 
(n=6) 
Total of 
probands 
studied 
(n=23) 
COL4A5 mutation 
detection rate per number 
of diagnostic criteria met 
(%) 
COL4A3/4 mutation 
detection rate per 
number of diagnostic 
criteria met (%) 
COL4An mutation 
detection rate per 
number of diagnostic 
criteria met (%) 
1 0 0 2 2 0 0 0 
2 2 2 3 7 29 29 57 
3 1 7 1 9 11 78 89 
4 4 1 0 5 80 20 100 
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DISCUSSION 
We have identified 17 novel and 4 previously reported pathogenic COL4A3 or COL4A4 
mutations in 25 (62.5%) patients from a cohort of 40 apparently unrelated probands 
from Portuguese families with a diagnosis of non-XLAS or of TBMN. Exclusion of X-
linked inheritance was based on pedigree evidence or the negative result of previous 
mutational analysis of COL4A5. Although gross deletions and gross 
insertions/duplications of COL4A3 or COL4A4 have rarely been reported in patients with 
collagen IV-related GBM nephropathies [Human Gene Mutation Database – HGMD®; 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A4 and 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL4A3, accessed on March 1, 2014], 
the lack of testing for deletions/duplications not readily detectable by sequence analysis 
was a major limitation of our study, and deep intronic mutations – like those affecting 
the normal splicing of COL4A5 mRNA, described in families with XLAS (King, Flinter et 
al. 2002; King, Flinter et al. 2006) –, might have been overlooked as well. Consequently, 
we may have slightly underestimated the contribution of pathogenic COL4A3 or 
COL4A4 mutations to the molecular genetics epidemiology of collagen IV-related GBM 
nephropathies in Portugal, and even possibly missed their genetic diagnosis in some 
families.  
The overall frequencies of different types of pathogenic COL4A3 and COL4A4 
mutations identified in our cohort did not significantly differ from those reported to the 
HGMD®. Small deletions/duplications were predominant, constituting 42.9% (9/21) of 
the total. In all but one case, these mutations caused a shift in the mRNA reading frame 
with premature termination of translation. Missense mutations, all of them involving 
glycine substitutions, accounted for 28.6% (6/21). Like in other genetic disorders of 
collagen,(Shoulders and Raines 2009) glycine substitutions in the collagenous domain 
of the α3, α4 or α5 chains of type IV collagen are a common type of pathogenic 
mutation in AS.(Kashtan 2001) Such mutations are thought to interfere with the normal 
folding of the mutant chain into triple helices with other type IV collagen α-chains, 
leading to increased susceptibility to proteolytic degradation. The COL4A3 glycine 
substitution p.Gly407Arg was identified in 8 apparently unrelated probands, making it a 
181 
 
 
 
particularly frequent disease-causing mutation in Portuguese families with collagen IV-
related GBM nephropathies. Two nonsense point mutations were identified in COL4A3, 
accounting for 9.5% (2/21) of all pathogenic mutations identified in this study. The four 
splice site mutations, which accounted for 19% (4/21) of the total, were all novel and 
affected the highly conserved guanine residues at positions +1 or –1, respectively in the 
consensus donor and acceptor splice regions.  
Twelve probands were apparently homozygous or compound heterozygotes for 
pathogenic COL4A3 or COL4A4 mutations. Although we were not able to confirm the 
heterozygous condition of their parents in all cases, the phenotypes of these probands, 
and their family histories, were compatible with a clinical diagnosis of ARAS. In the 
ARAS patients, the disease was five times more frequently caused by COL4A3 
mutations than by mutations in COL4A4.  
Taking into account the data reported herein and the results of our previous 
scanning for COL4A5 mutations, [manuscript submitted to the JMG simultaneously] the 
prevalences of XLAS and ARAS in Portuguese families with clinical and/or EM 
diagnosis of AS are respectively 35.5% (22/62; 95%CI: 25–48%) and 19.4% (12/62; 
95%CI: 11–31%). On the other hand, in 15 out of 62 (24%) of those families where all 
three genes were analyzed, no pathogenic mutations could be identified. Overall, the 
results of our COL4A3/COL4A4/COL4A5 genetic analyses allowed us to confirm the 
diagnosis of a collagen IV-related GBM nephropathy in about two-thirds of 65 families, 
of which 46.8% (22/47) had XLAS and 53.2% (25/47) had ARAS or familial 
hematuria/TBMN with or without progressive renal function deterioration. The lower than 
expected prevalence of XLAS in our cohort is in accordance with the results of a recent 
Italian study,(Fallerini, Dosa et al. 2013) which showed that the prevalence of patients 
with familial hematuria or TBMN with CRF, carrying one pathogenic COL4A3 or 
COL4A4 mutation may be underestimated, at least in specific populations. The >50% 
mutation detection rate in the Italian patients with only 1 or 2 diagnostic criteria of AS, is 
also consistent with our own findings. The proportion of Portuguese families with no 
pathogenic mutation identified in any of the three genes was significantly lower than in 
the Italian study.  
182 
 
 
 
The hemizygous condition for pathogenic COL4A5 mutations, as well as the 
homozygous, compound or double heterozygous conditions for pathogenic COL4A3 
and/or COL4A4 mutations, are associated with a significantly higher risk of developing 
ESRD and extrarenal complications of AS, manifesting at younger ages, than the 
heterozygous condition for any of the three genes.(Jais, Knebelmann et al. 2000; Jais, 
Knebelmann et al. 2003; Marcocci, Uliana et al. 2009; Temme, Peters et al. 2012; 
Storey, Savige et al. 2013) Likewise, we observed a significantly higher frequency of 
ESRD and SNHL in our patients with apparently homozygous or compound 
heterozygous pathogenic mutations in COL4A3 or COL4A4, when compared with the 
apparently heterozygous patients; median ages at the diagnosis of advanced CRF were 
in the early second decade of life in the former and in the beginning of the fourth decade 
of life in the latter patients; and the apparently heterozygous condition was less often 
associated with extrarenal manifestations. These observations are consistent with 
current knowledge about the collagen IV-related GBM nephropathies, suggesting that 
we did not misclassify a significant number of families with ARAS as having a 
heterozygous condition. Furthermore, the lower than expected prevalence of XLAS in 
Portuguese patients diagnosed with AS, which was a major finding of this study, cannot 
be explained by the methodological limitations discussed above.  
Given the age-related penetrance of their clinical manifestations, the phenotypic 
prevalence of familial hematuria/TBMN with progressive CRF in heterozygous patients 
for pathogenic COL4A3 or COL4A4 mutations increases with age, even into late 
adulthood.(Voskarides, Damianou et al. 2007; Pierides, Voskarides et al. 2009; Temme, 
Peters et al. 2012) The risk of CKD progression to ESRD in late adulthood for patients 
carrying a single COL4A3 or COL4A4 pathogenic mutation (Voskarides, Damianou et 
al. 2007; Marcocci, Uliana et al. 2009; Temme, Peters et al. 2012) must be 
acknowledged for proper planning of clinical follow-up and in genetic counseling. 
Furthermore, it is particularly important to it be addressed with prospective donors when 
live-related kidney transplantation is being considered for patients with  collagen IV-
related GBM nephropathies.(Gross, Weber et al. 2009)  
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It is recommended that all at-risk relatives of patients diagnosed with any of the 
autosomally inherited collagen IV-related GBM nephropathies should be 
comprehensively screened for the typical disease manifestations, either renal or 
extrarenal, and that individuals with urinary abnormalities (even asymptomatic), or with 
hypertension, should be periodically re-evaluated for CKD progression.(Frasca, Onetti-
Muda et al. 2005; Temme, Peters et al. 2012)  
Genotyping is the most clinically useful diagnostic method of collagen IV-related 
GBM nephropathies, providing an effective tool for age- and phenotype-independent 
family screening, and for accurate genetic counselling. It also allows for earlier 
therapeutic intervention with renin–angiotensin–aldosterone system (RAAS) blockade in 
carriers of single COL4A3 or COL4A4 pathogenic from families with autosomal 
dominant collagen IV-related GBM nephropathies, and is a key requisite for primary 
prevention of those diseases by PIGD or PND. It is advisable that all carriers of a single 
COL4A3 or COL4A4 mutation have lifelong renal follow-up, even if asymptomatic at 
baseline.  
Given the high number of exons per gene in COL4A3, COL4A4, COL4A5, 
(respectively 52, 48 and 51) and the absence of mutational hot-spots due to the private 
nature of most pathogenic mutations, a primary molecular genetics diagnostic approach 
to collagen IV-related GBM nephropathies by Sanger sequencing becomes quite 
laborious, time consuming and expensive, particularly in those families without a clear 
inheritance pattern. Next-generation sequencing (NGS) is a promising new analytical 
method for detection of pathogenic mutations in genetically heterogeneous disorders 
like AS.(Artuso, Fallerini et al. 2012; Hertz, Thomassen et al. 2012) The relative 
prevalence of XLAS as compared with ARAS in our cohort was about fivefold lower than 
expected, and the mutation detection rate in COL4A5/COL4A4/COL4A3 was >50%, 
even in patients with only one or two diagnostic criteria of AS. In these conditions, NGS 
may be particularly cost-effective as first-tier approach to the genetic diagnosis of 
patients with clinical suspicion of AS.  
 
184 
 
 
 
ACKNOWLEDGEMENTS 
This work is part of the PhD project of Maria João Nabais Sá (supervisor: João Paulo 
Oliveira), to be presented at the ICBAS – “Instituto de Ciências Biomédicas Abel 
Salazar” (Abel Salazar Biomedical Sciences Institute), University of Porto, Portugal. The 
studies reported herein were mainly supported by the European Regional Development 
Fund (ERDF) through the Competitive Factors Operational Programme (COMPETE), 
and by the Portuguese Foundation for Science and Technology (FCT), in the framework 
of the Cooperation Agreement between Portugal and Harvard Medical School-2009, 
through the project FCOMP-01-0124-FEDER-HMSP-ICJ/SAU-ICT/0003/2009. 
Additional funding was obtained from a research grant of the Portuguese Society of 
Nephrology. The Unit of Research & Development in Nephrology (FCT-725) at the 
Department of Nephrology of the Faculty of Medicine, University of Porto, and the São 
João Hospital Centre, Porto, Portugal, provided secretarial support.  
Complete genotyping of the COL4A3 and COL4A4 genes was performed in 30 families 
as research collaboration with GSTS Pathology (London, UK) and Moldiag – Center for 
Nephrology and Metabolic Diseases (Weisswasser, Germany). In 5 additional families, 
the complete genotyping of the COL4A3 and COL4A4 genes was performed as 
outsource diagnostic service by Gendia (Antwerp, Belgium).  
The authors thank the patients and their relatives for the invaluable collaboration in this 
study; NephroCare – Portugal, for having allowed the nationwide ascertainment of 
patients with Alport syndrome in their dialysis center; Dr.s Adelino Carvalho 
(NephroCare, Santarém), Ana Bernardo (NephroCare, Covilhã), Bernardo Faria 
(NephroCare, Guarda), Carlos Botelho (NephroCare, Viseu), Joana Felgueiras 
(NephroCare, Montijo), Liliana Pinho (Dialysis clinic, Paredes), Luís Carvalho 
(NephroCare, Restelo) and Miguel Gonçalves Rocha (Hospital de Braga) for 
contributing clinical data of patients enrolled in this study; Dr.s Ana Oliveira, Augusta 
Praça, Isabel Tavares, João Frazão, Ricardo Neto (Department of Nephrology, São 
João Hospital Centre, Porto), and Dr. Ana Gomes (Department of Nephrology, Hospital 
Centre, Vila Nova de Gaia) for referring patients for this study.  
185 
 
 
 
The authors also thank Dr. Francis Earl Cook, from the Department of Epidemiology, 
Harvard School of Public Health, Boston, MA, for his advice and supervision of the 
epidemiological and statistical analyses.  
Parts of these data were presented as posters at the European Human Genetics 
Conference 2012, Nürnberg, Germany, June 23-26, 2012 (P12.007) and at the 62nd 
Annual Meeting of the American Society of Human Genetics, November 6-10, 2012 San 
Francisco, California (3122F).  
 
 
 
 
 
 
 
 
 
 
186 
 
 
 
Supplementary figure S1. Study flowchart. 
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Supplementary table S2: Primer sequences, annealing temperatures and product size for PCR amplification of the COL4A3 gene.† 
Exon Forward primer Reverse primer Annealing 
temperature 
PCR  
product size 
2  CTCCTAACAGATAGTGTCC   CGGATCTTTCTGCTACCGAT  56ºC 267 bp 
7  AGCCTCATGACCCAGTAGC   GAATGTCTACTATGGCTACC  58ºC 308 bp 
19 TGA TGT TTG GTG AGC TGT C TCC TGC CCT CCA GCA AAT G 58ºC 417 bp 
21  TCTCCATTGTGCAATTTTTA   CTAAGCTGTGAGGAGGGTTT  55ºC 367 bp 
23 TCT GAG GAC TCA ATG TAG C CGT TGT GAC ATC CAC CAA T 56ºC 242 bp 
26  ACGGAAGAAACCTGCAGTG   CCTGGTATCTGTGAGTTGAC  56ºC 483 bp 
28  GTGCAAAAGGGATAGGACG   CTTCTAAATATCCACAACAA  55ºC 259 bp 
30  GTTGATGACATGGTAGTGG   GGAAGAAAGGTAGGGCAGG  58ºC 391 bp 
33 GAC CCA TCT CCT AGA CTA A GGC TAA CAG TGC TGA GAA C 56ºC 499 bp 
35 TCG TTC TGT CGC CCA CGC T CTG CTG GAA CAC TAT CAG A 58ºC 392 bp 
44  ACTTCAGCTTATTCTCACCC   GGAGCCTTCCTACTTCACTC  61ºC 333 bp 
48 GCC ACT CTT CTC TAG GAT T GTA TCA GGA GAC ACT CAA G 56ºC 458 bp 
†
 Cycling conditions (adapted from (Heidet, Arrondel et al. 2001)) were: initial denaturation for 5 minutes at 94ºC, followed by 35 
cycles of denaturation at 94ºC for 60 seconds, annealing for 60 seconds, and extension at 72ºC for 90 seconds, ending with a final 
extension at 72ºC for 10 minutes. The PCR products were automatically sequenced in forward and reverse directions in an ABI 
Prism® 310 Genetic Analyzer (Applied Biosystems) using the BigDye® Terminator v3.1 Cycle Sequencing kit, and the 
corresponding electropherograms were visually inspected for the anticipated mutation in each case.  
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Supplementary table S3: Primer sequences, annealing temperatures and product size for PCR amplification of the COL4A4 gene.† 
Exon Forward primer Reverse primer Annealing 
temperature 
PCR  
product size 
2  TCTGGAAGAGAAGACTGGCA   AAGCAGGCAATCACACTGAG  60ºC 152 bp 
9  ACCTCCGCATATCCCTTCC   TTCATGTTCTGTGGTCGCC  58ºC 375 bp 
20  CTCCAGCTCCGTCTCTTTC   TGCTTTCTTAGTGGCACTG  60ºC 365 bp 
28  ATTGGTTCTATACTTGCACA   TCTATGCACCAAAAGGACAG  55ºC 309 bp 
30  TGCTGTGTGTGAAGCCAGTG   AGGACAAGAGCAAGGGAGG  61ºC 400 bp 
31  GACTCTGTCCACCTCCCAC   CCAAGCTTCAGACAAGTCC  61ºC 328 bp 
33 GCT TAA CTA TTA CCT AGC TC TCT CCT TGA GCT ACA CCT T 56ºC 383 bp 
38  GCGTTTGTGGCTAGAGTGAG   ATACCAGGGAGGGTACCAC  61ºC 218 bp 
47  GCAAAGGCCAGATGGAGG   GCGGGAGAAGGTGTTAGG  56ºC 433 bp 
 
†
 Cycling conditions (adapted from (Boye, Mollet et al. 1998)) were: initial denaturation for 5 minutes at 94ºC, followed by 35 cycles 
of denaturation at 94ºC for 60 seconds, annealing for 60 seconds, and extension at 72ºC for 90 seconds, ending with a final 
extension at 72ºC for 10 minutes. The PCR products were automatically sequenced in forward and reverse directions in an ABI 
Prism® 310 Genetic Analyzer (Applied Biosystems) using the BigDye® Terminator v3.1 Cycle Sequencing kit, and the 
corresponding electropherograms were visually inspected for the anticipated mutation in each case.  
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Supplementary table S4. Genotype and phenotype of Portuguese probands with pathogenic homozygous or compound heterozygous 
COL4A3 or COL4A4 mutations and of their relatives with heterozygous, homozygous or compound heterozygous condition.   
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CKD: chronic kidney disease. pCr: plasma creatinine level, in micromol/L; to convert micromoles/L (SI units) into mg/dL dividing by 88.4. eGFR: estimated glomerular filtration 
rate, in mL/min/1.73m2. SNHL: sensorineural hearing loss. GBM: glomerular basement membrane. a In brackets, the age at diagnosis or at last screening, in years. b In 
brackets, the age at start of hemodialysis (HD), peritoneal dialysis (PD) or of kidney transplant (KTx). c In brackets, the age at kidney biopsy. d +: Family history of hematuria 
and/or end stage renal disease (ESRD); in parenthesis, the number of enrolled relatives who were confirmed to be heterozygotes; † Family history of ESRD. e In brackets, 
kinship / age at diagnosis or at last screening in the relative, in years. <: before the age indicated within brackets. Fa: father; Mo: mother; Br: brother; Si: sister; D: daughter; (if 
there are more than one relative of the same kinship, they are identified in subscript by the order of age). Hom: homozygous. Comp het: compound heterozygous. +: Clinical 
feature present. –: Clinical feature not present. § GBM changes observed in this patient: thinning, thickening, lamellation and electrondense bodies. ND: effect on splicing not 
determined by mRNA analysis. NA: data not available. 
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Supplementary table S5. Genotype and phenotype of Portuguese probands and their relatives with pathogenic heterozygous 
COL4A3 or COL4A4 mutations. 
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CKD: chronic kidney disease. pCr: plasma creatinine level, in micromol/L; to convert micromoles/L (SI units) into mg/dL divide by 88.4. eGFR: estimated glomerular filtration 
rate, in mL/min/1.73m2. SNHL: sensorineural hearing loss. GBM: glomerular basement membrane.  a In brackets, the age at diagnosis or at last screening, in years. b In 
brackets, the age at start of hemodialysis (HD) or peritoneal dialysis (PD). c In brackets, the age at kidney biopsy. d +: Family history of hematuria and/or end stage renal 
disease (ESRD); in parenthesis, the number of enrolled relatives who were confirmed to be heterozygotes; † Family history of ESRD; # clinical data from the mother was not 
available. e In brackets, kinship and age at diagnosis or at last screening in the relative, in years. <: Before the age indicated within brackets. Fa: father; Mo: mother; Br: brother; 
Si: sister; S: son; D: daughter; mA: maternal aunt; mGA: maternal grand-aunt; (if there are more than one relative of the same kinship, they are identified in subscript by the 
order of age). Het: Heterozygous. +: Clinical feature present. –: Clinical feature not present. § GBM changes observed in this patient: thinning and lamellation. ND: effect on 
splicing not determined by mRNA analysis. NA: data not available. 
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Chapter 4 Discussion 
 
1. Aim 1: Molecular analysis of COL4A5, COL4A4 and COL4A3 in 
Portugal  
 
1.1. The epidemiology of pathogenic COL4A5, COL4A4 and COL4A3 
mutations in Portugal is different from other countries 
The COL4A5 molecular analysis was performed by direct sequencing and 
MLPA in 60 out of 65 probands (Supplementary figure S1 of manuscript 3). XLAS 
was genetically confirmed in 22 families (22/60; 37%), in whom pathogenic COL4A5 
mutations were identified. In the remaining five out of 65 probands, the inheritance 
pattern was not compatible with XLAS and direct sequencing of COL4A3 and 
COL4A4 was performed as the first tier molecular investigation. Pathogenic COL4A3 
or COL4A4 mutations were detected in all five probands. Thirty-five probands without 
pathogenic COL4A5 mutations were also studied by direct sequencing of COL4A3 
and/or COL4A4, and pathogenic mutations were detected in either one of the two 
genes in 20 of these families (25/40; 63%). Since the common pathogenic COL4A3 
missense mutation c.1219G>C (p.Gly407Arg) was identified by targeted mutation 
analysis in one proband, full mutational screening of COL4A4 was avoided in his 
family.  
 
1.1.1. High detection rate of pathogenic COL4A5, COL4A4 and COL4A3 
mutations 
Among 62 probands with clinical diagnosis or suspicion of AS, pathogenic 
COL4A5, COL4A4 or COL4A3 mutations were identified in 47 (76%). We have used 
PCR followed by direct sequencing as the first tier investigation in the genetic 
diagnosis of type IV collagen nephropathies. This laboratory approach is considered 
the gold standard for the analysis of genes with different mutation types, including for 
the detection of small mutations and the determination of breakpoints of large 
rearrangements (Sanger, Nicklen et al. 1977). PCR and direct sequencing of 
genomic DNA demonstrated a COL4A5 mutation detection rate over 80% (Martin, 
Heiskari et al. 1998; Hertz, Thomassen et al. 2012). In this study, it enabled: (i) 
detection of point mutations in the coding region of COL4A5, COL4A4 and COL4A3, 
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both in males and females; (ii) detection of large COL4A5 deletions in males; (iii) 
identification of pathogenic variants in intron-exon boundary regions of the three 
genes.  
Small COL4A5 pathogenic mutations were previously identified using 
screening methods followed by confirmation of the mutation in genomic DNA, with 
single-stranded conformation polymorphism (SSCP) analysis being one of the most 
widely used (Hertz, Juncker et al. 2001). However, the relative insensitivity of some 
of these earlier mutation scanning methods is likely to be worsened when applied to 
XLAS, because of the large gene size, coupled with the unusually high GC content of 
most of the COL4A5 exons and the sudden change in GC content at the exon-intron 
boundaries (King, Flinter et al. 2006). As the high GC content is typical of the exons 
coding for the proline- and hydroxyproline-rich amino acid triplet Gly-X-Y, which is a 
hallmark feature of collagens, the same cautionary thoughts regarding the analytical 
sensitivity of SSCP-based methods can be generalised to the molecular study of 
COL4A3 and COL4A4.  
A mutation detection rate of over 90% was achieved using direct sequencing 
of cDNA obtained from ectopically expressed COL4A5 mRNA in peripheral blood 
leukocytes (Inoue, Nishio et al. 1999). However, since COL4A5 mRNA is object of 
variant splicing in leukocytes (Guo, Van Damme et al. 1993), the results of these 
analyses require careful interpretation, particularly if no mutation is found, as the 
absence of an alternativelly spliced exon in the COL4A5 mRNA of peripheral blood 
leucocytes, but expressed in skin or kidney cells, may hide a pathogenic mutation 
present in genomic DNA.   
The expression of α5(IV) chains in EBM makes it possible to study cDNA 
obtained from cultured skin fibroblasts, with the advantages of performing 
immunohistochemistry for α5(IV) chain and to analyze the coding sequence in a 
compact form, being mutations subsequently confirmed in genomic DNA, with a high 
detection rate (Hertz, Juncker et al. 2008). In recent studies, analysis of COL4A5 
cDNA fragments from skin fibroblasts yielded a mutation detection rate of 83% and 
was particularly valuable for identification of cryptic splicing mutations (Wang, Zhao 
et al. 2012). However, this laboratory approach requires a skin biopsy, which is a 
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more invasive procedure, and for this reason it was not chosen as first tier screening 
method in our study.  
Furthermore, MLPA was additionally used for deletion/duplication analysis of 
COL4A5 (Hertz, Thomassen et al. 2012). In females, MLPA was shown to be 
effective in detecting large deletions/duplications as well as point mutations that 
coincide with the location of the probes (Uberbacher, Hyatt et al. 2004; Hertz, 
Juncker et al. 2008). Although not being an appropriate method to screen for 
unknown point mutations, in our cohort MLPA analysis confirmed the presence of a 
frameshift mutation resulting from deletion of a single base pair in family 1, and of a 
missense mutation in family 48, both affecting hybridization sites for the MLPA 
probes. Hence, while it has been specifically designed to identify 
deletions/duplications not readily detectable by sequence analysis, MLPA also allows 
the detection of small mutations that prevent effective hybridization of its probes to 
test samples.  
Fifteen out of 62 probands did not carry any pathogenic COL4A5, COL4A4 or 
COL4A3 mutations (24%). The specific detection rate of a pathogenic COL4A5 
mutation among Portuguese families with clinical diagnosis or suspicion of AS was 
37% (22/60). However, the commercial P191/P192 Alport MLPA assay does not 
contain probes for three of the 51 exons of COL4A5, leaving exons 8, 25 and 40 out 
of the analysis. Although isolated exon deletions are rare, DNA diagnostic 
laboratories should be aware of this limitation, which may be particularly relevant for 
families in whom the proband is a female and no pathogenic COL4A5, COL4A4 or 
COL4A3 mutations were identified. Of three probands in whom the mutational 
screening was limited to COL4A5, two were males (so deletion of each COL4A5 
exon was excluded by PCR), but the other was a female from a family in whom all 
affected males were deceased. Among the 15 probands without a pathogenic 
COL4A5, COL4A4 and COL4A3 mutation, four were males and 11 were females. 
One female did not have family history of hematuria, CKD or deafness; three females 
had only affected female relatives; five females reported family history of affected 
male relatives but none of them was alive; the remaining two female probands, who 
were enrolled through dialysis clinics, had affected male relative(s) but none of them 
was referred for molecular analysis. However, the major explanation for the lower 
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than expected proportion of families with genetically confirmed XLAS was the 
detection of pathogenic COL4A4 or COL4A3 mutations in 25 out of 40 (63%) of the 
families. This mutation detection rate is an estimate since the molecular study of 
COL4A4 and COL4A3 did not include deletion/duplication analysis.  
Several other reasons may have concurred for not identifying pathogenic 
COL4A5, COL4A4 or COL4A3 mutations in 24% of the enrolled families (Flinter and 
Plant 1998): (i) occurrence of pathogenic mutations in non-coding regions of 
COL4A5, COL4A4 and COL4A3, namely in the promoter region and in the intronic 
regions which were not screened; (ii) the laboratory methods employed did not 
enable detection of complex rearrangements (e.g. a karyotype was not performed as 
part of the molecular study protocol) (Hertz, Persson et al. 2005); (iii) occurrence of 
pathogenic mutations in other genomic locations (e.g. mutations in other genes); and 
(iv) enrollment of patients with diseases that have clinical manifestations in common 
with AS (Deltas, Pierides et al. 2013). Of note, in our cohort, the 5’ UTR and the 
promoter region of COL4A5 were sequenced in three families with multiexon 
COL4A5 deletions, excluding point mutations or a deletion of this region (manuscript 
2).  
 
1.1.2. The prevalence of pathogenic COL4A5 mutations is similar to that of 
pathogenic COL4A4 and COL4A3 mutations in Portugal 
We studied a genetically heterogeneous group of patients with clinical 
diagnosis or suspicion of AS: (i) 65 individuals, belonging to 22 families, had a 
pathogenic COL4A5 mutation; and (ii) 59 individuals, from 25 families carried one or 
two pathogenic COL4A3 or COL4A4 mutations. The prevalences of X-linked and 
autosomal AS in our cohort is in contrast with the expected occurrence of X-linked 
inheritance in 80-85% of families and of autosomal inheritance in 15-20% of families. 
Indeed, according to publicly available data from Human Gene Mutation Database® 
(http://www.hgmd.cf.ac.uk; last accessed on March 9, 2014), 755 pathogenic 
mutations were published in COL4A5 (82.2%), 67 in COL4A4 (7.3%) and 97 in 
COL4A3 (10.5%). However, a recent study of 87 Italian families with clinical 
suspicion of AS, which used an unbiased NGS protocol to simultaneously screen the 
COL4A3, COL4A4 and COL4A5 genes for disease-causing mutations, showed that, 
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among the 48 families with pathogenic mutations identified in one of the three genes, 
65% had a COL4A5 mutation and the remaining had COL4A3 or COL4A4 mutations 
(Fallerini, Dosa et al. 2013). In our study, the proportion of families with a pathogenic 
COL4A5 mutation (22/47; 47%) was similar to the proportion of families with at least 
one pathogenic COL4A3 or COL4A4 mutation (25/47; 53%). We hypothesize that the 
prevalence of XLAS might have been underestimated in the Portuguese families 
because of the following possible reasons: (i) the use of broader inclusion criteria 
(less than three classic diagnostic criteria of AS) enabled the enrollment of probands 
with less severe renal manifestations and/or without extra-renal features and might 
have favoured the recruitement of patients with TBMN caused by heterozygous for 
pathogenic COL4A3 or COL4A4 mutations (Fallerini, Dosa et al. 2013); (ii) 
Portuguese patients with genetically confirmed XLAS who have been previously 
enrolled in ECASCA study were not included in this cohort; (iii) the non-participation 
in this study of some major Portuguese kidney transplantation centers might have 
also caused a selection bias against patients with more severe presentations of AS. 
Interestingly, however, if the 13 families in whom a single pathogenic mutation was 
detected in COL4A3 or COL4A4  are excluded from the analyses (assuming a 
second pathogenic COL4A3 or COL4A4 mutation would not have occured in the 
proband and that these families would have TBMN), the proportion of families with 
XLAS rises to 65% (22/34), which is still significantly lower than the expected 80-85% 
prevalence, but which is in agreement with the reported findings in the Italian 
population (Fallerini, Dosa et al. 2013). 
Furthermore, among the Portuguese families with a clinical diagnosis of AS or 
TBMN and pathogenic COL4A5, COL4A4 or COL4A3 mutations, the proportion of 
probands with heterozygous COL4A3 or COL4A4 mutations (13/47; 28%) was similar  
to the proportion of probands with molecularly confirmed ARAS (12/47; 26%). 
Contrastingly, in the Italian study, the proportion of families with pathogenic 
heterozygous mutations in COL4A3 or COL4A4 was higher (31%) than the 
proportion of families with molecularly confirmed ARAS (4%) (Fallerini, Dosa et al. 
2013). Although the latter findings are not concordant with our own results, in both 
studies the proportion of probands with heterozygous pathogenic COL4A3 or 
COL4A4 mutations was significantly above the expected 5%. Possible reasons for 
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the finding of a higher than expected proportion of heterozygous patients with 
pathogenic COL4A3 or COL4A4 mutations are the following: (i) the presence of a 
second pathogenic mutation in either COL4A3 or COL4A4 may have been missed, 
either because of the inability of direct sequencing to detect specific types of 
mutations in these genes (e.g. exon or multiexon deletions and/or duplications) or 
because the mutations occurred in non-scanned gene regions (e.g. promotor and 
deep intronic mutations); (ii) individuals with heterozygous COL4A3 or COL4A4 
mutation may be more susceptible to the effects of major risk factors for CKD (e.g. 
hypertension or diabetes mellitus), which are highly prevalent in the population, or to 
the effects of other genetic variants and polymorphisms that may modulate the risk of 
progressive kidney disease in the population; (iii) the chance occurrence in the same 
patient of another genetic or non-genetic kidney disease, unrelated to GBM collagen 
IV.  
1.1.3. Documentation of pathogenic COL4A5, COL4A4 and COL4A3 
mutations 
It is important to emphasize that this study not only confirmed the diagnosis in the 
probands, but also promoted the combined clinical and molecular study of their family 
members for precise genetic conselling. Regarding the molecular characterization of 
the 156 affected and unnafected individuals, from the 47 families who were found to 
carry pathogenic COL4A5, COL4A4 or COL4A3 mutations, the following results were 
obtained:  
- Among 22 families with pathogenic COL4A5 mutations (Table I of manuscript 1): 
 - 30 patients were hemizygotes; 
 - 35 patients were heterozygotes; 
 - 23 participants did not carry the pathogenic COL4A5 mutation of the family. 
- Among 17 families with pathogenic COL4A3 mutations (Table I of manuscript 3): 
 - 13 patients were homozygotes or compound heterozygotes; 
 - 27 patients were heterozygotes; 
 - 4 participants didn’t carry the pathogenic COL4A3 mutation of the family. 
- Among 8 families with pathogenic COL4A4 mutations (Table I of manuscript 3): 
 - 2 patients were homozygotes; 
 - 17 patients were heterozygotes; 
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 - 5 participants did not carry the pathogenic COL4A4 mutation of the family. 
 
The parents of probands were clinically and molecularly evaluated in 23 
families (23/47; 49%). Mutations were confirmed to be de novo in 2 out of 13 families 
with pathogenic COL4A5 mutations (15%). De novo COL4A5 mutations were 
identified in a female with a large COL4A5 deletion encompassing exons 43 to 45, 
which is predicted to lead to a truncated protein; and in a male with a previously 
reported missense mutation c.2633G>T (p.Gly878Val) (Plant, Green et al. 1999). In 
two of the probands carrying apparently homozygous pathogenic COL4A3 or 
COL4A4 mutations, parental screening confirmed the heterozygous condition of both 
parents. In eight families, the proband and one of the proband’s parents carried a 
same pathogenic COL4A3 and COL4A4 mutation, in heterozygosity.  Among the 24 
families in which parents of the proband were not evaluated, both parents were 
deceased in six families with pathogenic COL4A3 or COL4A4 mutations (6/47; 
12.8%) and the at-risk mother of the proband was already deceased in four families 
carrying a pathogenic COL4A5 mutation (4/47; 8.5%). In 12 families, at-risk parents 
of the proband were alive, but were not enrolled in the study (12/47; 25.5%). In two 
families (2/47; 4.2%), the available family history did not include information on the 
proband’s parents. Among four of the ten probands with an apparently homozygous 
or compound heterozygous pathogenic COL4A3 or COL4A4 mutations of whom 
parents were not enrolled, at least one other adult first degree relative was found to 
carry one mutation, in heterozygosity. Further clinical and molecular analyses will 
need to be persued in at-risk relatives in the remaining families to prove the 
occurrence of the pathogenic mutations in distinct alleles. Of note, the parents of the 
genetic probands were consanguineous in only three out of the 65 families. 
1.1.4. Pathogenicity of the novel COL4A5, COL4A4 and COL4A3 variants 
The results of this study extended the spectrum of known disease-causing 
mutations in the three genes, leading to the identification of 29 novel pathogenic 
mutations: 12 in COL4A5, 10 in COL4A3, and 7 in COL4A4. Our data are also in 
agreement with the notion that collagen IV-related nephropathies do not result from 
digenic mutations (Heidet, Arrondel et al. 2001), as none of the 34 probands who 
were screened for both COL4A3 and COL4A4 mutations was a double heterozygous. 
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1.1.4.1. According to the mutation type 
Similarly to what was observed in other populations, collagen IV-related 
nephropathies also show a high degree of allelic heterogeneity in Portuguese 
families, with a considerable proportion of private mutations. As expected, missense 
mutations were the most frequent type of mutation detected in the three genes, and 
large deletions accounted for 19% of all COL4A5 mutations (Table IX). The 
proportion of large COL4A5 deletions identified in the Portuguese families is 
consistent with previous reports on the genetic pathology of XLAS (Jais, Knebelmann 
et al. 2000).  
Respectively 89.9% (196/218), 78.6% (22/28) and 87.1% (27/31) of the 
pathogenic COL4A5, COL4A4 and COL4A3 missense mutations reported at the 
HGMD® database (last accessed on September 19, 2013), occurred within the 
collagenous domain of the protein; of those, respectively 95.4% (187/196), 90.9% 
(20/22) and 96.3% (26/27) were glycine substitutions. In keeping with those data, all 
pathogenic COL4A5, COL4A4 and COL4A3 missense mutations detected in our 
cohort were located in the collagenous domains and substituted glycine residues. As 
pointed out by several investigators (Wang, Ding et al. 2004; King, Flinter et al. 
2006), the predicted substitution of glycine residues in the collagenous domain of 
these proteins enables, in most cases, to classify the underlying COL4A5, COL4A4 
or COL4A3 mutations as pathogenic. This is because glycine substitutions in 
collagenous domains affect the triple helical folding of the alpha chains, thereby 
disturbing the quaternary structure of the corresponding collagen. 
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Table IX. Comparison of the types of pathogenic COL4A5, COL4A4 and COL4A3 
mutations deposited in HGMD® and detected in this study (last accessed on 
September 19, 2013).  
Mutation type Number of mutations in HGMD® Number of mutations in this study 
 COL4A5 COL4A4 COL4A3 COL4A5 COL4A4 COL4A3 
 n % n % n % n % n % n % 
Missense 218 41.
7 
28 50.0 31 44.3 7 33.3 2 25.0 4 30.8 
Nonsense 35 6.7 5 8.9 11 15.7 2 9.5 0 0.0 2 15.4 
Splicing 88 16.
8 
7 12.5 11 15.7 6 28.6 2 25.0 2 15.4 
Small deletions 83 15.
9 
11 19.6 10 14.3 2 9.5 2 25.0 3 23.0 
Small insertions 29 5.5 3 5.4 4 5.7 0 0.0 2 25.0 2 15.4 
Small indels 4 0.8 1 1.8 1 1.4 0 0.0 0 0.0 0 0.0 
Gross deletions 58 11.
1 
1 1.8 2 2.9 4 19.0 0 0.0 0 0.0 
Gross insertions 
/duplications 
4 0.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Complex 
rearrangements 
4 0.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Total 523 100 56 100 70 100 21 100 8 100 14 100 
 
1.1.4.2. According to the protein domain 
Pathogenic variants occurred dispersed throughout the coding region of the 
gene, with the number of point mutations in a specific domain being proportional to 
the size of the domain of the alpha chain. In COL4A5, the majority of the pathogenic 
point mutations (n=17) detected in this study were located in the collagenous domain 
(15/17; 88.2%), while a minority was identified in the NC1 domain or C-terminal 
domain (2/17; 11.8%). Similar findings were observed in COL4A4, with the majority of 
mutations being identified in the large collagenous domain (6/8; 75.0%), while one 
mutation was located in 7S domain or N-terminal domain (12.5%) and another 
mutation in the NC1 domain (12.5%). Finally, in COL4A3, all pathogenic point 
mutations were detected in the collagenous domain of the protein. These results 
overlap with data reported at the HGMD® (last accessed on September 19, 2013), 
showing that the majority of the pathogenic mutations identified in each of the three 
genes occurred in the collagenous domain of the corresponding alpha chain (Table 
X). Interestingly, pathogenic point mutations were dispersed throughout the coding 
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region of the gene, and the proportion of pathogenic mutations per protein domain 
correlates with the relative length of the domain within the protein.  
 
Table X. Comparison of the location in different protein domains of pathogenic 
COL4A5, COL4A4 and COL4A3 mutations deposited in HGMD® (last accessed on 
September 19, 2013) with those detected in this study.  
 
Protein domain Domain size  Number of 
mutations in 
HGMD 
Number of 
mutations in this 
study 
 
 codons % of 
protein 
n % n % 
COL4A5 N-terminal domain 1 - 26 1.5 5 1.1 0 0.0 
 Collagenous domain 27 - 1456 84.9 402 88.7 15 88.2 
 C-terminal domain 1457 - 1685 13.6 46 10.2 2 11.8 
COL4A4 N-terminal domain 1 - 38 2.2 2 3.6 1 12.5 
 Collagenous domain 39 - 1459 84.1 46 83.6 6 75.0 
 C-terminal domain 1460 - 1690 13.7 7 12.7 1 12.5 
COL4A3 N-terminal domain 1 - 28 1.7 1 1.5 0 0.0 
 Collagenous domain 29 - 1438 84.4 55 80.9 13 100.0 
 C-terminal domain 1439 - 1670 13.9 12 17.6 0 0.0 
 
Moreover, when comparing the number of base pairs per exon with the 
number of reported pathogenic point mutations per exon in COL4A5, COL4A4 and 
COL4A3, the two distributions seem to superimpose (Figures 5 and 6). Because the 
majority of the larger exons (approximately 100 bp) are located between the exons 
19 and 51, and the majority of the reported pathogenic mutations are also in that 
region, the molecular analysis of the COL4A5 gene in every index-case was started 
from the 3’ end of the gene. A further reason for this decision was the fact that the 
NC1 domain, which is critical for the assembly of collagen heterotrimers, is encoded 
by COL4A5 exons 47 to 51 and, therefore, mutations affecting these exons are very 
likely pathogenic. 
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Figure 5. Number of base pairs per exon, in the COL4A5 gene.  
 
 
Figure 6. Number and type of pathogenic point mutations per exon, in the COL4A5 
gene. 
 
1.1.4.3. Recurrent location of pathogenic mutations 
Although there are no mutational hotspots described in the COL4A5 gene, our 
study showed recurrent mutation locations in families with XLAS: (i) in exon 47, which 
harbored two distinct point mutations – c.4342G>C, p.(Gly1448Arg), and c.4444C>T, 
p.(Gln1482*); (ii) adjacent to or involving the acceptor splice site of intron 30, namely 
two distinct deletions – c.2510_2554del (45bp) and c.2510(-1)_2525del (15bp); (iii) 
and in intron 1, which included one of the breakpoints of two distinct multiexonic 
deletions. Furthermore, the pathogenic p.(Gly1448Arg) mutation in exon 47 was 
identified in two apparently unrelated families, but the results of the haplotype 
analysis were suggestive that they are related by a common ancestor. Interestingly, a 
mutation at the same nucleotide position, but changing a glycine to serine, was 
originally reported in a 39-year-old Chinese male diagnosed with AS (Wang, Wang et 
al. 2005). With 213 base pairs, exon 47 is the largest of the COL4A5 exons, partially 
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encoding both the collagenous and the NC1 domains; for this reason, it should be 
prioritized in the molecular analysis of COL4A5 by direct sequencing.  
Although we did not perform RNA studies to prove the pathogenicity of the two 
microdeletions identified in the boundary of intron 30 with exon 31, their presumed 
effects at the protein level are severe enough to justify classification as disease-
causing. Indeed, a much smaller c.2510delG frameshifting deletion had already been 
described in a male diagnosed with AS (Flinter, Cameron et al. 1988) and was 
classified as pathogenic (King, Flinter et al. 2006). Molecular genetics studies on 
patient’s cell lines (e.g. skin fibroblasts), including with reverse transcriptase-PCR 
and quantitative real-time PCR, would be of help to characterize the consequences 
of those microdeletions at the RNA level. 
Regarding the two gross COL4A5 deletions with proximal breakpoints located 
in intron 1, both occurred within LINE1 repeats, more precisely 9.5 kb proximal to 
exon 2 (chrX:107,773,340) at the end of a MA3-LINE1 repeat, in the ATS-DL family 
(COL4A5 deletion of exons 2 to 51),  and in a 700 bp region 24.5 kb distal to 
COL4A5 exon 1 (chrX:107,707,634-107,708,329) in a ME1-LINE1 repeat, in the 
family with the COL4A5 deletion of exons 2 to 29. The occurrence of microdeletion 
breakpoints within LINE1 repeats in intron 1 of COL4A5 has been previously 
reported, which may predispose to non-allelic homologous recombination (NAHR), if 
significant homology exists between the subfamilies of LINE1 repeats in both, 
proximal and distal, breakpoints (Segal, Peissel et al. 1999).  
The previously reported pathogenic COL4A3 missense mutation c.1219G>C 
p.(Gly407Arg), was identified in eight apparently unrelated families, suggesting that it 
is a common cause of collagen IV-related nephropathies in Portugal. This mutation 
was originally described in compound heterozygosity in a family with two affected 
siblings, who both needed to start dialysis treatment early in the third decade of life 
(Heidet, Arrondel et al. 2001). As the clinical report does not give details about the 
renal phenotype of their mother, who was heterozygous for the same mutation, it 
may be assumed that, at least, she was not severely affected. However, our study 
demonstrates that heterozygosity for this particular COL4A3 mutation is associated 
with a broad spectrum of clinical phenotypes, including TBMN with and without 
progression to ESRD.   
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1.1.4.4. According to the population screening and bioinformatic tools 
The splice site mutation c.1339+6C>G, detected in the male proband of family 
3, is a novel variant, which occurs within a nucleotide sequence that is immediately 
adjacent to the highly conserved splice junction consensus sequence. Pathogenic 
mutations were not identified in COL4A3 and COL4A4 genes in the proband, after 
performing direct sequencing. Due to the fact that the proband’s mother, already 
deceased, also had reached ESRD and had severe high tone SNHL, an autosomal 
inheritance pattern was less likely than the X-linked pattern. This previously 
unpublished variant segregates with the disease in the family, as it was also detected 
in heterozygosity in the proband’s sister who has XLAS, but not in a maternal aunt of 
the proband, who didn’t have microscopic hematuria, high tone SNHL, nor ocular 
signs of AS. This COL4A5 variant was also not identified in 150 X-chromosomes of 
healthy controls, nor in 85 X-chromosomes from Portuguese AS probands. A new 
donnor splice site is predicted to occur in the position of the variant, within intron 20 
of COL4A5, according to NNSplice (http://www.fruitfly.org/seq_tools/splice.html, last 
accessed on October 26, 2013) and Human Splicing Finder 
(http://www.umd.be/HSF/, last accessed on October 26, 2013). The consistency of 
this bioinformatic tool results was used to predict the pathogenic effect of genomic 
DNA variants into proteins. This option was justified given the accuracy of the 
publicly available bioinformatic programs in the prediction of the pathogenicity of the 
change based upon the effect of the change on the specific functional domains of the 
protein (Fairbrother, Yeh et al. 2002; Calabrese, Capriotti et al. 2009; Adzhubei, 
Schmidt et al. 2010; Thusberg, Olatubosun et al. 2011; Adzhubei, Jordan et al. 
2013). Additionally, the bioinformatic approach has overcome the refusal of 
collaboration of patients for biopsy of skin and saved time and financial resources 
required for the implementation and accomplishment of the analysis of mRNA. 
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2. Aim 2: Clinical characterization of Portuguese patients 
 
2.1. Phenotype of the 65 genetic probands 
2.1.1. Microscopic hematuria and thinning of the GBM were  hallmarks 
Clinical information was available on 166 participants regarding renal function, 
renal structure, audiologic and ophthalmologic evaluation. The evaluation of the four 
typical clinical criteria of AS was completed in 24 participants (24/166; 14%); three of 
these evaluations were performed in 56 participants (56/166; 34%); the evaluation of 
two parameters was achieved in 42 participants (42/166; 25%); and in 44 participants 
only one out of the four parameters was investigated or reported in this study 
(44/166; 27%). Clinical evaluation information was not available for 12 individuals 
(five autosomal recessive AS carriers and seven non-carrier unaffected family 
members). 
Regarding the 65 probands, the median age at enrollment was 38 years 
(interquartile range 20 years) (Table XI). Only one male proband was enrolled before 
reaching 18 years old, but he had manifested microscopic hematuria and hearing 
loss and was known to carry a pathogenic COL4A5 mutation. Interestingly, besides 
microscopic hematuria being a renal impairment sign common to the vast majority of 
index cases (98%), the occurrence of thin GBM was observed in all kidney biopsies 
(100%), which were performed at a median age of 21 years old (adult age). Although 
an excess of males was expected due to the occurrence of XLAS in approximately 
80-85% of the families and the increased severity of the disease in male patients with 
XLAS, the frequency of male and female patients among probands was similar, 
which prompted us to persue the molecular study of the COL4A3 and COL4A4 
genes. 
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Table XI. Descriptive characteristics of the probands (n=65).  
 Index cases 
(n=65) 
  N 
Phenotype   
Male gender (%) 52.3 34/65 
Age at enrollment (median (interquartile range) 38 (20) 65 
Renal anomalies 
  
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
45.8 
6 (10.5) 
22/48 
17 
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
98 
17 (24) 
50/51 
43 
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
98.2 
14.2 (18) 
54/55 
49 
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
66.7 
25 (20) 
40/60 
29 
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (mean (SD)) 
75.4 
24.5 (20.5) 
56.5 (25.5) 
46/61 
38 
24 
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
61.9 
23 (17.25) 
9.5 (6) 
39/63 
38 
14 
Hearing loss 
  
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
69.8 
14(15.75) 
44/63 
24 
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
93.9 
32 (24.5) 
46/49 
29 
Ocular anomalies 
  
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
19.5 
27 (17) 
8/41 
6 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
31.8 
26 (20.75) 
14/44 
10 
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
25 
34 (25) 
9/36 
7 
Ultrastuctural anomalies 
Age at diagnosis (median (interquartile range)) 
 
20.5 (16) 
 
26 
Thinning (%) 100 23/23 
Thickening (%) 94.4 17/18 
Lamellation (%) 73.7 14/19 
Electrondense bodies (%) 89.5 17/19 
Leiomyomatosis (%) 1.5 1/65 
Intellectual disability and facial dysmorphy 
(%) 
0 0/65 
Family History 
  
Family history of hematuria (%) 78.4 40/51 
Family history of CKD (%) 79 49/62 
Family history of hearing loss (%) 67.2 39/58 
Family history of ocular abnormalities (%) 42.1 8/19 
SD: standard deviation. Age is expressed in years; eGFR is expressed in ml/min/1.73m2. 
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Historically, affected males have been preferably selected as genetic 
probands of AS families, with the aim of optimizing the mutational analysis of the 
COL4A5 gene due to the interpretation of sequencing results (Plant, Green et al. 
1999). In our study, all patients with suspected or clinical diagnosis of collagen IV-
related nephropathy, irrespective of their gender, were accepted as genetic 
probands. The current availability of molecular analysis techniques that make 
possible the diagnosis of the different types of variants in the COL4A5 gene, both in 
males (DNA amplification by PCR followed by direct sequencing) and females (DNA 
amplification by PCR followed by direct sequencing and MLPA), also allowed the 
gender-unbiased selection of probands. By assessing the information provided in the 
clinical protocol of this study, several other reasons were found for the enrollment of 
females as genetic probands, including: (i) absence of family history of AS 
manifestations (n = 5); (ii) males with suspected or clinical diagnosis of AS were 
deceased (n = 8); (iii) suspected or clinical diagnosis of AS only in females (n = 6); 
and (iv) males and females equally affected, i.e., renal disease with similar severity in 
both genders (n = 2). In a minority of genetic probands, the reason that led to the 
recruitment of a female, instead of a male relative is not traceable (n = 5).  
In families where a pathogenic mutation was identified in the COL4A5, 
COL4A4 or COL4A3 genes, the probable reasons for the enrollment of a female 
proband are summarized in Table XII. This distribution shows that 71% of the 
pathogenic mutations identified in female probands were in COL4A3 or COL4A4 
(10/14), confirming an autosomal inheritance pattern in those families. Among the 22 
families carrying pathogenic COL4A5 mutations, only in four the genetic proband was 
a female. It may additionally be hypothesized that the putative genetic defect 
underlying the AS-like phenotype in the remaider families (i.e., those with no 
pathogenic mutation identified in COL4A5, COL4A4 or COL4A3), results in an 
autosomal inheritance pattern.  
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Table XII. Probable reasons to study a female as a genetic proband, instead of a 
male, and result of the COL4A5, COL4A4 and COL4A3 molecular analysis (n=26).  
 Absence 
of family 
history 
(n=5) 
Deceased 
affected 
males 
(n=8) 
Only 
affected 
females 
(n=6) 
Males 
and 
females 
equally 
affected 
(n=2) 
Unknown 
reason 
(n=5) 
Pathogenic variant in  
COL4A5 1 0 1 0 2 
Pathogenic variant in 
COL4A3 or COL4A4 3 2 2 1 2 
Without pathogenic 
variants in COL4A5, 
COL4A4 or COL4A3 
1 6 3 1 1 
 
All 65 probands had microscopic hematuria and/or CKD (stage 2 or higher). 
Among the probands, 13 (20%) had one known diagnostic clinical criterion of AS, 28 
(43%) had two known criteria, 19 (29%) had three known criteria and only a minority 
(8%) had four diagnosed clinical criteria. Among the 113 enrolled family members of 
these probands, 75 (66%) were enrolled due to family history of hematuria and/or 
CKD, 26 (23%) had two clinical diagnostic criteria of AS and 12 (11%) had three 
known diagnostic criteria of AS. Twenty family members did not have microscopic 
hematuria or CKD (stage 2 or higher): 17 unaffected (non-carrier) family members 
and three heterozygous relatives of probands with ARAS. 
The retrospective, cross-sectional design and the relatively small size of the 
patient cohort, which is an inherent problem with rare diseases, are major limitations 
of this study. Careful review of all the available patient’s clinical records allowed 
minimizing the recall bias. The age-dependent and the sex-dependent penetrance of 
renal, audiological and ocular manifestations also tried to be minimized by enrolling 
adult individuals and by specialist referral for screening of the ophthalmological and 
audiological manifestations of AS, which however was not systematically done. For 
these reasons, generalization of the genotype-phenotype correlations observed in 
our cohort, as well as of the phenotypic descriptions should be cautious. 
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3. Aim 3: A novel genotype-phenotype correlation among other 
correlations 
 
3.1. Deletion of the common COL4A5/COL4A6 promotor and 5’ exons of 
COL4A6 is not needed for development of diffuse leiomyomatosis in 
X-linked Alport syndrome 
 
A large deletion involving COL4A5 but not COL4A6 was detected in three 
patients of the same family with ATS-DL. Previously, all patients reported with ATS-
DL had deletions involving 5’ exons of both COL4A5 and COL4A6 genes. Our results 
show that the deletion of the common promoter and the 5’ exons of COL4A6 is not 
required for the development of diffuse leiomyomatosis. The particularity of the novel 
mutation also resides in the fact that its breakpoints in intron 1 and beyond exon 51 
in COL4A5 are the most 3’ proximal and distal described to date in patients with 
ATS-DL.  By performing high-resolution X-oligo-array, it was demonstrated that all 
other exons (and genes) on the entire X chromosome are neither deleted nor 
duplicated in the proband of the ATS-DL family. By cloning the junction sequence, a 
complex recombination between the COL4A5 and the COL4A6 genes was excluded 
and it was shown that the large COL4A5 deletion identified in this family is the result 
of a single recombination event with no inversion or insertion at the deletion 
breakpoints. By direct sequencing the COL4A5/COL4A6 common promoter and the 
entire first four exons of COL4A6 in the X chromosome of the ATS-DL male proband, 
it was shown that these genomic regions are present and non-mutated. Additionally, 
by performing qPCR at several locations within COL4A6 intron 2, it was shown that 
all the segments of COL4A6 intron 2 that were probed by qPCR are present at the 
expected copy number. In conclusion, the deletion involving COL4A5 but not 
COL4A6 was the only genomic defect detected in this family. It is possible that the 
reason for leiomyoma predisposition in ATS-DL is aberrant regulation, for example 
due to the disruption of a regulatory domain within the large COL4A5 intron 1 or due 
to the potential role of the 3’ UTR of COL4A5.  
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3.2. An unknown family history of hematuria, CKD and hearing loss is not 
synonymous of a negative family history 
 
When family history of different AS manifestations was analyzed separately, 
history of hematuria was not identified in 3 families (family 18, 26 and 41); history of 
CKD was not identified in 3 families (family 18, 41 and 50); and history of hearing 
loss was not identified in 3 families (18, 26 and 41). Two probands had unknown 
family history of hematuria, CKD and hearing loss (one from family 18 and one from 
family 41). In family 18, the negative family history of AS was confirmed by the 
negative results of the genetic screening of both parents of the female proband. In 
family 41, the apparently negative family history of AS was not confirmed by the 
molecular analysis, since the male proband had inherited the pathogenic mutation 
from his asymptomatic mother. Comprehensive clinical evaluation of the proband’s 
mother, following the molecular genetic screening, showed that she had 
microhematuria, proteinuria and stage 3 CKD. Regarding family 26, in which only 
females were affected, hematuria and hearing loss were reported, but there was no 
family history of CKD. These observations demonstrate that all the at-risk relatives of 
patients with collagen IV-related nephropathies should be systematically screened for 
possible disease manifestations. Regarding family 50, in which the proband’s mother 
was known to have hematuria and hearing loss, the absence of the mutation in 
COL4A5 gene has shown that she does not have AS. Two consequences arise from 
this molecular result: 1) no other family members need to be screened for this 
mutation; 2) other causes for the mother health problems should be pursued. Taken 
together, these are examples of what may be faced during a consultation: 1) “true” 
negative family history, both phenotypically and molecularly; 2) “false” negative family 
history, when no manifestations of the syndrome are reported (e.g. due to variable 
expressivity of the disease), but the pathogenic mutation is detected in other family 
members; 3) “false” positive family history, when manifestations compatible with AS 
are reported, but the familial mutation is not present in the presumably affected 
relative. 
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3.3. Kidney biopsy with ultrastructure examination is recommended to 
clarify the etiology of urinary abnormalities 
 
In total, photographs from 25 kidney biopsies performed prior to the molecular 
study of AS in 24 individuals, from 22 unrelated families, were collected and 
reviewed, corresponding to 34% of the families (22/65). Twenty three of those 
photographs were collected at Hospital São João, Porto, and two at Hospital Curry 
Cabral, Lisbon. From five patients – two index cases and three family members – 
only the clinical report was available. Three of these reports (including one from an 
index case) were excluded from the following analysis, either because they did not 
specify the GBM changes that led to the conclusion of a probable diagnosis of AS, or 
because the number of glomeruli was insufficient for a reliable diagnosis. 
Ultrastructural findings suggestive of AS were present in 97% (29/30) of the 
kidney biopsies. All ten patients carrying hemizygous pathogenic COL4A5 mutations 
or homozygous or compound heterozygous pathogenic COL4A3 and COL4A4 
mutations manifested GBM thinning, thickening and lamellation with electrondense 
bodies surrounded by a halo, which are the typical GBM abnormalities of AS. 
Interestingly, four kidney biopsies from three females with XLAS, carrying 
heterozygous pathogenic COL4A5 mutations, also showed the four typical 
ultrastructural signs of AS. Among four patients with heterozygous pathogenic 
COL4A3 and COL4A4 mutations, GBM thinning was observed in all four biopsies, 
GBM thickening and lamellation was found in 2/3 of the biopsies and electron-dense 
bodies were present in 2/2 of the biopsies. Among kidney biopsies of eight patients in 
whom pathogenic COL4A3, COL4A4 and COL4A5 mutations were not identified, 
GBM thinning was found in all biopsies, thickened GBM in 7/8 biopsies, lamellation in 
2/8 biopsies (two patients from the same family) and electron dense bodies in 4/8, 
but none on these biopsies showed the characteristic electron-dense bodies 
surrounded by an electrolucent halo. The only kidney biopsy on which none of the 
typical ultrastructural signs of AS was found was from a patient who had a negative 
COL4A5 genetic analysis and in whom the molecular study of COL4A3 and COL4A4 
was decided not to be performed due to absence of typical ultrastructural criteria of 
AS. Moreover, immunohistochemistry analysis of the GBM from the proband of family 
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51 showed that both expression of α3(IV) and α5(IV) chains are present in the 
glomeruli of the kidney, supporting the absence of a pathogenic mutation in COL4A3, 
COL4A4 and COL4A5. 
  
3.4. Skin biopsy is helpful in determining the inheritance pattern 
 
Immunohistochemical analysis of the α5 chain of type IV collagen in the EBM 
from nine patients with clinical diagnosis of AS who underwent skin biopsy showed: 
(i) complete absence of staining of EBM in the proband and his brother from family 
15, both carrying the pathogenic COL4A5 frameshift mutation c.590delC, 
p.(Pro197Glnfs*6); (ii) complete absence of staining of EBM in the proband from 
family 57, carrying the pathogenic COL4A5 missense mutation c.1718G>A, 
p.(Gly573Asp); (iii) discontinuous staining of EBM in five out of seven females from 
family 57, carrying the same heterozygous pathogenic missense mutation in 
COL4A5. These results suggest that immunohistochemical analysis of the α5 chain 
of type IV collagen in EBM correlates better with the genotype in males than in 
females with XLAS.  
3.5. The mutation status influences the severity of the phenotype 
 
When the severity of the clinical phenotypes was compared according to the 
patients’ mutation status – males versus females with XLAS and patients with ARAS 
versus patients with TBMN – consistent statistically significant differences were found 
between the groups under comparison. History of macroscopic hematuria, 
proteinuria, progressive CRF needing RRT and of extra-renal manifestations was 
more prevalent in males than in females with XLAS (Table II of manuscript 1). 
Nonetheless, CKD stage 2 or higher was diagnosed in 62% of the heterozygous 
females, not rarely at young adult age. Likewise, a higher frequency of renal, 
audiologic and ocular manifestations was observed in patients with homozygous or 
compound heterozygous pathogenic mutations in COL4A3 or COL4A4, when 
compared with the apparently heterozygous patients (Table V of manuscript 3). 
Noteworthy, while diagnosis of CKD stage 2 or higher was performed at a median 
age of 20 years in patients carrying two pathogenic mutations in COL4A3 or 
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COL4A4, it was performed medianly in the fourth decade of life in apparent 
heterozygote patients. Interestingly, the occurrence of microscopic hematuria was 
not statistically different among groups with different mutation status. 
3.6. The type of mutation influences the severity of the phenotype 
 
Male patients with truncating pathogenic COL4A5 mutations reported higher 
proportion and younger ages at diagnosis of renal and extra-renal manifestations 
than patients with non-truncating mutations, although these results were not 
statistically significant (Supplementary table S11 of manuscript 1). Patients with 
hemizygous truncating COL4A5 mutations were significantly younger when they 
underwent kidney biopsy for diagnosis of GBM ultrastructural changes and when 
tonal audiogram was performed. The need of undergoing these diagnostic 
investigations at younger ages may also indicate an earlier age of expression of renal 
and audiologic signs. Female patients with truncating pathogenic COL4A5 mutations 
developed more often CKD (≥ stage 2) and hearing loss than females with non-
truncating mutations (Supplementary table S12 of manuscript 1). Tonal audiogram 
was also performed at a significantly younger age. 
 
3.7. Deliniation of the natural history of the disease in our sample 
 
When comparing the phenotype of patients with hemizygous pathogenic 
COL4A5 mutations and patients with homozygous or compound heterozygous 
COL4A3 or COL4A4 mutations, no significant differences were found (Table XIII). 
This finding suggests that it is feasible to use the diagnostic criteria defined for XLAS 
by Flinter et al. (1988) to clinically diagnose patients with ARAS. When comparing 
the phenotype of patients carrying heterozygous COL4A5 and COL4A3/COL4A4 
mutations, differences were not statistically significant, except for the proportion of 
patients who reported microscopic hematuria, which was statistically higher in the 
group of heterozygotes with COL4A5 mutations than in the group of heterozygotes 
with COL4A3 and COL4A4 mutations (Table XIV). 
Since the overall phenotype of males with XLAS did not vary significantly from 
patients with ARAS, and the phenotype of females with XLAS did not deviate 
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considerably from patients with TMBN, these two larger groups of patients were 
assembled with the purpose of comparing the natural history of the disease in 
patients with hemizygous pathogenic COL4A5 mutations, or homozygous or 
compound heterozygous pathogenic COL4A3 and COL4A4 mutations, with subjects 
with heterozygous pathogenic COL4A3, COL4A4 and COL4A5 mutations (Table XV). 
Microscopic hematuria was confirmed to be the hallmark of collagen IV-related 
nephropathies, as it manifested in both groups of patients, besides being diagnosed 
at significantly different median ages in both groups. Typical ultrastructural changes 
of the GBM were also observed at a similar proportion in both groups of patients. 
Altogether, these clinical findings may suggest a collagen IV-related nephropathy and 
may be indicative of the molecular analysis of the COL4A3, COL4A4 or COL4A5 
genes. 
The proportion of all other renal manifestations and all extra-renal 
manifestations was significantly higher in patients with a hemizygous pathogenic 
COL4A5 mutation and homozygous or compound heterozygous pathogenic COL4A3 
or COL4A4 mutations than in patients with a heterozygous pathogenic mutation in 
any of the three genes. When present, ocular manifestations corresponded to those 
previously reported. Diagnosis of microscopic hematuria, hypertension, CKD (≥ stage 
2), characteristic GBM ultrastructural changes and hearing loss was made at a 
significantly younger age in the group of male patients with XLAS and patients with 
ARAS.  
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Table XIII. Comparison of clinical characteristics between male patients with 
pathogenic COL4A5 mutations and patients with pathogenic homozygous and 
compound heterozygous COL4A3 or COL4A4 mutations. 
 
 Male XLAS  
(n=30) 
ARAS 
(n=15) 
p-value 
  N  N  
Phenotype      
Index-cases (%) 60.0 18/30 80.0 12/15 0.180 
Male gender (%) 100.0 30/30 53.3 8/15 0.000 
Age at enrollment (median (interquartile range)) 33.5 (18.5) 30 42 (17) 15 0.123 
Renal abnormalities 
     
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
61.9 
5 (4) 
13/21 
11 
54.5 
8 (15*) 
6/11 
3 
0.721  
0.156  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
12.5 (20.3) 
25/25 
22 
100.0 
12 (14.3) 
9/9 
6 
a 
0.625  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
96.2 
18 (22.5) 
25/26 
21 
100.0 
16 (13.5) 
12/12 
9 
1.000 
0.217  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
73.1 
20 (11.5) 
19/26 
12 
92.3 
18 (14.8) 
12/13 
8 
0.229 
0.324  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
86.2 
20.5 (10) 
40 (35) 
25/29 
16 
13 
100.0 
20 (10) 
59  (15*) 
14/14 
9 
3 
0.286  
0.563  
0.092  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
76.7 
23 (19.5) 
9 (6) 
23/30 
21 
12 
100.0 
23 (12) 
9.5 (3*) 
15/15 
15 
2 
0.077  
0.301  
0.783  
GBM ultrastuctural changes 
Age at diagnosis (median (interquartile range)) 
 
20 (14.5) 
 
6 
 
17.5 (7.8) 
 
6 
 
0.235  
Thinning (%) 100.0 6/6 100.0 5/5 a 
Thickening (%) 100.0 6/6 100.0 4/4 a 
Lamellation (%) 100.0 6/6 100.0 5/5 a 
Electrondense bodies (%) 100.0 6/6 100.0 5/5 a 
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
86.7 
15 (30) 
26/30 
15 
93.3 
9 (19) 
14/15 
9 
0.651  
0.575  
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
94.1 
27.5 (18) 
16/17 
16 
90.0 
32 (22) 
9/10 
7 
1.000  
0.898  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
33.3 
19 (12) 
5/15 
5 
33.3 
30 (-) 
3/9 
1 
1.000  
0.665 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
50.0 
25 (19.3) 
10/20 
8 
62.5 
34 (25*) 
5/8 
3 
0.686  
0.213  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
46.2 
29.5 (35.8) 
6/13 
6 
83.3 
42.5 (17*) 
5/6 
2 
0.177 
0.676 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
3.3 
24 (-) 
1/30 
1 
0.0 
- 
0/15 
0 
1.000 
- 
Family History 
     
Family history of hematuria (%) 96.6 28/29 72.7 8/11 0.056 
Family history of CKD (%) 90.0 27/30 71.4 10/14 0.184 
Family history of hearing loss (%) 93.1 27/29 76.9 10/13 0.162 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The range 
is indicated instead of the interquartile range. a Statistics cannot be computed for this variable because 
the proportion in the two groups is a constant. 
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Table XIV. Comparison of clinical characteristics between female patients with 
pathogenic COL4A5 mutations and patients with pathogenic heterozygous COL4A3 
and COL4A4 mutations. 
 Female XLAS  
(n=35) 
TBMN 
(n=44) 
p-value 
  N  N  
Phenotype      
Index-cases (%) 11.4 4/35 29.5 13/44 0.052 
Male gender (%) 0.0 0/35 31.8 14/44 0.000 
Age at enrollment (mean (SD)) 42 (14.8) 35 45.5 (26.8) 45 0.348  
Renal abnormalities 
     
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
17.4 
3 (11.5*) 
4/23 
3 
12.0 
17 (12*) 
3/25 
3 
0.696  
0.025 
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
21 (26.5) 
35/35 
28 
77.1 
26 (20.5) 
27/35 
26 
0.005 
0.216  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
78.8 
24 (19) 
26/33 
23 
69.7 
24.5 (19.5) 
23/33 
22 
0.574  
0.315  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
52.9 
34 (22.3) 
18/34 
16 
51.5 
42 (18.5) 
17/33 
13 
0.907  
0.692  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
61.8 
31.5(17.5) 
61 (26.3) 
21/34 
20  
20 
51.4 
46 (19.5) 
67 (20) 
18/35 
17  
15 
0.387 
0.269  
0.257  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
17.1 
40 (14) 
6 (1) 
6/35 
6 
5 
13.9 
36 (22) 
14 (-) 
5/36 
5 
1 
0.705  
0.541  
0.120 
GBM ultrastuctural changes 
Age at diagnosis (median (interquartile range)) 
 
24 (11*) 
 
3 
 
34 (19) 
 
9 
 
0.149  
Thinning (%) 100 3/3 100 8/8 a 
Thickening (%) 100 3/3 100 3/3 a 
Lamellation (%) 100 3/3 60 3/5 0.464 
Electrondense bodies (%) 100 3/3 67 2/3 1.000 
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
45.5 
39 (19) 
15/33 
9 
35.3 
36 (32*) 
12/34 
3 
0.397  
0.557  
Confirmed by audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
66.7 
41 (10) 
14/21 
13 
52.6 
44 (26.5) 
10/19 
9 
0.366  
0.567  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/18 
0 
0.0 
- 
0/25 
0 
a   
b 
Maculopathy (%)  
Age at diagnosis (median (interquartile range)) 
26.3 
44 (22) 
5/19 
5 
9.1 
40.5 (35*) 
3/33 
2 
0.124  
0.419  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
15.0 
56 (56*) 
3/20 
3 
12.0 
58 (15*) 
3/25 
3 
1.000  
0.832  
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
5.7 
18 (-) 
2/35 
1 
0.0 
- 
0/44 
0 
0.193  
- 
Family History 
     
Family history of hematuria (%) 94.3 33/35 97.6 41/42 0.588 
Family history of CKD (%) 97.1 34/35 95.5 42/44 1.000 
Family history of hearing loss (%) 94.3 33/35 73.2 30/41 0.015 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The range 
is indicated instead of the interquartile range. a Statistics cannot be computed for this variable because 
the proportion in the two groups is a constant. b No analysis was performed because all cases are 
missing. 
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Table XV. Comparison of the phenotype of patients with hemizygous pathogenic 
COL4A5 mutations or homozygous and compound heterozygous pathogenic 
COL4A3 and COL4A4 mutations (Male XLAS and ARAS) and patients with 
heterozygous pathogenic COL4A3, COL4A4 and COL4A5 mutations (Female XLAS 
and TBMN).  
 Male XLAS 
and ARAS 
(n=45) 
Female XLAS 
and TBMN 
(n=79) 
p-value 
  N  N  
Phenotype      
Index-cases (%) 66.7 30/45 21.5 17/79 0.000 
Male gender (%) 84.4 38/45 17.7 14/79 0.000 
Age at enrollment (mean (SD)) 37.9 (14.9) 45 43.9 (23) 79 0.040  
Renal abnormalities 
     
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
59.4 
5 (6) 
19/32 
14 
14.6 
12.5 (16.6) 
7/48 
6 
0.000  
0.323  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100 
12.5 (18) 
34/34 
28 
88.6 
24 (24.3) 
62/70 
54 
0.051 
0.006 
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
97.4 
18 (17.5) 
37/38 
30 
74.2 
24 (19.5) 
49/66 
45 
0.002  
0.059  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
79.5 
19.5 (12.3) 
31/39 
20 
52.2 
40 (21.5) 
35/67 
29 
0.005  
0.000  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (median (interquartile range)) 
90.7 
20 (10) 
46 (35.5) 
39/43 
25 
16 
56.5 
39 (20) 
65 (24) 
39/69 
37  
35 
0.000  
0.000  
0.001  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
84.4 
23 (12) 
9 (4.75) 
38/45 
36 
14 
15.5 
39 (15) 
6 (3) 
11/71 
11 
6 
0.000  
0.065  
0.062  
GBM ultrastuctural changes 
Age at diagnosis (median (interquartile range)) 
 
19 (8.75) 
 
12 
 
28 (19.25) 
 
12 
 
0.006  
Thinning (%) 100 11/11 100 11/11 a 
Thickening (%) 100 10/10 100 6/6 a 
Lamellation (%) 100 11/11 75 6/8 0.164 
Electrondense bodies (%) 100 11/11 83.3 5/6 0.353 
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
88.9 
14 (21.5) 
40/45 
24 
40.3 
38.5 (18) 
27/67 
12 
0.000  
0.029  
Confirmed by audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
92.6 
30 (19) 
25/27 
23 
60.0 
44 (15) 
24/40 
22 
0.003  
0.001  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
33.3 
21.5 (13) 
8/24 
6 
0 
- 
0/43 
- 
0.000  
- 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
53.6 
26 (21) 
15/28 
11 
15.4 
44 (26) 
8/52 
7 
0.000  
0.258  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
57.9 
34 (29.3) 
11/19 
8 
13.3 
57 (25.3) 
6/45 
6 
0.000  
0.159  
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
2.2 
24 (0*) 
1/45 
1 
2.5 
18 (0*) 
2/79 
1 
1.000  
0.317 
Family History 
     
Family history of hematuria (%) 90.0 36/40 96.1 74/77 0.228 
Family history of CKD (%) 84.1 37/44 96.2 76/79 0.034 
Family history of hearing loss (%) 88.1 37/42 82.9 63/76 0.452 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. *The range 
is indicated instead of the interquartile range. a Statistics annot be computed for this variable because 
the proportion in the two groups is a constant. 
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3.8. Patients without known mutations: differences and similarities 
  
The group of probands in whom no pathogenic COL4A3, COL4A4 or COL4A5 
mutation was identified is heterogeneous (Tables XVI and XVII). The median age at 
enrolment was 37 years old (interquartile range 23 years) and there was a 
preponderance of female probands (73%). Microscopic hematuria and proteinuria 
were detected in all probands without known pathogenic COL4A3, COL4A4 or 
COL4A5 mutations. The proportion of patients who manifested CKD (≥ stage 2) was 
significantly lower in the group of patients without COL4A3, COL4A4 or COL4A5 
mutations than in the group of male XLAS and ARAS, although the proportion of 
patients who needed RRT was not significantly different. Extra-renal manifestations 
were less frequent in the group of patients without COL4A3, COL4A4 or COL4A5 
mutations than in the group of male XLAS and ARAS. Could other disorders cause 
these manifestations or is this an Alport-like subgroup of patients? Although thinning, 
thickening and electron-dense bodies were observed in the GBM of the majority of 
kidney biopsies of patients without a known pathogenic mutation, lamellation was 
only observed in a minority of patients. This might point to an AS-like phenotype. This 
phenotypic heterogeneity might be caused by locus heterogeneity (known or 
unknown genes), modifier genes (predisposing/high-risk versus protecting genetic 
variants) and/or environmental factors.  
In this Portuguese cohort, the clinical screening for AS based in three out of 
four clinical criteria in a patient with unexplained hematuria and/or CKD had a 
reasonably high clinical sensitivity, but a low specificity. It was effective in selecting 
individuals for COL4A5, COL4A4 and COL4A3 molecular analysis, but it also 
selected a relatively high number of individuals with a similar phenotype who did not 
have detectable mutations in any of the three genes. Using the cut-off of ≥ two 
clinical criteria, the clinical sensitivity and specificity are similar. In conclusion, the 
characteristics, particularly the low specificity, of the clinical criteria proposed by 
Flinter and colleagues (1988) to diagnose patients with AS and that was used to 
recruit participants for this study, may be the reason for not identifying pathogenic 
mutations in any of the three genes in 15 out of 62 probands (24%) enrolled in this 
research study. These sensitivity and specificity figures are reasonable and indicate 
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that a cut-off of two clinical diagnostic criteria may also perform fairly well as a clinical 
test in the selection of patients for molecular analysis. Despite the large overall 
sample size (n=146), the clinical manifestations were age- and gender-dependent 
and many values were missing. The wide confidence intervals demonstrate that the 
estimates of sensitivity based on small numbers were imprecise. In other words, 
since there were very few ‘positives’, the precision of the sensitivity is low. However, 
the lower specificity of the clinical screening test fitted an additional aim of the study 
by enabling the recruitment of a further group of patients with a phenotype similar to 
AS for future etiologic investigation. 
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Table XVI. Comparison of the phenotype of probands without known pathogenic 
COL4A3, COL4A4 and COL4A5 mutations (Probands without known mutations) and 
patients with hemizygous pathogenic COL4A5 mutations or homozygous and 
compound heterozygous pathogenic COL4A3 and COL4A4 mutations (Male XLAS 
and ARAS).  
 Probands without 
known mutations 
(n=15) 
Male XLAS 
and ARAS 
(n=45) 
p-value 
  N  N  
Phenotype      
Index-cases (%) 100.0 15/15 66.7 30/45 0.013 
Male gender (%) 26.7 4/15 84.4 38/45 0.000 
Age at enrollment (median (interquartile range)) 37 (23) 15 37.9 (14.9) 45 0.585  
Renal abnormalities 
     
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
27.3 
11 (8*) 
3/11 
2 
59.4 
5 (6) 
19/32 
14 
0.066  
0.584  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
28 (38) 
9/9 
7 
100.0 
12.5 (18) 
34/34 
28 
a 
0.229  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
100 
26 (26) 
11/11 
9 
97.4 
18 (17.5) 
37/38 
30 
1.000  
0.366  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
66.7 
31 (26) 
10/15 
9 
79.5 
19.5 (12.3) 
31/39 
20 
0.478  
0.084  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (mean (SD)) 
60.0 
23 (31) 
33 (65.3) 
9/15 
9 
4 
90.7 
20 (10) 
46 (35.5) 
39/43 
25 
16 
0.013  
0.246  
0.539  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
53.8 
35 (29) 
7 (2*) 
7/13 
7 
2 
84.4 
23 (12) 
9 (4.75) 
38/45 
36 
14 
0.053  
0.171  
0.299  
GBM ultrastuctural changes 
Age at diagnosis (median (interquartile range)) 
 
20.5 (20.8) 
 
6 
 
19 (8.75) 
 
12 
 
0.876  
Thinning (%) 100.0 5/5 100.0 11/11 a 
Thickening (%) 80.0 4/5 100.0 10/10 0.333 
Lamellation (%) 25.0 1/4 100.0 11/11 0.009 
Electrondense bodies (%) 80.0 4/5 100.0 11/11 0.313 
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
38.5 
29 (29*) 
5/13 
3 
88.9 
14 (21.5) 
40/45 
24 
0.001  
0.448  
Confirmed by audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
90.9 
52.5 (32.3) 
10/11 
4 
92.6 
30 (19) 
25/27 
23 
1.000  
0.025  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/8 
- 
33.3 
21.5 (13) 
8/24 
6 
0.081  
- 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
11.1 
- 
1/9 
- 
53.6 
26 (21) 
15/28 
11 
0.050  
- 
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/9 
- 
57.9 
34 (29.3) 
11/19 
8 
0.004  
- 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/15 
- 
2.2 
24 (0*) 
1/45 
1 
1.000  
- 
Family History 
     
Family history of hematuria (%) 85.7 6/7 90.0 36/40 0.571 
Family history of CKD (%) 76.9 10/13 84.1 37/44 0.680 
Family history of hearing loss (%) 53.8 7/13 88.1 37/42 0.014 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. 
*The range is indicated instead of the interquartile range. a Statistics cannot be computed for this 
variable because the proportion in the two groups is a constant. 
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Table XVII. Comparison of phenotype between probands without COL4A3, COL4A4 
and COL4A5 mutations (Probands without known mutations) and patients with 
heterozygous mutations in the COL4A3, COL4A4 or COL4A5 genes. 
 Probands without 
mutations 
(n=15) 
Female XLAS 
and TBMN 
(n=79) 
p-
value 
  N  N  
Phenotype      
Index-cases (%) 100 15/15 21.5 17/79 0.000 
Male gender (%) 26.7 4/15 17.7 14/79 0.476 
Age at enrollment (median (interquartile range)) 37 (23) 15 43.9 (23) 79 0.451  
Renal abnormalities 
     
History of macroscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
27.3 
11 (8*) 
3/11 
2 
14.6 
12.5 (16.6) 
7/48 
6 
0.376  
0.749  
History of microscopic hematuria (%) 
Age at diagnosis (median (interquartile range)) 
100.0 
28 (38) 
9/9 
7 
88.6 
24 (24.3) 
62/70 
54 
0.586 
0.789  
History of proteinuria (%) 
Age at diagnosis (median (interquartile range)) 
100 
26 (26) 
11/11 
9 
74.2 
24 (19.5) 
49/66 
45 
0.109  
0.982  
History of hypertension (%) 
Age at diagnosis (median (interquartile range)) 
66.7 
31 (26) 
10/15 
9 
52.2 
40 (21.5) 
35/67 
29 
0.310  
0.088  
History of CKD stage 2 or higher (%) 
Age at diagnosis (median (interquartile range)) 
eGFR at diagnosis (mean (SD)) 
60.0 
23 (31) 
33 (65.3) 
9/15 
9 
4 
56.5 
39 (20) 
65 (24) 
39/69 
37  
35 
0.805  
0.465  
0.115  
History of renal replacement therapy (%) 
Age at onset (median (interquartile range)) 
eGFR at onset (median (interquartile range)) 
53.8 
35 (29) 
7 (2*) 
7/13 
7 
2 
15.5 
39 (15) 
6 (3) 
11/71 
11 
6 
0.005  
0.884  
0.864  
GBM ultrastuctural changes 
Age at diagnosis (median (interquartile range)) 
 
20.5 (20.8) 
 
6 
 
28 (19.25) 
 
12 
 
0.038  
Thinning (%) 100.0 5/5 100.0 11/11 a 
Thickening (%) 80.0 4/5 100.0 6/6 0.455 
Lamellation (%) 25.0 1/4 75.0 6/8 0.222 
Electrondense bodies (%) 80.0 4/5 83.3 5/6 1.000 
Hearing loss 
     
Self-noticed or subjective (%) 
Age at self-noticed or subjective 
(median (interquartile range)) 
38.5 
29 (29*) 
5/13 
3 
40.3 
38.5 (18) 
27/67 
12 
0.902  
0.296  
Audiogram (%) 
Age at diagnosis of hearing loss by audiogram 
(median (interquartile range)) 
90.9 
52.5 (32.3) 
10/11 
4 
60.0 
44 (15) 
24/40 
22 
0.075  
0.412  
Ocular abnormalities 
     
Anterior Lenticonus (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/8 
- 
0 
- 
0/43 
- 
a  
a 
Maculopathy (%) 
Age at diagnosis (median (interquartile range)) 
11.1 
- 
1/9 
- 
15.4 
44 (26) 
8/52 
7 
1.000  
-  
Cataracts (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/9 
- 
13.3 
57 (25.3) 
6/45 
6 
0.574  
- 
Leiomyomatosis (%) 
Age at diagnosis (median (interquartile range)) 
0.0 
- 
0/15 
- 
2.5 
18 (0*) 
2/79 
1 
1.000  
- 
Family History 
     
Family history of hematuria (%) 85.7 6/7 96.1 74/77 0.299 
Family history of CKD (%) 76.9 10/13 96.2 76/79 0.035 
Family history of hearing loss (%) 53.8 7/13 82.9 63/76 0.029 
SD: standard deviation. Age is expressed in years. eGFR is expressed in ml/min/1.73m2. 
*The range is indicated instead of the interquartile range. a Statistics cannot be computed for this 
variable because the proportion in the two groups is a constant. 
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3.9. Diagnostic criteria defined for XLAS by Flinter and colleagues (1988) 
also enable the diagnosis of patients with ARAS 
 
A complete clinical evaluation (assessment of the four classic criteria of AS) 
was achieved in 5 probands (5/65; 8%) (Table XVIII). Among the probands in whom 
the four typical clinical criteria were diagnosed, four had a hemizygous pathogenic 
COL4A5 mutation (4/5; 80%) and one had pathogenic compound heterozygous 
COL4A3 mutations (1/5; 20%). Among 19 patients with at least three clinical criteria, 
four had a pathogenic COL4A5 mutation (4/19; 21%) and 11 had pathogenic 
COL4A3 or COL4A4 mutations (4/19; 58%). Among 28 probands patients with at 
least two clinical criteria, 10 had a pathogenic COL4A5 mutation (10/28; 36%) and 10 
had pathogenic COL4A3 or COL4A4 mutations (10/28; 36%). Among 13 probands 
patients with one clinical criterion, four had a pathogenic COL4A5 mutation (4/13; 
31%) and 4 had pathogenic COL4A3 or COL4A4 mutations (4/13; 31%). The global 
detection mutation rate of pathogenic COL4A5, COL4A4 and COL4A3 mutations 
among probands who met one, two, three or four clinical criteria was 62%, 71%, 79% 
and 100%, respectively. 
The clinical diagnosis of collagen IV-related nephropathies is amongst the 
biggest challenges in clinical genetics, as it is not always unambiguous (Flinter, 
Cameron et al. 1988). Precise and strict diagnostic criteria have been used to best 
identify those patients most likely to harbour COL4A5 mutations. Additionally, the 
clinical criteria defined by Flinter and colleagues (1988) to diagnose patients with 
XLAS proved also useful in the diagnosis of patients with ARAS. This was an 
expected finding, since the clinical course of severe collagen IV-related 
nephropathies is similar. More interesting was the fact that these criteria also work for 
the diagnosis of TBMN, if not used so strictly (Frasca, Onetti-Muda et al. 2005). 
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Table XVIII. Mutation detection rate according to number of diagnostic criteria met in probands (n=65). 
Clinical Criteria 
Number of probands with and without 
pathogenic mutations   
 Detection mutation rate 
  
FH AC OC UC 
COL4A5 
mutation 
COL4A4 
mutation 
COL4A3 
mutation 
Without 
mutation 
Total 
number 
of 
probands 
Per 
combination 
of clinical 
criteria 
Per 
number 
of criteria 
met 
1 criterion 
FH     10 
   
4 1 2 3 10 70% 62% 
AC     
 
1 
  
0 0 1 0 1 100% (8/13) 
OC     
  
0 
     
0 
  UC     
   
2 0 0 0 2 2 0% 
 
2 criteria 
FH 
    
 
15 
  
8 2 2 3 15 80% 71% 
    
  
1 
 
0 1 0 0 1 100% (20/28) 
    
   
7 1 2 1 3 7 57% 
 
AC       1  0 0 0 1 1 0%  
    
   
4 1 0 2 1 4 75% 
 
OC     
   
0 
    
0 
  
3 criteria 
FH AC   9  2 1 3 3 9 67% 79% 
   
7 1 2 3 1 7 86% (15/19) 
FH OC 
   
0 
    
0 
  
  AC OC 
   
3 1 0 2 0 3 100% 
 
4 criteria FH AC OC 
   
5 4 0 1 0 5 100% 100% (5/5) 
FH: Family history. AC: Hearing loss (Audiologic criteria), including hearing loss with and without confirmation by audiogram. 
OC: Ocular signs (Ophthalmologic criteria), including anterior lenticonus, cataracts and retinopathy. UC: Characteristic glomerular 
basement membrane (GBM) changes (Ultrastructural criteria), including thinning, thickening, lamellation and presence of electron-
dense bodies in the GBM. 
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4. Short term impact of the study: Massive parallel sequencing is 
recommended to simultaneously study the COL4A5, COL4A4 
and COL4A3 genes 
 
The involvement of the COL4A5, COL4A4 and COL4A3 genes in the etiology 
of a majority of families with clinical diagnosis or suspicion of AS and in an estimated 
high proportion of TBMN families poses a major challenge in the identification of the 
underlying molecular cause of this spectrum of glomerulopathies. Sanger sequencing 
of these genes for each proband requires a great amount of repetitive, hard work and 
has time and cost limitations. Notably, new sequencing technologies termed Massive 
Parallel Sequencing (MPS) – also called Next-Generation Sequencing (NGS) – were 
developed as methods to overtake the disadvantages of laborious, time-consuming 
and expensive methodologies. NGS offer the opportunity to detect single nucleotide 
variants (SNVs), copy number variations (CNVs), insertions and deletions (indels) 
and other structural variations in a single test (Harismendy, Ng et al. 2009; Ng, 
Turner et al. 2009; Gullapalli, Lyons-Weiler et al. 2012). Particularly in the case of 
genetic diseases with high phenotypic and genotypic heterogeneity such as collagen 
IV-related nephropathies, the simultaneous analysis of the COL4A5, COL4A4 and 
COL4A3 genes by NGS has been successfully applied to identify the disease-
causing genetic defect (Artuso, Fallerini et al. 2012; Fallerini, Dosa et al. 2013).  
NGS has advantages over direct Sanger sequencing to be used in the 
identification of pathogenic variants in COL4A5, COL4A4 and COL4A3. Firstly, the 
molecular etiology of collagen type IV nephropathy proved to be heterogeneous in 
the Portuguese population of patients with AS and TBMN. More than 70% of 
participants had mutations in one of these three genes, being the participant’s ratio 
with pathogenic COL4A5 mutations to COL4A3 and COL4A4 mutations of 
approximately 1:1. Secondly, as expected, collagen IV-related nephropathies in this 
Portuguese cohort were caused by different types of mutations, located throughout 
any of the three genes, which are 48 to 51 exons long. Thirdly, low grade mosaicism 
is very difficult to detect by Sanger sequencing, but more readily by NGS (Beicht, 
Strobl-Wildemann et al. 2013). The use of NGS directed to the study of these three 
genes will avoid the detection of incidental findings, which raise ethical problems 
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posed by the returning of potential health or reproductive importance of genetic 
variants information to the patients. In the end, the time (turn-around-time) and cost 
of the molecular study of collagen IV-related nephropathies would be reduced, while 
improving the quality of health care. Clinical reasons would also justify performing 
genetic diagnosis of collagen type IV nephropathies by NGS (Deltas, Pierides et al. 
2013). Firstly, collagen IV-related nephropathies have a wide spectrum of 
manifestations, which are age-dependent and may be gender-dependent. 
Additionally, a number of XLAS patients follow a milder course reminiscent of that of 
patients with heterozygous COL4A3 or COL4A4 mutations and TBMN, while at the 
same time a significant subset of patients with TBMN and familial microhematuria 
progress to CKD or ESRD (Deltas, Pierides et al. 2012). Secondly, in particular if the 
proband is the only known affected individual in the family, an inheritance pattern 
would only be confirmed by molecular analysis of the proband. Even when a 
complete phenotypic characterization of AS patients was performed, our results 
showed that, comparing the phenotype of XLAS males versus ARAS and XLAS 
females versus TBMN, there were very few statistically significant differences 
between the compared groups. If family history is not clear, the three genes would 
eventually be tested. Thirdly, clinical non-invasive differential diagnosis with other 
glomerulopathies may be difficult. The challenges of NGS would be the complexity of 
the workflow of this methodology, which result in high implementation and 
maintenance costs, and the posterior classification of the pathogenicity of each novel 
variant. Overall, it is recommended to adjust the molecular genetic analysis strategy 
of collagen IV-related nephropathies to the Portuguese population for its use in 
clinical practice.  
Whenever COL4A3 and COL4A4 direct sequencing is considered in a 
Portuguese family, we recommend screening for the c.1219G>C (p.Gly407Arg) 
mutation in the COL4A3 gene, prior to the screening of the complete COL4A3 and 
COL4A4 coding regions, since it is rapid and cost-effective. This mutation was found 
in heterozygosity, as well as in compound heterozygosity, in patients who manifested 
progressive or non-progressive renal disease, with or without extra-renal signs of AS, 
warranting its study in patients with clinical diagnosis of TBMN and AS, in particular if 
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an autosomal dominant or recessive inheritance pattern is suggested by the family 
history. 
In the end, the molecular characterization of collagen type IV-related 
nephropathies, using NGS to simultaneously analyse the COL4A5, COL4A4 and 
COL4A3 genes, has the potential to improve the quality of the healthcare system at 
three levels: prevention (upstream intervention), diagnosis and treatment 
(downstream intervention). At the diagnosis level, molecular testing enables: (1) 
confirmation of the clinical diagnosis in the affected individuals, at a younger age and 
avoiding an extensive, and eventually invasive, etiologic investigation; (2) 
identification of at-risk family members and determination of their carrier status, by a 
geneticist. At the treatment level, the molecular diagnosis supports the decision of an 
early start of effective medical treatment for the prevention of the progression of the 
glomerulopathy, since very young ages (Massella, Muda et al. 2010; Gross, Friede et 
al. 2012; Gross, Licht et al. 2012).    At the prevention level, the molecular diagnosis 
of collagen IV-related nephropathies enables an accurate genetic counseling, 
providing insight into the natural history of the disease (including genotype-
phenotype correlations), and contributing to the prevention of severe manifestations 
in family members by two means: (1) preventing kidney donation between affected 
family members; (2) enabling PND and PGD for couples at-risk of having severely 
affected offspring, specifically in a time shortage context of a preconceptional 
counseling.  
 
5. Long term impact of the study: Future perspectives 
 
Looking into the long term impact of our studies, different lines of investigation 
may be followed, both directed to basic science and to clinical practice, aiming for a 
better understanding of genotype-phenotype correlations. A first research question 
that should be posed is if patients with ARAS and severe TBMN have a similar 
genetic background. In other words, are patients with severe TBMN indeed patients 
with ARAS, in whom only one pathogenic mutation was found? A first option to 
investigate this question could be to search for pathogenic exonic COL4A3 or 
COL4A4 deletions or duplications in patients with a pathogenic heterozygous 
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mutation in one of these genes, who developed proteinuria and CKD ≥ stage 3, 
eventually reaching ESRD. Secondly, may known polymorphisms in COL4A5, 
COL4A4 and COL4A3 confer a higher risk for progressive CKD? Or, thirdly, may yet 
unknown genetic variants influence the progression of CKD to ESRD in patients with 
a collagen IV-related nephropathy? It may be possible that different genetic 
backgrounds, other than solely pathogenic variants in the COL4A5, COL4A4 and 
COL4A3 genes, influence the progression of the kidney disease. These variables 
should be searched for and tested. In this cohort, around 25% of patients did not 
have identified pathogenic mutations in COL4A5, COL4A4 or COL4A3. May 
mutations in other genes may be responsible for Alport- and TBMN-like 
nephropathies? NGS, including exome sequencing and/or whole genome 
sequencing, may enable identification of these variants.  
In this study, renal data from patients with heterozygous mutations in the 
COL4A3, COL4A4 and COL4A5 genes showed that proteinuria and progressive CKD 
were more frequent than expected in this sample of the population, in particular in 
patients with the mutation c.1219G>C (p.Gly407Arg) that is a common variant in the 
Portuguese population. Previous studies have shown that microscopic hematuria is 
not rare. Patients with microscopic hematuria tend to have a higher risk of developing 
CKD and this occurs at an earlier age when compared with people without 
microscopic hematuria (Vivante, Afek et al. 2011; Vivante, Calderon-Margalit et al. 
2013). Consequently, unexplained microscopic hematuria is not as benign as 
previously thought. So, future research studies of patients with isolated microscopic 
hematuria are recommended to determine the proportion of individuals in the 
Portuguese population with TBMN caused by pathogenic mutations in the COL4A3 
and COL4A4 genes or in early stages of AS caused by pathogenic COL4A5 
mutations, since it would be a non-invasive method to confirm the diagnosis at an 
early age and counsel the patients and family members of patients affected by an 
heterogeneous group of disorders, as the collagen type-IV nephropathies.  
Regarding ATS-DL, the development of diffuse leiomyomatosis in three 
patients of a family with XLAS carrying a COL4A5 deletion, suggested that the 
deletion of a previously proposed critical region involving the 5’ of COL4A5 and 
COL4A6 genes, as well as the common promotor, is not needed for the development 
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of diffuse leiomyomatosis. Identifying further patients with a similar genotype-
phenotype correlation and mapping deletion breakpoints would help clarifying the 
molecular pathogenic mechanisms underlying the development of diffuse 
leiomyomatosis accompanying XLAS. Besides studying COL4A5 and COL4A6 in 
ATS-DL patients, transcriptome (gene expression) analysis in these patients would 
be crucial to demonstrate the effect of the genomic COL4A5 deletion in the mRNA 
synthesis and how it is related with the expression of other genes in the 
leiomyomatosis pathway. In this case, we hypothesize that the reason for leiomyoma 
predisposition in ATS-DL is aberrant regulation.  
 
6. Main recommendations 
 
The following practical aspects resulting from the clinical and molecular 
studies performed in this project are worth to emphasize: 
- Microscopic hematuria is not always benign; so, early diagnosis of collagen type 
IV-related nephropathy as its cause, using reliable molecular genetic methods or 
renal biopsy should be persued, in order to increase the rate of ethiologic 
diagnosis, to individualize genetic counseling and to personalize the treatment, 
since early nephroprotective pharmacological treatment is effective. 
- AS should be suspected in any patient with an isolated microscopic hematuria of 
unknown etiology, as this is the earliest and most consistent manifestation of 
collagen type IV-related nephropathies across all ages and gender. 
- The multidisciplinary study of probands and family members may be extremely 
informative in the investigation of collagen type IV-related glomerulopathies: 
screening of extra-renal manifestations should be systematically pursued, namely 
by audiometric and ophthalmologic evaluation.  
- The referral of patients with collagen IV-related nephropathies and their at-risk 
family members to Medical Genetics consultations is recommended for clinical 
and molecular diagnosis of collagen IV-related nephropathies, as well as for 
genetic couselling and ultimately prevention by PND and PGD. 
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- Patients with collagen IV-related nephropathies should regularly perform renal, 
audiologic and ophthalmologic evaluation for detection and surveillance of 
progressive renal and extra-renal manifestations. 
- Since earlier stages of CKD can be detected through routine laboratory 
measurements and adverse outcomes of CKD can be delayed through early 
detection and effective treatment, the following annual renal screening protocol is 
suggested for at-risk family members: plasma creatinine, urea, uric acid and 
ionogram; summary analysis of urine (three occasional urin samples), including 
the determination of the albumin-to-creatinine ratio (ACR) or the protein-to-
creatinine ratio, assessment of blood pressure and renal ultrasound. 
- In patients with hematuria and without proteinuria, the basis for annual follow-up 
is to survey or rule out the appearance of proteinuria, a risk factor for CKD. 
- When AS is suspected, an ophthalmologic examination directed to the screening 
of anterior lenticonus and retinopathy should include at least: 1) biomicroscopy; 2) 
funduscopy and/or retinography; 3) Optical Coherence Tomography (OCT).  
- Since patients with molecularly confirmed XLAS or ARAS had typical kidney 
biopsies, ie, they manifested the four characteristic ultrastructural changes in the 
GBM, a more widespread and larger renal biopsy policy, including ultrastructural 
examination, is recommended, even in cases with moderate urinary abnormalities 
(isolated persistent hematuria with or without proteinuria), in order to increase the 
number of patients with an etiology for identified urinary abnormalities. 
- The evaluation of ultrastructural changes of the GBM on a kidney biopsy should 
result in a medical report discriminating the presence or absence of GBM 
thinning, GBM thickening, GBM lamellation and GBM with electrodense bodies 
(EB) surrounded by a halo, as the presence of four typical GBM changes 
correlates with a higher mutation detection rate. 
- If a patient (particularly a female or a child) presents with microscopic persistent 
or intermittent microscopic hematuria, and audiologic and ophthalmologic criteria 
were excluded, performing a kidney biopsy with electron microscopy analysis may 
be the only method to clinically diagnose a collagen IV-related nephropathy.  
- Consider performing a kidney biopsy in at least one affected member in the 
family, as it may assist in the interpretation of molecular genetic analysis and may 
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obviate the need for kidney biopsies in other relatives; however, in a well-studied 
population with known common mutations, specific mutation analysis may avoid a 
kidney biopsy. 
- The molecular study of COL4A5 and COL4A6 is recommended in patients with 
diffuse leiomyomatosis (namely of the gastrointestinal and female reproductive 
tracts), particularly in females even without any clinical or laboratory evidence of 
nephropathy, due to the risk of males with ATS-DL in the offspring.  
- Conversely, diffuse leiomyomatosis should be successively investigated in 
patients with XLAS caused by large COL4A5 deletions, since deletion of the 
common COL4A5/COL4A6 promoter and the 5’exons of COL4A6 is not needed 
for the development of diffuse leiomyomatosis. 
- Molecular genetics analysis may allow the diagnosis of patients not satisfying all 
Flinter’s criteria. 
- Finding the exact gene and the mutation is important for risk assessment, genetic 
counselling and family programming.  
- DNA sequencing remains the gold-standard for the final diagnosis, especially in 
diseases of genetic heterogeneity; but NGS is expected to enhance the analysis 
process and lead to robust characterization of more patients.  
- MLPA assays should include probes for COL4A5 exons 8, 25 and 40, as well as 
for the exon 3 of COL4A6. 
- The establishment of a national AS database of individuals with COL4A5, 
COL4A4 and COL4A3 variants is helpful in the long-term surveillance of clinical 
manifestations and the treatment of affected individuals (including to provide 
access to multicentric clinical trials) and effective in the study of family members; 
its creation will help maintaining good quality clinical archives and a biobank from 
these patients. 
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Conclusion 
 
The studies in this thesis contributed to an increase of knowledge on collagen 
IV-related nephropathies. Pathogenic mutations in the protein coding region of 
COL4A5, COL4A4 or COL4A3 were detected in 76% (47/62) of families with 
suspected or clinical diagnosis of AS. NGS of these genes, including the promotor 
region and introns, may increase this yield even more. Finding novel genes in 
patients with an AS-like phenotype will shed light on the molecular foundations of the 
development and functioning of the kidney through the identification of pathways that 
lead to glomerulopathies. 
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Protocol P1 Clinical protocol 
  
Médico: ________________________________________________________   Contacto(s):  
______________________________ 
Hospital, Serviço / Unidade de Saúde: 
________________________________________________________________ 
Identificação do paciente:  
Caso-índice 
Familiar afectado 
Familiar não-afectado 
 
 
Manifestações de Síndrome de Alport e sua cronologia: 
Assinale “[S]” para indicar as manifestações de Síndrome de Alport observadas no doente e a idade 
aproximada em que foram identificadas; “[N]” para indicar as manifestações que foram excluídas por 
rastreio específico; “[I]” para indicar as manifestações que ignore que o doente apresente ou que não 
tenham sido especificamente rastreadas. 
1 - Hematúria:  macroscópica [S] (idade) / [N] / [I] ; microscópica [S] (idade) / [N] / [I] . 
2 - Proteinúria: [S] (idade) / [N] / [I] ; grau máximo de proteinúria: ≤0,5g / 0,5-1,0g / 1,0-3,5g / 
≥3,5g (data: mês / ano ) . 
[Proteinúria definida como ≥0,3g/dia, expressa em g/dia ou g/gcreatinina].  
3 - Hipertensão arterial: [S] (idade) / [N] / [I] ; medicação anti-hipertensiva: [S] (idade) / [N] / 
[I] . 
[Hipertensão arterial definida como ≥140/90 mmHg].  
4 - Insuficiência renal crónica (IRC): [S] (idade) / [N] / [I] ; doença renal crónica, estádios 3-
5: [S] (idade) / [N] / [I] . 
[Insuficiência renal crónica definida como creatinina sérica ≥1,2 mg/dl no homem e ≥0,9 mg/dl na mulher;  
doença renal crónica, estádios 3-5, definida como creatinina sérica >1,5 mg/dl no homem e >1,2 mg/dl na mulher].  
5 - Tratamento de substituição de função renal: [S] (idade) / [N] / [I] ; modalidade inicial: HD 
/ DP / TR . 
[HD – Hemodiálise / DR – Diálise Peritoneal / TR – Transplante Renal].  
6 - Surdez neuro-sensorial bilateral: [S] (idade) / [N] / [I] ; audiograma mais recente (data: 
mês / ano ) . 
7 - Sinais oculares:  maculopatia [S] (idade) / [N] / [I] ; lenticone anterior [S] (idade) / [N] / [I] 
; outro(s): _____________________________________ ; exame oftalmológico mais recente 
(data: mês / ano ) . 
Nome: ______________________________________________________ 
Data de Nascimento: _____ / _____ / __________  
Sexo: Masculino / Feminino 
(ou colar etiqueta) 
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8 - Leiomiomatose: [S] (idade) / [N] / [I] ; localização: 
_____________________________________________  
9 - Dificuldades de aprendizagem / atraso mental: [S] (idade) / [N] / [I] ; dismorfia facial [S] 
(idade) / [N] / [I] . 
10 - Biopsia renal: [S] (idade) / [N] ; microscopia óptica: 
_____________________________________________  
microscopia electrónica: [S] / [N] ; alterações da membrana basal glomerular – 
estreitamento: [S] / [N] / [I]; espessamento: [S] / [N] / [I]; lamelação: [S] / [N] / [I]; corpos 
electrodensos intralacunares [S] / [N] / [I].  
História Familiar: 
História familiar de hematúria: [S] / [N] / [I]     Existe mutação familiar identificada? [S] / [N] 
História familiar de IRC : [S] / [N] / [I]                 Em que gene? COL4A5          COL4A4          
COL4A3   
História familiar de surdez: [S] / [N] / [I]     Descrição da mutação: 
_____________________________ 
 
Árvore Familiar (inclua, pelo menos, 3 geraç ões) 
 
 
 
 
 
 
 
 
 
 
 
Legenda:  
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Requisição de Análise Genética 
Produto biológico enviado:  
Sangue         ADN            Data da Colheita:_____/_____/_________ 
Assinatura do Médico: __________________________________________   (Cédula 
Profissional: __________ ) 
Data:  _____ / _____ / __________ 
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Protocol P2 Molecular protocol 
 
SEQUENCIAÇÃO DIRECTA DO GENE COL4A5 
A sequenciação directa do gene COL4A5 tem como objectivo identificar 
mutações pontuais e grandes delecções, em doentes do sexo masculino. Nos 
doentes do sexo feminino, não é tão informativa, permitindo apenas detectar 
mutações pontuais. Nestes casos, deve ser adicionalmente efectuada a técnica 
Multiplex-Ligation dependent Probe Amplification (MLPA), que permite a 
identificação de delecções e duplicações.  
O estudo de um probando inclui a sequenciação directa da região codificante 
de 53 exões do gene COL4A5 (incluindo os exões sujeitos a splicing alternativo 41A 
e 41B), assim como das regiões de transição exão-intrão. Este estudo não inclui a 
sequenciação da região promotora comum aos genes COL4A5 e COL4A6. As 
sequências de primers (iniciadores) e condições de amplificação e sequenciação do 
ADN genómico foram adaptadas do estudo efectuado por Martin et al. (1998) 
(Supplementary table S2 do manuscript 1). No caso de mutações pontuais, a 
variante é confirmada em dois PCR independentes, incluindo, sempre que possível 
um controlo positivo (familiar afectado) e um controlo negativo (controlo saudável). 
No caso das delecções, a variante é confirmada em indivíduos do sexo masculino 
através de duas técnicas (sequenciação e MLPA). O estudo de uma variante 
patogénica em familiares do probando deverá ser efectuado através da análise do 
exão (ou exões) relevante(s), por sequenciação directa e/ou MLPA. 
 
I. Colheita e envio da amostra 
 
Instruções para colheita da amostra: 
Programar a colheita da amostra de sangue de modo a que possa ser 
enviada por correio e chegar ao Laboratório do Departamento de Genética dentro de 
48 horas. 
Colher 5-10 ml de sangue venoso em tubo(s) de plástico com K-EDTA 
(Vacutainer® ou análogo – tampa roxa). 
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Se o doente estiver em programa de hemodiálise, a colheita deverá ser feita 
antes da heparinização inicial. 
 
Instruções para envio da amostra: 
Manter e enviar o tubo à temperatura ambiente. 
Colocar o(s) tubo(s) de plástico, devidamente identificados, no interior de envelope 
almofadado, endereçado a: 
Departamento de Genética  
Faculdade de Medicina da Universidade do Porto  
Alameda Prof. Hernâni Monteiro 
4200 – 319 Porto 
 
II. Extracção do ADN e armazenamento da amostra 
Extrair ADN genómico a partir de linfócitos de sangue venoso, usando um 
método de salting-out (Citomed, Lisboa), e armazenar a 4ºC. Armazenar parte do 
pellet de linfócitos a -80ºC, que pode ser utilizado para extrair ADN ou mARN. 
 
III. Quantificação da concentração de DNA de cadeia dupla da amostra 
As amostras de ADN foram quantificadas num espetrofotómetro 
NanoDrop2000C (ThermoScientific). A medição da absorvância no comprimento de 
onda de 260 nm permitiu calcular a concentração de ADN em ng/µL. 
 
IV. Amplificação do ADN genómico por Polymerase Chain Reaction (PCR) 
A mistura para a reação de amplificação do ADN genómino por PCR tem um 
volume de 50 µl, contendo: tampão Fermentas® (1x), MgCl2 Fermentas® (1,5mM), 
dNTPs (0,2mM), primers forward e reverse (5 pmol/µl), Taq DNA polymerase 
Fermentas® (5U/µl), água destilada e ADN (100ng/µl). O ADN genómico é 
amplificado in vitro, usando os termocicladores GeneAmp PCR System 9700 ou 
Veriti Thermal Cycler (Applied Biosystems), do seguinte modo:  
1. Desnaturação inicial a 94ºC, durante 5 minutos. 
2. Repetição de 35 ciclos com as seguintes condições: 
i. Desnaturação da dupla cadeia de ADN a 94ºC, durante 1 minuto. 
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ii. Emparelhamento dos primers à temperatura definida, durante 1 
minuto. 
iii. Extensão da dupla cadeia emergente de ADN a 72ºC, durante 1 
minuto e 30 segundos. 
3. Extensão final das duplas cadeia de DNA a 72ºC, durante 10 minutos. 
4. Manutenção do produto da amplificação a 4ºC, após a conclusão do número total 
de ciclos de PCR. 
A confirmação e a determinação dos tamanhos dos produtos amplificados 
foram realizadas através de eletroforese capilar no aparelho QIAxcel, com o kit 
QIAxel DNA Screening e com o software BioCalculatorTM (Qiagen). 
 
V. Sequenciação directa de produtos de PCR 
A. Purificação do ADN 
O ADN amplificado pode ser purificado usando o kit comercial illustra GFX PCR 
DNA and Gel Band Purification Kit (GE Healthcare®), do seguinte modo: 
1. Captura do produto de PCR  
a. Colocar a coluna num tubo de recolha (2 ml) e identificá-lo. 
b. Pipetar 500 µl de Capture buffer type 3 para a coluna. 
c. Transferir o produto de PCR (50 µl) para a coluna, misturando o produto 
com o Capture buffer type 3 vigorosamente até obter uma solução 
homogénea. 
2. Ligação do produto de PCR  
a. Centrifugar a mistura durante 30 segundos, a 14000 r.p.m. 
b. Desperdiçar o centrifugado e reutilizar o tubo de recolha com a coluna. 
3. Lavar e secar  
a. Pipetar 500 µl de Wash buffer para a coluna. 
b. Centrifugar a mistura durante 30 segundos, a 14000 r.p.m. 
c. Transferir a coluna para um tubo de 1,5 ml. 
4. Eluição   
a. Pipetar 30 µl de Elution buffer type 6 para a coluna. 
b. Incubar o produto de PCR na coluna à temperatura ambiente, durante 1 
minuto. 
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c. Centrifugar a mistura durante 1 minuto, a 14000 r.p.m. 
d. Desperdiçar a coluna e guardar o ADN purificado a – 20ºC. 
 
O ADN purificado pode ser utilizado para sequenciação directa. 
 
B. Reacção de Sequenciação: 
A preparação da mistura para a reacção de sequenciação é realizada com um 
suporte colocado sobre gelo e usando o BigDye® Terminator v3.1 Cycle Sequencing 
kit (Life Technologies; Carlsbad, CA, USA), seguindo o seguinte procedimento: 
. 
1. Preparar uma mistura para cada amostra, adicionando 2µl ADN purificado, 2µl 
Premix, 1µl Buffer, 0,2µl primer foward ou reverse (10pmol/µl) e 4,8µl com 
água esterilizada. 
2. Realizar a reacção de sequenciação com as seguintes condições: 
a. Desnaturação inicial a 96ºC, durante 3 minutos. 
b. Repetir 24 ciclos: 
i. Desnaturação da dupla cadeia a 96ºC, durante 10 segundos. 
ii. Emparelhamento do primer a 50ºC, durante 5 segundos. 
iii. Extensão da cadeia simples emergente a 60ºC, durante 4 
minutos. 
c. Manter as amostras a 4ºC, após a conclusão do número total de ciclos 
de PCR. 
 
C. Precipitação dos produtos: 
A preparação da mistura é realizada à temperatura ambiente, sem gelo, do 
seguinte modo: 
1. Preparar uma mix para cada amostra, adicionando 25µl de etanol 100%, 1µl 
EDTA (125mM) e 1µl acetato de sódio (3M), todos previamente armazenados 
a 4ºC. 
2. Adicionar 27µl da mix a cada amostra a sequenciar e incubar a 4ºC durante 
25 minutos ou à temperatura ambiente durante 30 minutos. 
3. Centrifugar a 14.000rpm, a 4ºC, durante 30 minutos. 
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4. Retirar o sobrenadante sem tocar no pellet. 
5. Adicionar 100µl etanol 70%. 
6. Centrifugar a 14.000rpm, a 4ºC, durante 20 minutos. 
7. Retirar o sobrenadante sem tocar no pellet e secar o pellet, a 90ºC, durante 1 
minuto. 
8. Guardar a -20ºC. 
 
D. Antes de sequenciar: 
1. Adicionar 20µl formamida ao pellet. 
2. Incubar à temperatura ambiente, protegido da luz com papel de alumínio, 
durante 30 minutos. 
3. Colocar 21µl do produto a sequenciar em tubos de sequenciação, após 
efectuar vortex e short spin do produto incubado. 
4. Desnaturar o ADN a sequenciar a 95ºC, durante 5 minutos, seguidos de 
conservação da amostra em gelo, durante 5 minutos. 
 
E. Sequenciação automática: 
1. Efectuar a sequenciação automática dos produtos amplificados e purificados, 
nas direcções foward e/ou reverse, através de um serviço de outsourcing 
(STABVIDA®) ou no Departamento de Genética, da Faculdade de Medicina 
da Universidade do Porto, usando os sequenciadores automáticos ABI Prism® 
310 ou 3500 Genetic Analyzer (Applied Biosystems; Foster City, CA, USA). 
2. Analisar os electroferogramas visualmente, usando o software ABI 
sequencing Analysis v.5.0 (Applied Biosystems, USA). 
3. Comparar a sequência da amostra sequenciada com controlos, recorrendo ao 
software Blast®, para detecção de variantes patogénicas 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastSearch
&VIEW_SEARCH=on&UNIQ_SEARCH_NAME=A_SearchOptions_1PvEPK_3
7vW_DP1lHXE04Xw_GTR6V_2FOw0G#). 
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Appendix I Clinical and molecular characterization of patients (CD) 
 
 
 
